

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0511

TITLE: Regulation of Breast Cancer-Induced Angiogenesis by a  
Growth Arrest-Specific Homeobox Transcription Factor

PRINCIPAL INVESTIGATOR: David H. Gorski, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Medicine and  
Dentistry of New Jersey  
New Brunswick, NJ 08901

REPORT DATE: May 2004

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040922 027

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> May 2004	<b>3. REPORT TYPE AND DATES COVERED</b> Annual Summary (29 Apr 2003 - 28 Apr 2004)	
<b>4. TITLE AND SUBTITLE</b> Regulation of Breast Cancer-Induced Angiogenesis by a Growth Arrest-Specific Homeobox Transcription Factor			<b>5. FUNDING NUMBERS</b> DAMD17-02-1-0511	
<b>6. AUTHOR(S)</b>  David H. Gorski, M.D., Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> University of Medicine and Dentistry of New Jersey New Brunswick, NJ 08901  E-Mail: gorskidh@umdnj.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. ABSTRACT (Maximum 200 Words)</b>  Homeobox genes represent a class of transcription factors important in embryogenesis, organogenesis, cell growth and differentiation, and cell migration. However, there is little known about their role in regulating endothelial cell (EC) phenotype in response to proangiogenic factors secreted by breast cancer, although at least two homeobox genes ( <i>HOXD3</i> and <i>HOXD10</i> ) have been implicated in inducing the angiogenic phenotype in ECs. We are therefore testing the hypothesis that the homeobox gene <i>Gax</i> regulates breast cancer-induced angiogenesis through its ability to regulate the expression of downstream target genes in ECs. Using in vitro tube formation assays, we have found that <i>Gax</i> expression inhibits <i>in vitro</i> angiogenesis. Moreover, by quantitative real time reverse transcriptase real time PCR, we have found that <i>Gax</i> expression is downregulated by proangiogenic factors, while cDNA microarray analysis demonstrates that <i>Gax</i> downregulates pro-angiogenic adhesion molecules in ECs and upregulates the cyclin-dependent kinase inhibitor p19 <sup>INK4D</sup> . More importantly, <i>Gax</i> expression downregulates NF-κB activity in ECs. These observations will allow us to study the mechanism of <i>Gax</i> -mediated activation or repression of their expression to be studied and will form the basis for future studies that will examine in more detail the mechanism by which <i>Gax</i> activates downstream target genes and the detailed signaling pathways involved in this activation. Given the profound effect <i>Gax</i> has on endothelial cell activation, it is likely that these studies will identify new molecular targets for the antiangiogenic therapy of breast cancer. Ultimately, these same techniques will be applied to other homeobox genes implicated in regulating EC phenotype during breast cancer-induced angiogenesis.				
<b>14. SUBJECT TERMS</b> Angiogenesis, homeobox genes, endothelial cells, transcriptional control, integrins, cDNA microarray				<b>15. NUMBER OF PAGES</b> 72
				<b>16. PRICE CODE</b>
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

## Table of Contents

Cover.....	
SF 298.....	1
Table of Contents.....	2
Introduction.....	3
Body.....	3
Key Research Accomplishments.....	20
Reportable Outcomes.....	20
Conclusions.....	21
References.....	23
Appendices.....	30

## **DOD Career Development Award**

### **INTRODUCTION**

Homeobox genes represent a class of transcription factors important in embryogenesis, organogenesis, cell growth and differentiation, and cell migration (1-6). However, there is little known about their role in regulating endothelial cell (EC) phenotype in response to pro- and antiangiogenic factors secreted by breast cancer cells and the surrounding normal stroma. When we originally submitted our proposal, only two homeobox genes, *HOXD3* and *HOXB3*, had been implicated in regulating tumor-induced angiogenesis (2, 7, 8). Of these and other HOX cluster genes, *HOXD3* and *HOXD10* expression in vascular ECs have subsequently been correlated with angiogenesis in DCIS and breast cancer (9, 10). Since then, one non-HOX homeobox gene (*Hex*) has also been implicated in regulating angiogenesis (2, 10-15). In addition, both before this project and as part of this project, we have developed more evidence implicating another (*Gax*) (16). Because, of the handful of homeobox genes implicated in regulating angiogenesis, only *Gax* shows a strong restriction in its expression to cardiovascular tissues in the adult (17, 18), we originally proposed to test the hypothesis that *Gax* (16-32) regulates breast cancer-induced angiogenesis through its ability to regulate the expression of specific downstream target genes in vascular endothelial cells (ECs). We based this hypothesis on our preliminary data showing that *Gax* is expressed in vascular ECs and inhibits EC proliferation *in vitro* (16). Using a quantitative real-time PCR assay (33) and *in situ* hybridization (9, 10), we proposed to identify proangiogenic and antiangiogenic stimuli that determine *Gax* modulation and to examine the effect of breast cancer-secreted proangiogenic peptides and antiangiogenic therapies on *Gax* expression *in vitro* and in *in vivo* models of breast cancer angiogenesis. Next, using an adenovirus expressing *Gax* (28), we proposed to drive *Gax* expression in ECs in order to determine the effect of *Gax* expression on breast cancer angiogenesis, both *in vitro* and in *in vivo* models. Finally, because few downstream targets of *Gax* have been identified (27, 28, 31), we proposed to evaluate changes in global gene expression in ECs that result from *Gax* expression in order to identify and evaluate likely downstream targets. Our results will form the basis for future studies that will examine in more detail the mechanism by which *Gax* activates downstream target genes and the detailed signaling pathways involved in this activation. Given the profound effect *Gax* has on EC activation, it is likely that these studies will identify new molecular targets for the antiangiogenic therapy of breast cancer. Ultimately, these same techniques will be applied to other homeobox genes implicated in regulating EC phenotype during breast cancer angiogenesis.

### **BODY**

#### **Background**

In order to grow and metastasize, breast malignancies are critically dependent upon inducing the ingrowth of blood vessels from the host (34, 35). Numerous studies have suggested a correlation between secretion of proangiogenic molecules and increased angiogenesis and increased likelihood of lymph node metastases with poorer prognosis in breast cancer (36, 37). Inhibition of tumor-induced angiogenesis has thus emerged over the last decade as a promising new strategy for breast cancer therapy, either alone or in combination with conventional therapies (38-41). During angiogenesis, whether physiologic or tumor-induced, vascular ECs undergo distinct changes in phenotype and gene expression, including activation of proteolytic enzymes to degrade basement membrane, sprouting, proliferation, tube formation, and production of extracellular matrix (42-44). Although the EC receptors and signaling pathways



### DOD Career Development Award

activated by proangiogenic factors secreted by breast cancer cells, such as vascular endothelial growth factor (VEGF) (45, 46) and basic fibroblast growth factor (bFGF) (45), have been extensively studied (47-49), much less is known about the molecular biology of the downstream transcription factors activated by these signaling pathways, which then activate the genes necessary for EC phenotypic changes during breast cancer-induced angiogenesis.

Homeobox genes encode transcription factors containing a common DNA-binding motif (1, 4-6, 50). Important regulators of body plan and cell fate during embryogenesis, homeobox genes also have pleiotropic roles in many cell types in the adult and can modulate cell cycle progression and arrest, cell differentiation, migration, and apoptosis (1, 3-5, 7, 16, 51, 52). As a gene family, they are thus excellent candidates to be involved in the final transcriptional control of genes responsible for the changes in EC phenotype induced by breast cancer-secreted proangiogenic factors. Until recently, little was known about how homeobox genes might influence angiogenesis. There is now evidence for their involvement in phenotypic changes ECs undergo during angiogenesis, and, in particular, breast cancer angiogenesis (7, 8, 10, 13, 16). For instance, one homeobox gene, *HOXD3*, induces the expression of  $\alpha_v\beta_3$ , an integrin important in angiogenesis (53), resulting in the conversion of ECs to an angiogenic phenotype both *in vitro* and *in vivo* (7); impaired *HOXD3* expression is associated with impaired angiogenesis in a mouse model (52) and increased *HOXD3* expression is observed in the vasculature of breast cancer and DCIS compared to the vasculature of the surrounding normal breast (9). Similarly, overexpression of the homeobox gene *HOXB3* results in an increase in capillary vascular density and angiogenesis (8). Taken together, these data suggest significant roles for specific homeobox genes in responding to extracellular signals and activating downstream genes to induce phenotypic changes associated with breast cancer-induced angiogenesis. More recently, two additional homeobox genes have been implicated in the regulation of EC phenotype during angiogenesis. First, in contrast to *HOXB3* and *HOXD3*, another HOX cluster gene (*HOXD10*) inhibits EC conversion to the angiogenic phenotype (10). *HOXD10* expression is elevated in quiescent vascular endothelium in the stroma compared to breast cancer-associated vascular endothelium (10). Consistent with these observations, *in vivo* human ECs overexpressing *HOXD10* fail to form new blood vessels when embedded in sponges containing Matrigel and proangiogenic factors (10) in nude mice. Second, *Hex* overexpression in human umbilical vein endothelial cells (HUVECs) inhibits angiogenesis and blocks VEGF receptor signaling (12, 13). Given that previous data showing high levels of *Hex* expression in proliferating vasculature had suggested that *Hex* would be more likely to induce EC proliferation and angiogenesis (11, 14, 15), this subsequent observation that *Hex* inhibits VEGF signaling and angiogenesis suggests a more complex role for this gene in postnatal angiogenesis than previously understood.

The cardiovascular-specific homeobox gene *Gax* appears more likely to function as a negative regulator of breast cancer-induced angiogenesis in ECs, like *HOXD10* or *Hex*. After isolating it from a rat aorta cDNA library (17, 54), we (and others) have shown that *Gax* has profound effects on cardiovascular tissues (16, 21, 23, 24, 26-28, 31). In vascular smooth muscle cells (VSMCs) *Gax* expression is downregulated by mitogenic signals and upregulated by growth arrest signals (17, 32). Consistent with this observation, *Gax* induces G<sub>1</sub> cell cycle arrest (28) and can induce apoptosis in VSMCs under stress (26). Also, *Gax* overexpression inhibits VSMC migration, downregulating the expression of integrins,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$ , both of which are associated with the activated ("synthetic") state in VSMCs and the angiogenic phenotype in ECs (31, 53). *In vivo*, *Gax* expression in arteries inhibits proliferative restenosis of the arterial lumen

### **DOD Career Development Award**

after injury (23, 24, 27, 28). We now have evidence that *Gax* mRNA is also expressed in ECs (16). Understanding the actions of *Gax* on downstream target genes, as well as signals that activate or repress *Gax* expression, could thus lead to a better understanding of the mechanisms of breast cancer-induced angiogenesis and the identification of new molecular targets for the antiangiogenic therapy of breast cancer.

Little is known about specific transcription factors involved in the control of endothelial cell phenotype during breast cancer-induced angiogenesis, especially transcription factors that inhibit angiogenesis. *Gax* is a novel homeobox transcription factor (17) whose antiproliferative (31), pro-apoptotic (26), and antimigratory (31) activities were originally characterized by us and others in vascular smooth muscle. Although other homeobox genes have been implicated in promoting or inhibiting EC conversion to the angiogenic phenotype (7, 8, 10, 13, 16), of these *Gax* is the only homeobox transcription factor described thus far with a potential role in regulating angiogenesis whose expression is largely restricted to the cardiovascular system in the adult (17, 18). It is thus a new and unique candidate transcription factor for regulating EC conversion to the angiogenic phenotype in response to proangiogenic factors secreted by breast tumors. The hypothesis that *Gax* inhibits the phenotypic changes in ECs that occur when they are stimulated by the proangiogenic factors secreted by breast cancer cells represents an innovative approach to the study of the transcriptional control of EC phenotypic changes during angiogenesis, as does our use of *Gax* as a molecular tool to study the mechanisms of breast cancer-induced angiogenesis. More importantly, identification of downstream targets of *Gax* has the potential of identifying previously unsuspected molecular targets for the antiangiogenic therapy of breast cancer and other tumors, leading to new lines of investigation into breast cancer-induced angiogenesis and new therapies based on these observations. Thus, the studies we have proposed and undertaken with support from the Department of Defense have attempted to use *Gax* as a molecular tool to: (1) enhance our understanding of the mechanisms by breast cancer stimulates endothelial cells to become angiogenic; and (2) provide the basis for the design of antiangiogenic therapies of breast cancer targeting *Gax* or its downstream targets.

#### **Overview of progress over the last year**

Since this project began, we have made considerable progress in meeting the milestones originally proposed in our original Statement of Work. Most of the tasks originally proposed are on schedule. Of particular interest, in analyzing our early cDNA microarray experiments, we made the unexpected observation that *Gax* expression downregulates NF- $\kappa$ B-dependent gene expression in ECs (see Task #6). This observation has suggested an entirely new area of research into the mechanism by which *Gax* expression inhibits angiogenesis, as there is now considerable evidence that NF- $\kappa$ B activity is proangiogenic in ECs. Consequently, during Year Two, we formally requested a change in our Statement of Work, which was granted. The changes to the SOW include:

1. *Eliminating the proposed subtraction hybridization studies. Justification:* Given the cDNA microarray results we have developed, these results are redundant, and in any case we have not yet made significant progress on them. We have identified NF- $\kappa$ B pathway as being inhibited by *Gax* using cDNA microarrays and anticipate that other pathways will be identified as we do more microarray experiments.
2. *Temporarily suspending work on trying to construct stable transfectants with inducible *Gax* expression and instead continue our studies using viral constructs. Justification:*

### **DOD Career Development Award**

Using HMEC-1 cells to make stable transfectants with inducible *Gax* expression has proven more difficult than anticipated, and we do not presently have cells to use. Consequently, we are in the process of obtaining a different cell line (HPMEC-ST1.6R) to use (55). However, we do not need stable transfectants with inducible *Gax* expression to do our initial studies on the mechanism by which *Gax* inhibits NF- $\kappa$ B signaling. Given that investigating this potential interaction seems a more fruitful area to pursue and was identified in studies funded by this Career Development Award, following this lead is appropriate.

3. *Changing our previously proposed immunohistochemical studies of Gax expression in breast cancer tumor vessels to in situ hybridizations. Justification:* Our anti-*Gax* antibodies have not been staining paraffin-embedded tissue sections well. To address this problem, we have developed a collaboration with Dr. Nancy Boudreau, who has long experience doing in situ hybridizations using homeobox gene probes and is helping us to do in situ hybridizations with a *Gax* probe we have constructed. We will also do this with the Matrigel plug assays. We note, however, that, since we made this change to the Statement of Work, we have determined that our anti-*Gax* antibodies will work on frozen sections (see Task #2).
1. *Adding tasks to Task #6 to investigate the interaction between Gax and NF- $\kappa$ B. Justification:* Our preliminary cDNA microarray experiments demonstrate that *Gax* expression strongly downregulates NF- $\kappa$ B targets. If confirmed by additional experiments, this interaction could represent the primary mechanism by which *Gax* inhibits angiogenesis and is therefore important to investigate as fully as possible. To this end, we have enlisted the collaboration of Dr. Arnold Rabson, a noted expert in the field of NF- $\kappa$ B functions and mechanisms of activity.
5. *Altering the timeframe of remaining tasks proposed to be completed by the end of month 24 but not yet completed to encompass the third year. Justification:* We believe we can still complete most, if not all, of the remaining tasks (tasks not put aside in favor of studying the *Gax*-NF- $\kappa$ B interaction) before the end of the final year.

This report will discuss our progress within the context of the new modified Statement of Work that was recently submitted and accepted.

#### **Detailed progress report by tasks in the modified Statement of Work**

##### **Task 1: Characterize the regulation of Gax expression in three different endothelial cell types in vitro, months 1 to 24:**

- a. **Develop and verify real time quantitative reverse transcriptase polymerase chain reaction assay to measure *Gax* transcript levels. (Months 1-6.)**

**Status: Accomplished.**

**Results and Discussion:** This was discussed in detail in our Annual Report for Year One (2003).

- a. **Measure changes in *Gax* mRNA levels in three different endothelial cell types in response to growth factors, pro-angiogenic, and antiangiogenic factors. (Months 6-24)**


## DOD Career Development Award

Status: In progress.

**Results and Discussion:** Using our quantitative real time reverse transcriptase PCR assay, we completed the *in vitro* experiments and found that, for nearly every breast cancer cell line we have studied, serum-free media conditioned for 24 hours by breast cancer cells strongly downregulated *Gax* expression in ECs within four hours. Two cell lines, MCF7 and MDA-MB231, were as potent as fetal bovine serum in downregulating *Gax* (Figure 1).


To begin to identify the specific factors secreted by breast cancer cells that are likely to be the ones that result in downregulation of *Gax* expression, we have followed up these observations by examining the effect of VEGF, bFGF, and TNF- $\alpha$  on *Gax* message levels using quantitative real time PCR (Figure 2). In all cases, *Gax* was rapidly downregulated and then more slowly returned to baseline after stimulation with proangiogenic factors. First, we studied the time course of *Gax* downregulation. HUVECs made quiescent by incubation for 24 hrs in 0.1% FBS were stimulated with 10% FBS. *Gax* was rapidly downregulated by more than 5-fold within four hours and slowly returned to basal over 24 hours (Figure 2A). Conversely, when sparsely plated randomly cycling HUVECs were placed in medium containing 0.1% serum, *Gax* was upregulated nearly 10-fold within 24 hours (see Manuscript #3, Figure 1, in Appendix). We then stimulated quiescent HUVECs with proangiogenic or proinflammatory factors, including bFGF, VEGF, and TNF- $\alpha$ . *Gax* was rapidly downregulated with a similar time course (Figure 2, B through D). Similar results were observed in HMEC-1 cells, an immortalized human microvascular endothelial cell line (56) that retains many characteristics of microvascular endothelial cells (data not shown). We are presently repeating these experiments using the endothelial cell line HPMEC1.6R (55).

Finally, we examined whether antiangiogenic peptides that might be used either alone or in combination (57, 58) to treat breast cancer affected *Gax* expression. Randomly cycling HUVECs were incubated for varying times with 1  $\mu$ g/ml angiostatin (57) or endostatin (58). Cells were harvested for total RNA isolation and the RNA then subjected to quantitative real time PCR to measure *Gax* expression. We found that both angiostatin and endostatin upregulated *Gax* expression by two-fold over 48 hours, a time course that was slower and an upregulation that was less dramatic than that caused by serum deprivation (Figure 3). From these results, we are now preparing to test the ability of *Gax* to block angiogenesis due to breast cancer-conditioned media in the Matrigel plug assay, as we have described in Task #4 (see below). Thus far, we have not been able to find a growth stimulus that does not downregulate *Gax* or a growth arrest stimulus that does not upregulate it. Thus, the promoter mapping experiments originally proposed (Task #1d) will now be given a higher priority.



**Figure 1. Downregulation of *Gax* expression in endothelial cells by conditioned medium from tumor cell lines.** Quiescent HUVECs were treated with either low serum medium (LSM), 10% FBS, or 10% conditioned medium from the indicated breast cancer cell lines. Cells were harvested 4 hours after stimulation, total RNA harvested and real time quantitative RT-PCR performed. *Gax* message level was normalized to GAPDH. Units are arbitrary.

DOD Career Development Award



**Figure 2. Time course of *Gax* downregulation by mitogens and proinflammatory factors.** Quiescent HUVECs were treated with either (A) 10% fetal bovine serum (FBS); or 10 ng/ml of either (B) VEGF<sub>165</sub>; (C) TNF- $\alpha$ ; or (D) bFGF. At various time points, cells were harvested for extraction of total RNA, which was then subjected to quantitative real time TaqMan RT-PCR with *Gax*- and GAPDH-specific primer/probe sets. *Gax* mRNA levels were normalized to GAPDH. Units are arbitrary. E. Cells were treated identically to (C), except that after six hours cells were harvested for protein extraction and then subjected to Western blot with *Gax*-specific polyclonal antibody.

- c. Measure changes in *Gax* mRNA levels *in vitro* using three different endothelial cell types in response to common cytotoxic therapies used in breast cancer, including chemotherapy and radiation. (Months 12-36.)


Status: In progress.

**Results and Discussion:** These experiments were deferred in order to study more closely the interaction between *Gax* and NF- $\kappa$ B (see Task #6). We began these experiments recently, starting with the antiangiogenic factors angiostatin and endostatin, with the plan being to proceed to cytotoxic therapies this summer. We do not yet have reportable data from these experiments, but anticipate finishing them before the end of the grant period.

- d. Mechanistic studies to determine if regulation of *Gax* expression occurs at the level of transcription, translation, or mRNA stability and mapping of the *Gax* promoter, if necessary. (Months 12-36.)



## DOD Career Development Award



**Figure 3. Upregulation of *Gax* by antiangiogenic peptides.** Randomly cycling HUVECs were treated with either angiostatin or endostatin at 1  $\mu$ g/ml. At varying time points, cells were harvested for RNA isolation, which was then subjected to reverse transcriptase quantitative real time PCR. *Gax* mRNA levels were normalized to GAPDH and expressed as ratios to *Gax* levels in control HUVECs allowed to incubate in parallel in normal medium.  $p < 0.01$  at 48 hrs for angiostatin and endostatin.

**Status: In progress.**

### Results and Discussion:

These experiments were also deferred in order to study more closely the interaction between *Gax* and NF- $\kappa$ B (see Task #6) and are therefore behind schedule. We are presently in the early stages of doing these experiments, having recently obtained a series of *Gax* promoter deletion constructs (19) using Luciferase as the reporter gene to use to identify important elements for regulating *Gax* expression. We plan to begin these experiments in June and anticipate finishing them before the end of the grant period.

### Task 2: Measure differences in *Gax* expression between

*angiogenic blood vessels and normal blood vessels in vivo. (Months 13 to 36.)*

- a. Measure breast cancer cell line-induced angiogenesis *in vivo* using the Matrigel plug assay and breast cancer cell line-conditioned media, and measure *Gax* expression in endothelial cells *in vivo*. (Months 13-36.)

**Status: In progress.**


**Results and Discussion:** These results will be discussed together with the results of Task #2b. The experiments described are preliminary experiments in which we have been working out the conditions for our *in situ* hybridization and immunohistochemistry of frozen tissue sections. See below.

- b. Compare immunohistochemical staining for *Gax* expression in breast tumor blood vessels with that of blood vessels found in normal breast for 50 invasive human breast cancer specimens. (Months 13-36.)

**Status: In progress.**

**Results and Discussion:** In order to determine if *Gax* expression *in vivo* varies according to the angiogenic state of the EC, we measured *Gax* expression *in vivo* in frozen sections of normal human breast and in human breast cancer by *in situ* hybridization. We also measured *Gax* protein expression in the mouse tissues from Matrigel plug experiments. In initial preliminary experiments, we observed *Gax* message expression in the capillaries and blood vessels of normal breast tissue (Figure 4, A and B). More interestingly, in a human breast cancer specimen (Figure 4C) we could also detect *Gax* expression in capillaries in the surrounding normal stroma. However, we found very few capillaries or blood vessels in the tumor itself expressing *Gax*. Consistent with this, by immunohistochemistry in frozen sections we were able to detect *Gax*

# DOD Career Development Award



**Figure 4. Determination of *Gax* expression *in vivo*.** *Gax* expression was measured in human breast and breast cancer specimens by *in situ* hybridization with a riboprobe for *Gax* as described in the original grant in Specific Aim #3, p. 45 (A through C) and in Matrigel plugs harvested from mice by immunohistochemistry on frozen sections with previously described anti-*Gax* antibody (D through F). All photographs were taken at 400x magnification. Arrows indicate blood vessels or capillaries staining positive for *Gax* expression. (Legend: ST=stroma; SKM=skeletal muscle; MG=Matrigel plug.) **A. Normal breast (*in situ* hybridization).** In the fatty tissue of a normal human breast, a blood vessel is observed to stain positive for *Gax* expression. **B. Normal breast (*in situ* hybridization).** Several capillaries stain positive for *Gax* expression. **C. Breast cancer (*in situ* hybridization).** Multiple capillaries in the stroma stain positive for *Gax* expression. However, capillaries in the tumor either stain much more weakly or do not stain positive for *Gax* at all. **D. Mouse skeletal muscle (immunohistochemistry).** Blood vessels in the skeletal muscle near a Matrigel plug stain positive for *Gax* expression. **E and F. Immunohistochemistry of control Matrigel plugs (bFGF only, no virus).** Blood vessels in the surrounding skeletal muscle or connective tissue stroma stain strongly for *Gax* expression, but vessels noted within the Matrigel plugs, where angiogenesis is occurring, stain either weakly or not at all.

expression in blood vessels in the skeletal muscle (Figure 4D) and stroma surrounding the Matrigel plugs (Figure 4, E and F). In contrast, the neovessels we found in the Matrigel plugs either stained weakly for *Gax* or not at all. We caution that these results are preliminary and considerable work remains over the next year to determine whether *Gax* message and protein expression is indeed lower in angiogenic vasculature or in breast cancer vasculature than in resting vasculature. In particular, we need to define more carefully what represents positive staining for *Gax* and then quantify the number of vessels staining positive for *Gax*. This may require double-staining with antibodies to vascular-specific markers, such as CD31. Also, the frozen sections we obtained from our Tissue Retrieval Service were too thick, hence the poor tissue and cellular definition in Figure 4, A through C. These caveats aside, however, these data do at least suggest that *Gax* is regulated *in vivo* in a manner similar to how it is regulated *in vitro*, further implying a role for *Gax* in regulating *in vivo* angiogenesis. We will now use these preliminary results to determine whether *Gax* expression is downregulated *in vivo* by breast cancer-secreted angiogenic factors and whether its expression is truly downregulated *in vivo* in breast cancer- and DCIS-associated vasculature, as originally proposed.

## DOD Career Development Award

### **Task 3: Determine the effects of *Gax* overexpression in ECs in vitro. (Months 1-24.)**

#### **a. Determine effect of *Gax* overexpression on endothelial cell proliferation and expression of cell cycle regulatory genes. (Months 1-12.)**


**Status: In progress.**

**Results and Discussion:** These experiments were discussed in more detail in the Annual Report for Year One (2003). Using cDNA microarray experiments, we have identified several cyclin dependent kinase inhibitors that are upregulated by *Gax* expression, including p19<sup>INK4D</sup>, p57<sup>Kip2</sup>, and p21<sup>WAF1/CIP1</sup> (28, 59, 60). These experiments will be described in more detail in Task #4. The upregulation of these CDK inhibitors suggests redundant mechanisms by which *Gax* can induce G<sub>1</sub> cell cycle arrest. In Year One, we had also shown that the upregulation of p21 in ECs is due to a p53-independent activity of *Gax* on the p21<sup>WAF1/CIP1</sup> promoter [(16), in Appendix]. We are presently verifying the upregulation of p57<sup>Kip2</sup> and p19<sup>INK4D</sup>.

#### **a. Determine effect of *Gax* overexpression on expression of integrins, specifically if the expression of integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ are regulated by *Gax* expression (Months 18-36.)**

**Status: In progress.**

**Results and Discussion:** Migration of ECs through the basement membrane and into the surrounding stroma in response to proangiogenic stimuli is a critical step in tumor-induced angiogenesis, and integrins, particularly integrins  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$ , play a critical role in this process (53), as might integrin  $\alpha_5\beta_1$ , which has been implicated in both *HOXD3*-induced (9) and NF- $\kappa$ B-mediated angiogenesis (61). We therefore tested the ability of *Gax* to inhibit EC migration towards proangiogenic factors. HUVECs were transduced with Ad.r*Gax* or Ad.h*Gax* at varying MOI and



**Figure 5. *Gax* inhibits HUVEC migration towards serum.** HUVECs were transduced with varying MOI of either Ad.GFP or Ad.r*Gax* and their migration towards various growth factors and proangiogenic factors determined. *Gax* inhibits HUVECs migrating towards (A) FBS; and (B) FBS, bFGF, VEGF<sub>165</sub>, and TNF- $\alpha$ . Results are expressed relative to control HUVECs not transduced with any virus. Results were analyzed by one-way ANOVA (\* indicates  $p < 0.01$ ). Similar results were obtained with Ad.h*Gax* (data not shown).



## DOD Career Development Award

incubated overnight.  $10^5$  viable cells per well were plated in 6-well plates with inserts containing 8  $\mu$ m polycarbonate filters, and we measured their migration towards serum-containing media in the lower chamber. Ad.r*Gax* strongly inhibited the migration of HUVECs towards serum, VEGF, bFGF, and TNF- $\alpha$  (Figure 5), as did Ad.h*Gax* (data not shown). Both homologs also inhibited migration of HMEC-1 cells towards bFGF and VEGF (data not shown).

We have recently begun to examine the levels of integrin subunits in ECs and how they change in response to *Gax* expression. Our strategy will use real time quantitative reverse transcriptase PCR, Western blotting, and flow cytometry to measure changes in integrin expression induced by *Gax* expression. An initial flow cytometry experiment showed no change in the cell surface level of integrins  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  in response to *Gax* expression using our adenoviral vectors (data not shown). Given that this result conflicts with other data in vascular smooth muscle cells (31), we are presently attempting to repeat these experiments and determine if this result is correct. If it is correct, it would imply a cell type-specific difference in how *Gax* regulates integrin expression and suggest that the mechanism through which *Gax* inhibits angiogenesis does not involve integrin  $\alpha_v\beta_3$  or  $\alpha_v\beta_5$ .

### c. Characterize *Gax*-induced endothelial cell apoptosis and the effect of *Gax* on the expression of genes regulating apoptosis. (Months 24-36.)

**Status:** Not done.

**Results and Discussion:** These experiments are scheduled to be done in Year Three.


### Task 4: Determine the effects of *Gax* overexpression on angiogenesis in vivo. (Months 13-36.)

#### a. Matrigel plug assays in C57BL/6 mice to determine if Ad.*Gax* inhibits *in vivo* angiogenesis and to quantify how strong the effect is. 100 mice will be required. (Months 13-36)

**Status:** In progress

**Results and Discussion:** Matrigel containing proangiogenic factors, when implanted subcutaneously in mice, can stimulate the ingrowth of blood vessels into the Matrigel plug from the surrounding tissue, and this neovascularization can be estimated by counting CD31-positive cells and/or by measuring hemoglobin concentrations in the plug (62). Moreover, adenoviral vectors diluted in Matrigel implanted as subcutaneous plugs can serve as reservoirs to transduce ECs invading the plug and drive expression of exogenous genes (63, 64), producing effects on *in vivo* angiogenesis even when the gene transduced is a transcription factor (65). As originally proposed, we have taken advantage of this observation to test whether exogenously driven *Gax* expression can inhibit angiogenesis *in vivo*, using methodology previously described (63, 64). Matrigel plugs containing bFGF and either Ad.GFP, Ad.h*Gax*, or Ad.r*Gax* were injected subcutaneously in C57BL/6 mice (N=8 per experimental group). As a positive control for angiogenesis inhibition by a viral vector, we utilized an adenoviral construct expressing a dominant negative form of Akt (Ad.DN-Akt) (63, 64). We observed that the adenoviral vectors expressing *Gax* expression inhibit the neovascularization of the plugs with a potency slightly less than that observed for the Ad.DN-Akt construct (Figure 6), and that the Ad.DN.Akt construct inhibited neovascularization with a potency similar to what has previously been reported (63, 64). The results of these experiments indicate that *Gax* is capable of inhibiting angiogenesis in *in vivo* models and will form the basis of experiments proposed in Task #4.

DOD Career Development Award



**Figure 6. Effect of *Gax* expression on angiogenesis in Matrigel plugs.** Matrigel plugs (500  $\mu$ l each) containing 400 ng/ml bFGF and the indicated viral constructs at  $10^8$  pfu/plug were implanted subcutaneously in the flanks of C57BL/6 mice. Plugs were harvested after 14 days incubation for immunohistochemistry on frozen sections using CD31 antibodies and determination of CD31-positive cells per high powered (400x) field. Slides were photographed at 200x magnification. (Legend: MG = Matrigel plug; ST = stroma surrounding the plug; arrows indicate examples of CD31-positive blood vessels.) **A.** No growth factor. **B.** bFGF alone, no virus. **C.** Ad.GFP. Note the infiltration of the plug with CD31-positive vessels such that it is difficult to determine the exact edge of the plug in B and C. **D.** Ad.DN.Akt. **E.** Ad.hGax. **F.** Ad.rGax. **G.** Vessel counts. Results are plotted as means  $\pm$  standard error of the mean, and statistical differences determined with one-way ANOVA  $p < 0.0001$  for the overall, and the vessel counts were statistically significantly different from control (Ad.GFP group) for Ad.DN.Akt ( $p = 0.013$ ); Ad.hGax ( $p = 0.008$ ); and Ad.rGax ( $p = 0.028$ ). **H.** Gross photographs of selected plugs. Note the hemorrhage into one of the Ad.GFP plugs and the lack of vessels on the capsule of the Ad.Gax and Ad.DN.Akt plugs. **I.** Ad.rGax drives *Gax* protein expression in cells invading the Matrigel plug. A representative section of Matrigel plug containing Ad.rGax was subjected to immunohistochemistry with anti-Gax antibody. Cells embedded within the Matrigel plug are staining positive for Gax protein expression (photographed at 200X magnification).

## DOD Career Development Award


### Task 5: Identify potential downstream targets of *Gax*. (Months 1 through 24.)

- a. Compare global gene expression between *Gax*-expressing endothelial cells and non-*Gax*-expressing endothelial cells using cDNA microarrays. (Months 10 to 18.)

Status: In progress.

**Results and Discussion:** We reported on the preliminary results of our cDNA microarray experiments, in which we compared the global gene expression of HUVECs transduced with Ad.r*Gax* and Ad.h*Gax* with that of HUVECs transduced at an equal MOI with an adenoviral vector expressing GFP (Ad.GFP) in last year's Annual Report (2003). Since then, we have concentrated primarily on two tasks: (1) analyzing the data and verifying the regulation of downstream targets by real time PCR and/or Western blot; and (2) continuing to try to develop stable transfectants with tetracycline-inducible *Gax* expression as a strategy by which we will be able to manipulate *Gax* at more physiologically relevant expression levels than what is driven by adenoviral constructs and to allow time courses of changes in EC phenotype and gene expression secondary to *Gax* expression.

We have now successfully generated several clones based on HMEC-1 cells with the Tet-On system (Clontech). These cells have varying levels of doxycycline-inducible gene activity when plasmids containing the Luciferase gene under control of the Tet response element (TRE). Using the Tet-On system, we have generated HMEC-1 clones with constitutive expression of rTA. When these cells are transduced with a reporter construct in which Luciferase is driven by the Tet response element (TRE), expression of reporter gene is induced by exposure to doxycycline (Figure 7). There are several candidate clones with tetracycline-inducible expression, the most promising of which is clone #26. This clone will be transfected with pTRE-*Gax*, a construct in which expression of the *Gax* cDNA is controlled by TRE to produce tetracycline-inducible *Gax* expression. Completion of the construction of these stable transfectants is presently in progress. Despite our initial success in this first step of stably expressing rTA, it is still possible that we may not be able to develop stable transfectant HMEC-1 cells with inducible *Gax* expression using this system



**Figure 7. Tetracycline-inducible HMEC-1 constructs.** HMEC-1 cells were transduced with pTet-On, which introduces the rTA element. Cells were selected with Hygromycin B, and then Hygromycin B-resistant colonies selected and expanded. Cells from individual colonies were then transduced with pTRE-Luc, a plasmid in which Luciferase expression is driven by the Tet response element, which is active in the presence of tetracycline or doxycycline and silent otherwise. Luciferase expression was determined in the presence and absence of doxycycline. Clone #26 showed the most induction with doxycycline.

## DOD Career Development Award

or these cells. In this event, we will pursue two additional strategies. First, we have obtained another EC cell line, HPMEC-ST1.6R (66), which we are presently expanding for use in generating stable transfectants with inducible *Gax* expression. Second, we will consider using a retroviral system (such as the BD RevTet-On vector (BD Biosciences, Palo Alto, CA) to generate either stable transfectants with inducible *Gax* expression or to generate long term transient inducible *Gax* expression whose duration should be adequate to do the experiments originally proposed.

**Table 1.** Selected NF- $\kappa$ B-influenced genes downregulated by *Gax* expression (\*Implicated in angiogenesis)

Gene	Fold decrease
CXCL1 (GRO-1/Gro- $\alpha$ )*	238.0
Interleukin-8*	181.3
Gro- $\beta$	97.0
E-selectin*	62.6
Granulocyte chemotactic protein-2	17.5
VCAM-1*	13.0
A20 (TNF- $\alpha$ -induced protein-3)	7.5
TNF- $\alpha$ receptor-associated protein-1 (TRAF-1)*	4.0
Tissue factor*	3.0
Intracellular adhesion molecule-1 (ICAM-1)*	2.5
Endothelin-1	2.5
Heparin-binding EGF	2.1
Endothelial-specific molecule-1 (ESM-1)*	2.1
Interferon regulatory factor-1*	1.7
B94 (TNF- $\alpha$ -induced protein-2)	1.7
Monocyte chemotactic protein-3	1.4

### b. Data analysis of cDNA microarray data to identify putative downstream targets of *Gax*. (Months 19-24.)

**Status:** In progress.

**Results and Discussion:** We examined genes that were downregulated 24 hours after transduction of HUVECs with Ad.r*Gax* and were immediately struck by the number of CXC chemokines strongly downregulated (Manuscript #3, Table 1, in the Appendix). These results were reported in last year's Annual Report, but, because the experiments had been done immediately before the report was due, we had had little time to analyze them. Most strongly downregulated of all was GRO- $\alpha$  (CXCL1), a CXC chemokine and a growth factor for melanoma that has also been implicated in promoting angiogenesis (67). Similarly, several other CXC chemokines were also strongly downregulated by *Gax* expression. Many of these peptides are clearly important in mediating EC activation during inflammation and in promoting angiogenesis (68). Consistent with the hypothesis that *Gax* inhibits EC activation, we also observed the downregulation of several cell adhesion molecules known to be upregulated in ECs during activation and angiogenesis, including vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin (69, 70). These proteins have all been implicated in leukocyte-EC interactions and are upregulated by pro-inflammatory factors and by VEGF during angiogenesis (69). The pattern of downregulation of these adhesion molecules, coupled with the downregulation of CXC chemokines, suggested to us inhibition of genes normally induced by TNF- $\alpha$ , which in turn suggested the possibility that *Gax* may inhibit nuclear factor  $\kappa$ B (NF- $\kappa$ B) activity. Indeed, when we examined our data using GeneMAPP to look for patterns of signal-dependent gene regulation (71), we found numerous NF- $\kappa$ B-dependent genes (72) downregulated 24 hrs after *Gax* expression (Table 1). These data strongly implied that *Gax* somehow interferes with NF- $\kappa$ B activity in ECs. Given that NF- $\kappa$ B signaling has been implicated in angiogenesis, particularly through paracrine stimulation (73) and

## DOD Career Development Award

maintenance of EC survival pathways (74), these data also suggest a potential mechanism by which *Gax* inhibits angiogenesis.

The genes upregulated by *Gax* did not fall into any signal-dependent patterns as striking as the pattern of genes downregulated by *Gax* (Table 2). However, we did note results that might suggest specific pathways upregulated by *Gax*. First, there was a strong upregulation of ALK3 (bone morphogenetic receptor 1a) (75). Although it is known that, in ECs, ALK1 activates ECs through a SMAD1/5 pathway, whereas ALK5 inhibits EC activation through a SMAD2/3 pathway (76,

77), it is not known what role, if any, ALK3 plays in regulating EC phenotype. However, its upregulation by *Gax* implies that *Gax* may activate TGF- $\beta$  signaling or render ECs more sensitive to TGF- $\beta$ . Second, we noted the upregulation of three CDK inhibitors, p19<sup>INK4D</sup>, p57<sup>Kip2</sup>, and p21<sup>WAF1/CIP1</sup> (28, 59, 60), suggesting redundant mechanisms by which *Gax* can induce G<sub>1</sub> cell cycle arrest. Finally, we note that *Frizzled-2* was upregulated. Little is known about the potential role of *Frizzled* receptors and Wnt signaling in regulating postnatal angiogenesis, although *Frizzled-2* is known to be expressed in ECs and there is evidence suggesting Wnt signaling inhibits EC proliferation (78, 79). This data leads us to two potential other signaling pathways besides NF- $\kappa$ B to pursue in Years Two and Three.

**Table 2: Selected genes upregulated by *Gax* expression**

Gene	Fold increase
<i>Frizzled</i> homolog 2	30.4
Rab coupling protein	30.1
ALK3 (Bone morphogenetic protein receptor, type 1a)	29.7
Aquaporin 3	19.9
<i>Frizzled</i>	9.8
Pro-alpha 1 chain of type I collagen	6.4
Thrombomodulin	5.5
Id2	4.6
Integrin $\beta_4$ subunit	4.2
$\beta_2$ -arrestin	2.6
p19 <sup>INK4D</sup>	2.5
Insulin-like growth factor binding protein-1	2.5
Cyclin-dependent kinase inhibitor 1C (p57, Kip2)	2.1
HOXA5	2.1
Angiopoietin-2	2.0
p21 <sup>WAF1/CIP1</sup>	1.5

### **Task 6: Exploration of downstream pathways activating putative downstream targets of *Gax* identified by cDNA microarray. (Months 25-36.)**


#### **a. Northern and Western blots of genes identified in Task #6 in order to verify regulation by *Gax*. (Months 19-36.)**

**Status: In progress.**

**Results and Discussion:** We have now verified that a number of the genes identified in the cDNA microarray experiments as being downregulated by *Gax* are also downregulated. First, we examined several NF- $\kappa$ B-dependent genes, because that would represent independent verification that NF- $\kappa$ B signaling pathways are downregulated by *Gax* expression. We found that basal and TNF- $\alpha$ -induced expression of ICAM-1, VCAM-1, and E-selectin were all strongly inhibited by *Gax* expression (Figure 8). This is consistent with a role for *Gax* in inhibiting NF- $\kappa$ B-dependent gene expression. In addition, we noted that mRNAs for proangiogenic peptides such as VEGF and bFGF were also downregulated, at least at the message level (Figure 9). These observations are suggestive of a role for *Gax* in not only blocking NF- $\kappa$ B-dependent gene

## DOD Career Development Award

activity but for potentially blocking angiogenesis through inhibition of the autocrine stimulation of ECs.




**Figure 8. Effect of *Gax* expression on the level of E-selectin, VCAM-1, and ICAM-1.** **A.** Quantitative real time PCR. Cells were harvested for total RNA isolation. Total RNA was then subjected to quantitative real time RT-PCR using TaqMan primers and probes specific for each gene and the results normalized to GAPDH. Units were chosen such that controls were set to 100. A very strong downregulation of E-selectin, VCAM-1, and ICAM-1 message level was observed. **B.** *Gax* downregulates VCAM-1 and ICAM-1 proteins. HUVECs were transduced with Ad.rGax or Ad.GFP and then incubated overnight. Cells were harvested for total protein and 50  $\mu$ g protein was subjected to Western blot with appropriate antibodies. (C= control with no virus; GFP=Ad.GFP; Gax=Ad.rGax). E-selectin could not be visualized in unstimulated HUVECs. **C.** *Gax* blocks upregulation of VCAM-1 and E-selectin. HUVECs were transduced with Ad.rGax or Ad.GFP and then incubated overnight, after which they were stimulated with 10 ng/ml TNF- $\alpha$  for one hour. Cells were harvested for total protein and 50  $\mu$ g protein was subjected to Western blot with appropriate antibodies. Expression of *Gax* from the adenoviral vector was verified by Western blot with antibodies against *Gax* previously described. **D.** *Gax* downregulates cell surface expression of ICAM-1, E-selectin, and ICAM-1. HUVECs transduced overnight with either Ad.GFP or Ad.rGax at an MOI=100 were stimulated with TNF- $\alpha$  10 ng/ml for 4 hours and then harvested for flow cytometry using appropriate antibodies. Ad.rGax blocked the expression of VCAM-1, E-selectin, and ICAM-1.

### b. Determination of the effect of *Gax* expression on sequence-specific DNA binding by NF- $\kappa$ B. (Months 24-36.)

## DOD Career Development Award

Status: Not done

**Results and Discussion:** Given that NF- $\kappa$ B activity has been implicated in the changes in phenotype and gene expression ECs undergo during angiogenesis caused by VEGF, TNF- $\alpha$ , and other factors, and that a number of NF- $\kappa$ B targets have been implicated in inducing angiogenesis (61, 73, 80-84), we wished to confirm the finding from cDNA microarray studies that *Gax* inhibits NF- $\kappa$ B activity in ECs. We therefore performed electrophoretic mobility shift assays utilizing nuclear extracts from HUVECs transduced with either Ad.r*Gax* or the control adenoviral vector Ad.GFP to measure binding to a probe containing an NF- $\kappa$ B consensus sequence (85). Specific binding to NF- $\kappa$ B consensus sequence by nuclear extracts from HUVECs transduced with Ad.*Gax* and then induced with TNF- $\alpha$  (10 ng/ml) was much reduced compared to that observed in controls (Figure 10), implying that *Gax* expression interferes with the binding of NF- $\kappa$ B to its consensus sequence. These new data imply that *Gax* also likely inhibits transcriptional activation by NF- $\kappa$ B. This suggests a method by which *Gax* may inhibit angiogenesis in breast cancer and an important hypothesis to test in Year Three.



**Figure 9. *Gax* downregulates proangiogenic factors expressed by ECs.** HUVECs were transduced with either Ad.GFP (control), Ad.r*Gax*, or Ad.h*Gax* at MOI=100. After 24 hrs., cells were harvested for total RNA, which was then subjected to real time quantitative RT-PCR as described (Specific Aim 1). VEGF-C and bFGF message levels were normalized to GAPDH message. Units are arbitrary. A. bFGF. B. VEGF-C.

### c. Determination of the effect of *Gax* expression on transactivation by NF- $\kappa$ B. (Months 24-36.)

Status: In progress.

**Results and Discussion:** We are presently in the process of using the Luciferase reporter plasmid pIL-6-Luc (provided by Dr. Rabson), in which three copies of the IL-6 kB motif are cloned 5' to the IL-6 basal promoter element, to determine if *Gax* expression inhibits NF- $\kappa$ B transcriptional activation. If it does, then we will proceed as soon as possible with experiments to determine the levels of nuclear NF- $\kappa$ B subunits, whether *Gax* inhibits NF- $\kappa$ B localization to the nucleus, or whether it interacts with I $\kappa$ Bs or IKKs. We now note that there is at least one other homeobox gene (Cdx2) that similarly inhibits NF- $\kappa$ B, doing so by directly binding to the p65 subunit (86). However, to the best of our knowledge, no other homeobox gene has been described that directly inhibits NF- $\kappa$ B activity in ECs, particularly homeobox genes implicated in regulating angiogenesis.




## DOD Career Development Award

### d. Determination of the effect of *Gax* expression on NF- $\kappa$ B expression and signaling. (Months 24-36.)


Status: In progress.

**Results and Discussion:** With the help of our new collaborator, Dr. Arnold Rabson (UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ), we are developing the necessary assays to measure NF- $\kappa$ B expression by Western blot and to measure NF- $\kappa$ B signaling by measuring IKK activity and I $\kappa$ B activity. We will also determine the effects of *Gax* expression on the nuclear translocation of the NF- $\kappa$ B complex in response to stimulation by factors known to induce NF- $\kappa$ B activity in ECs, including VEGF and TNF- $\alpha$ .


A.



B.



C.



**Figure 10. *Gax* expression inhibits NF- $\kappa$ B binding to its consensus sequence.** A. *Gax* blocks NF- $\kappa$ B binding to its consensus sequence. HUVECs were infected with adenovirus containing GFP or r*Gax*, incubated overnight in EGM-2, and then induced with 10 ng/ml TNF- $\alpha$  for 1 hour. Controls were not induced with TNF- $\alpha$ . Nuclear extracts were prepared with the NE-PER nuclear extraction reagent (Pierce). Nuclear extracts were incubated with biotinylated oligonucleotides, containing the consensus NF- $\kappa$ B binding site, and the reactions were electrophoresed on a 6% acrylamide gel, transferred to positively charged nylon membranes, and detected with the LightShift EMSA kit (Pierce). Arrows denote NF- $\kappa$ B specific bands, and bands at the bottom of the gels represent unbound probe. B and C. Control EMSAs. These demonstrate failure of a random sequence oligonucleotide and an NF- $\kappa$ B consensus sequence with a point mutation that abolishes DNA binding to compete with wild-type NF- $\kappa$ B sequence (B) and competition with an excess of unlabeled wild-type NF- $\kappa$ B oligonucleotide (C). **Legend:** NT=no treatment; NV=no virus



## **DOD Career Development Award**

### **KEY RESEARCH ACCOMPLISHMENTS**

Our key research accomplishments during the past year include:

1. Demonstrated that mitogens and proangiogenic factors regulate *Gax* expression in ECs in a manner similar to that observed in vascular smooth muscle cells, with its expression maximal in quiescent cells and rapidly downregulated after ECs are treated with mitogens, VEGF, or bFGF.
2. Demonstrated that proangiogenic factors secreted by breast cancer cells downregulate *Gax* expression in ECs.
3. Completed analysis of initial cDNA microarray data obtained near the end of Year One and showed that *Gax* downregulates the expression of NF- $\kappa$ B-dependent genes.
4. Confirmed cDNA microarray results for several genes identified in our initial cDNA microarray experiment at the message and protein level.
5. Demonstrated that *Gax* expression inhibits EC migration towards serum and proangiogenic stimuli.
6. Determined that *Gax* expression inhibits angiogenesis *in vivo* in the Matrigel plug assay.

### **REPORTABLE OUTCOMES**

#### **Abstracts**

1. Patel, S., and D. H. Gorski (2004). Inhibition of endothelial cell activation and angiogenesis by the homeobox gene *Gax* is associated with downregulation of nuclear factor- $\kappa$ B (NF- $\kappa$ B)-dependent gene expression. *Proc. Amer. Assoc. Cancer Res.* 45:77. Presented at the Annual Meeting of the American Association for Cancer Research, Orlando, FL, March 28, 2004

#### **Journal articles:**

1. Gorski DH and AD Leal (2003). Inhibition of endothelial cell activation by the homeobox gene *Gax*. *J. Surg. Res.* 111: 91-99.
2. Gorski DH, and K Walsh (2003). Control of vascular cell differentiation by homeobox transcription factors. *Trends Cardiovasc Med* 13: 213-220.
3. Patel S, Leal AD, and DH Gorski (2004). The homeobox gene *Gax* inhibits angiogenesis through inhibition of nuclear factor- $\kappa$ B-dependent endothelial cell gene expression. *Mol. Cell. Biol.* In review.

#### **Funding applied for based on work done on this project:**

1 R01 CA111344-01	1/1/2005 –	40%
National Cancer Institute	12/31/2009	effort
Role: Principal investigator	\$ 1,749,375 (total	
<i>Mechanism of angiogenesis inhibition by a homeobox gene</i>	direct + indirect	
Status: Under review.	costs)	

## DOD Career Development Award

### CONCLUSIONS

Homeobox genes are master regulatory genes with diverse functions in many cell types, both during embryogenesis and in the adult (1, 3, 4, 6, 87). It is therefore not surprising that recently they have been implicated as important transcriptional regulators controlling endothelial cell phenotype during tumor-induced angiogenesis (7, 8, 10, 13, 15, 52). Until recently, little was known about how homeobox genes might influence endothelial cell phenotype and behavior during breast cancer-induced angiogenesis. However, evidence for their involvement in the phenotypic changes endothelial cells undergo during angiogenesis is now accumulating. For instance, Patel *et al* reported an endothelial cell-specific variant of *HOXA9* whose expression is regulated by tumor necrosis factor- $\alpha$ , which is proangiogenic (88). More direct evidence for the importance of homeobox genes in angiogenesis exists for *HOXD3* (7). *In vivo*, sustained expression of *HOXD3* on the chick chorioallantoic membrane (CAM) retains endothelial cells in an invasive state and prevents vessel maturation, leading to vascular malformations and endotheliomas. In diabetic mice, *HOXD3* expression is impaired in endothelial cells, as is its upregulation after wounding (52). Moreover, *HOXD3* expression is elevated in breast cancer tumor vasculature as compared to normal vasculature, as measured by *in situ* hybridization (9). More recently, overexpression of another homeobox gene, *HOXB3* has been shown to result in an increase in capillary vascular density and angiogenesis, and its blockade by antisense results in impaired capillary morphogenesis (8). In contrast, *HOXD10* inhibits EC conversion to the angiogenic phenotype, and sustained expression of *HOXD10* inhibits EC migration and blocks bFGF- and VEGF-induced angiogenesis *in vivo* (89). Consistent with this, *HOXD10* expression is decreased in breast cancer vasculature (10). Another homeobox gene, *Hex*, has a more complex role, being upregulated in angiogenic vasculature (11, 14, 15) during embryogenesis but inhibiting angiogenesis *in vitro* and *in vivo* (12, 13). Taken together, these data suggest significant roles for specific homeobox genes in responding to extracellular signals and activating batteries of downstream genes to induce or inhibit the phenotypic changes in endothelial cells associated with angiogenesis. These observations are what initially led us to look for additional homeobox genes likely to be involved in the final transcriptional control of genes determining angiogenic phenotype in breast cancer. Because blocking aberrant angiogenesis has the potential to be an effective strategy to treat or prevent multiple diseases, understanding how downstream transcription factors integrate upstream signals from pro- and anti-angiogenic factors to alter global gene expression and produce the activated, angiogenic phenotype, will be increasingly important in developing effective antiangiogenic therapies for breast cancer.

Based on our data, we postulated that at least one additional homeobox gene, *Gax*, is also likely to have an important role in the phenotypic changes that occur in ECs during angiogenesis and therefore wanted to study its role in regulating breast cancer-induced angiogenesis. We originally isolated *Gax* from a rat aorta library (17), and subsequently we found that in the adult its expression is restricted primarily to mesodermal tissues, particularly the cardiovascular system (17, 18), as have others (20, 90). Moreover, *Gax* expression is rapidly downregulated by growth factors and more slowly upregulated by growth arrest signals in VSMCs both *in vitro* and *in vivo* (17, 30, 32), and its expression results in cell cycle arrest (16, 28), p21 induction (16, 28), inhibition of migration (31), and modulation of integrin expression (31). *In vivo*, *Gax* expression in injured vasculature prevents the proliferative response that leads to restenosis after balloon angioplasty (23, 24, 27, 28). Based on these observations, we examined *Gax* expression in

### DOD Career Development Award

vascular ECs. We found that *Gax* is expressed in this cell type and that it has many of the same activities as in VSMCs. In addition, its expression inhibited EC tube formation on Matrigel *in vivo* (16). These observations led us to the present study, in which we wished to elucidate further the role(s) *Gax* may have in regulating angiogenesis, in particular breast cancer-induced angiogenesis. Consistent with its regulation in VSMCs, in ECs, *Gax* is rapidly downregulated by serum, proangiogenic, and pro-inflammatory factors (Figures 1 and 2), and is able to inhibit EC migration *in vitro* (Figure 5) and angiogenesis *in vivo* (Figure 6). These observations led us to examine the mechanism by which *Gax* inhibits EC activation utilizing cDNA microarrays to examine global changes in gene expression due to *Gax*. In addition to observing that *Gax* upregulates cyclin kinase inhibitors (Table 2) and downregulates a number of proangiogenic factors (Table 1), we also found that *Gax* inhibits the expression of a number of NF- $\kappa$ B target genes (Table 1). Consistent with the cDNA microarray data, *Gax* inhibits the binding of NF- $\kappa$ B to its consensus sequence (Figure 10).

The NF- $\kappa$ B/Rel proteins are an important class of transcriptional regulators that play a central role in modulating the immune response and promoting inflammation and cancer by regulating the expression of genes involved in cell growth, differentiation, and apoptosis. In many cell types, NF- $\kappa$ B promotes cell survival in response to pro-apoptotic stimuli, induces cellular proliferation, or alters cell differentiation. The NF- $\kappa$ B/Rel family is composed of at least five mammalian homologs, c-Rel, RelA (p65), RelB, p50/p105 (NF- $\kappa$ B1), and p52/p100 (NF- $\kappa$ B2), which form an array of homo- and heterodimers, known as the NF- $\kappa$ B complex (72). In most cell types, NF- $\kappa$ B exists in the cytoplasm as an inactive form bound to inhibitory proteins known as I $\kappa$ Bs. In the classical pathway of NF- $\kappa$ B activation, NF- $\kappa$ B inducers, such as TNF- $\alpha$  and other proinflammatory cytokines, growth factors, UV light, oxidative stress, and bacterial lipopolysaccharide, initiate a signaling cascade ultimately leading to the nuclear translocation of p50/RelA heterodimers, resulting from signal-induced phosphorylation of I $\kappa$ B by I $\kappa$ B kinase (IKK), which targets it for ubiquitination (72, 91). In addition to this classical pathway of NF- $\kappa$ B activation, a non-canonical pathway involving activation of p52-containing dimers through regulated processing of the p100 precursor protein (72, 91).

Several lines of evidence have implicated NF- $\kappa$ B activity in regulating EC phenotype during inflammation and angiogenesis and, in particular, the classic activation of RelA-containing heterodimers (61, 69, 73, 80-83, 92). For example, proangiogenic factors such as VEGF (69), TNF- $\alpha$  (92), and platelet-activating factor (73) can all activate NF- $\kappa$ B signaling and activity in ECs. In addition, inhibition of NF- $\kappa$ B activity inhibits EC tube formation *in vitro* on Matrigel (83, 93), and pharmacologic inhibition of NF- $\kappa$ B activity suppresses retinal neovascularization *in vivo* in mice. (94) Moreover, ligation of EC integrin  $\alpha_v\beta_3$  by osteopontin protects ECs against apoptosis induced by serum withdrawal, an effect that is due to NF- $\kappa$ B-dependent expression of osteopontin (81). Similarly,  $\alpha_5\beta_1$ -mediated adhesion to fibronectin also activates NF- $\kappa$ B signaling and is important for angiogenesis, and inhibition of NF- $\kappa$ B signaling inhibits bFGF-induced angiogenesis (61). One potential mechanism by which NF- $\kappa$ B signaling may promote angiogenesis is through an autocrine effect, whereby activation of NF- $\kappa$ B induces expression of proangiogenic factors such as VEGF, as has been reported for platelet-activating factor-induced angiogenesis (73). Alternatively, the involvement of NF- $\kappa$ B in activating EC survival pathways is also likely to be important for sustaining angiogenesis (93).

### DOD Career Development Award

Although NF- $\kappa$ B activity can influence the expression of homeobox genes (88, 95), there have been relatively few reports of functional interactions between homeodomain-containing proteins and NF- $\kappa$ B proteins. The first such interaction reported was between I $\kappa$ B $\alpha$  and HOXB7, where I $\kappa$ B $\alpha$  was found to bind through its ankyrin repeats to the HOXB7 protein and potentiate HOXB7-dependent gene expression (96). More recently, it was reported that I $\kappa$ B $\alpha$  can also potentiate the activity of other homeobox genes, including *Pit-1* and *Pax-8*, through the sequestration of specific histone deacetylases (97). In contrast, Oct-1 can compete with NF- $\kappa$ B for binding to a specific binding site in the TNF- $\alpha$  promoter (98). In addition, at least one interaction has been described in which a homeobox gene directly inhibits NF- $\kappa$ B-dependent gene expression, an interaction in which Cdx2 blocks activation of the COX-2 promoter by binding p65/RelA (86). It remains to be elucidated whether *Gax* inhibits NF- $\kappa$ B-dependent gene expression by a similar mechanism or a different one. Regardless of the mechanism, however, our observations made while doing the research funded by this Idea Award, to our knowledge, represent the first description of a homeobox gene that not only inhibits phenotypic changes that occur in ECs in response to proangiogenic factors, but also inhibits NF- $\kappa$ B-dependent gene expression in vascular ECs. These properties suggest *Gax* as a potential target for the antiangiogenic therapy of breast cancer. In addition, understanding the actions of *Gax* on downstream target genes, signals that activate or repress *Gax* expression, and how *Gax* regulates NF- $\kappa$ B activity in ECs is likely to lead to a better understanding of the mechanisms of breast cancer-induced angiogenesis and the identification of new molecular targets for the antiangiogenic therapy of breast cancer.

### REFERENCES

1. Cillo C, A Faiella, M Cantile, and E Boncinelli (1999). Homeobox genes and cancer. *Exp Cell Res* **248**: 1-9.
2. Gorski DH and K Walsh (2003). Control of vascular cell differentiation by homeobox transcription factors. *Trends Cardiovasc Med* **13**: 213-220.
3. Krumlauf R (1994). Hox genes in vertebrate development. *Cell* **78**: 191-201.
4. McGinnis W and R Krumlauf (1992). Homeobox genes and axial patterning. *Cell* **68**: 283-302.
5. Ford HL (1998). Homeobox genes: a link between development, cell cycle, and cancer? *Cell Biol Int* **22**: 397-400.
6. Scott MP, JW Tamkun, and GWI Hartzell (1989). The structure and function of the homeodomain. *Biochim. Biophys. Acta* **989**: 25-48.
7. Boudreau N, C Andrews, A Srebrow, A Ravanpay, and DA Cheresch (1997). Induction of the angiogenic phenotype by Hox D3. *J Cell Biol* **139**: 257-264.
8. Myers C, A Charboneau, and N Boudreau (2000). Homeobox B3 promotes capillary morphogenesis and angiogenesis. *J Cell Biol* **148**: 343-351.
9. Boudreau NJ and JA Varner (2004). The homeobox transcription factor Hox D3 promotes integrin  $\alpha_5\beta_1$  expression and function during angiogenesis. *J Biol Chem* **279**: 4862-4868.

### DOD Career Development Award

10. Myers C, A Charboneau, I Cheung, D Hanks, and N Boudreau (2002). Sustained expression of homeobox d10 inhibits angiogenesis. *Am J Pathol* **161**: 2099-2109.
11. Guo Y, R Chan, H Ramsey, W Li, X Xie, WC Shelley, JP Martinez-Barbera, B Bort, K Zaret, M Yoder, and R Hromas (2003). The homeoprotein Hex is required for hemangioblast differentiation. *Blood*.
12. Minami T, T Murakami, K Horiuchi, M Miura, T Noguchi, JI Miyazaki, T Hamakubo, WC Aird, and T Kodama (2004). Interaction between Hex and GATA transcription factors in vascular endothelial cells inhibits flk-1/KDR-mediated VEGF signaling. *J Biol Chem*.
13. Nakagawa T, M Abe, T Yamazaki, H Miyashita, H Niwa, S Kokubun, and Y Sato (2003). HEX Acts as a Negative Regulator of Angiogenesis by Modulating the Expression of Angiogenesis-Related Gene in Endothelial Cells In Vitro. *Arterioscler Thromb Vasc Biol* **23**: 231-237.
14. Newman CS, F Chia, and PA Krieg (1997). The XHex homeobox gene is expressed during development of the vascular endothelium: overexpression leads to an increase in vascular endothelial cell number. *Mech Dev* **66**: 83-93.
15. Thomas PQ, A Brown, and RS Beddington (1998). Hex: a homeobox gene revealing peri-implantation asymmetry in the mouse embryo and an early transient marker of endothelial cell precursors. *Development* **125**: 85-94.
16. Gorski DH and AD Leal (2003). Inhibition of endothelial cell activation by the homeobox gene *Gax*. *J. Surg. Res.* **111**: 91-99.
17. Gorski DH, DF LePage, CV Patel, NG Copeland, NA Jenkins, and K Walsh (1993). Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G<sub>0</sub>/G<sub>1</sub> transition in vascular smooth muscle cells. *Mol. Cell. Biol.* **13**: 3722-3733.
18. Skopicki HA, GE Lyons, G Schatteman, RC Smith, V Andres, S Schirm, J Isner, and K Walsh (1997). Embryonic expression of the *Gax* homeodomain protein in cardiac, smooth, and skeletal muscle. *Circ Res* **80**: 452-462.
19. Andrés V, S Fisher, P Wearsch, and K Walsh (1995). Regulation of *Gax* homeobox gene transcription by a combination of positive factors including myocyte-specific enhancer factor 2. *Mol Cell Biol* **15**: 4272-4281.
20. Candia AF and CV Wright (1995). The expression pattern of *Xenopus Mox-2* implies a role in initial mesodermal differentiation. *Mech Dev* **52**: 27-36.
21. Fisher SA, E Siwik, D Branellec, K Walsh, and M Watanabe (1997). Forced expression of the homeodomain protein *Gax* inhibits cardiomyocyte proliferation and perturbs heart morphogenesis. *Development* **124**: 4405-4413.
22. LePage DF, DA Altomare, JR Testa, and K Walsh (1994). Molecular cloning and localization of the human GAX gene to 7p21. *Genomics* **24**: 535-540.
23. Maillard L, E Van Belle, RC Smith, A Le Roux, P Deneffe, G Steg, JJ Barry, D Branellec, JM Isner, and K Walsh (1997). Percutaneous delivery of the *gax* gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. *Cardiovasc Res* **35**: 536-546.

### DOD Career Development Award

24. Maillard L, E Van Belle, FO Tio, A Rivard, M Kearney, D Branellec, PG Steg, JM Isner, and K Walsh (2000). Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. *Gene Ther.* **7**: 1353-1361.
25. Mankoo BS, NS Collins, P Ashby, E Grigorieva, LH Pevny, A Candia, CV Wright, PW Rigby, and V Pachnis (1999). Mox2 is a component of the genetic hierarchy controlling limb muscle development. *Nature* **400**: 69-73.
26. Perlman H, M Sata, A Le Roux, TW Sedlak, D Branellec, and K Walsh (1998). Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity. *EMBO J* **17**: 3576-3586.
27. Perlman H, Z Luo, K Krasinski, A Le Roux, A Mahfoudi, RC Smith, D Branellec, and K Walsh (1999). Adenoviral-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis. *Gene Ther* **6**: 758-763.
28. Smith RC, D Branellec, DH Gorski, K Guo, H Perlman, JF Dedieu, C Pastore, A Mahfoudi, P Deneffe, JM Isner, and K Walsh (1997). p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. *Genes Dev* **11**: 1674-1689.
29. Stamatakis D, M Kastrinaki, BS Mankoo, V Pachnis, and D Karagogeos (2001). Homeodomain proteins Mox1 and Mox2 associate with Pax1 and Pax3 transcription factors. *FEBS Lett* **499**: 274-278.
30. Weir L, D Chen, C Pastore, JM Isner, and K Walsh (1995). Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. *J Biol Chem* **270**: 5457-5461.
31. Witzembichler B, Y Kureishi, Z Luo, A Le Roux, D Branellec, and K Walsh (1999). Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. *J Clin Invest* **104**: 1469-1480.
32. Yamashita J, H Itoh, Y Ogawa, N Tamura, K Takaya, T Igaki, K Doi, TH Chun, M Inoue, K Masatsugu, and K Nakao (1997). Opposite regulation of Gax homeobox expression by angiotensin II and C-type natriuretic peptide. *Hypertension* **29**: 381-387.
33. Bustin SA (2000). Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol* **25**: 169-193.
34. Fidler IJ, R Kumar, DR Bielenberg, and LM Ellis (1998). Molecular determinants of angiogenesis in cancer metastasis. *Cancer J Sci Am* **4 Suppl 1**: S58-66.
35. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* **1**: 27-31.
36. Weidner N, JP Semple, WR Welch, and J Folkman (1991). Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. *N. Engl. J. Med.* **324**: 1-8.
37. Weidner N, J Folkman, F Pozza, P Bevilacqua, EN Allred, DH Moore, S Meli, and G Gasparini (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. *J Natl Cancer Inst* **84**: 1875-1887.



### DOD Career Development Award

38. Folkman J (1995). The influence of angiogenesis research on management of patients with breast cancer. *Breast Cancer Res Treat* **36**: 109-118.
39. Gorski DH, MA Beckett, NT Jaskowiak, DP Calvin, HJ Mauceri, RM Salloum, S Seetharam, A Koons, DM Hari, DW Kufe, and RR Weichselbaum (1999). Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. *Cancer Res* **59**: 3374-3378.
40. Gorski DH, HJ Mauceri, RM Salloum, A Halpern, S Seetharam, and RR Weichselbaum (2003). Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. *Cancer Res* **63**: 308-311.
41. Mauceri H, N Hanna, M Beckett, DH Gorski, MJ Staba, KA Stellato, K Bigelow, R Heimann, S Gately, M Dhanabal, G Soff, VP Sukhatme, D Kufe, and RR Weichselbaum (1998). Combined effects of angiostatin and ionizing radiation in anti-tumour therapy. *Nature* **394**: 287-291.
42. Bachetti T and L Morbidelli (2000). Endothelial cells in culture: a model for studying vascular functions. *Pharmacol Res* **42**: 9-19.
43. Bell SE, A Mavila, R Salazar, KJ Bayless, S Kanagala, SA Maxwell, and GE Davis (2001). Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. *J Cell Sci* **114**: 2755-2773.
44. St. Croix B, C Rago, V Velculescu, G Traverso, KE Romans, E Montgomery, A Lal, GJ Riggins, C Lengauer, B Vogelstein, and KW Kinzler (2000). Genes expressed in human tumor endothelium. *Science* **289**: 1197-1202.
45. Cross MJ and L Claesson-Welsh (2001). FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. *Trends Pharmacol Sci* **22**: 201-207.
46. Josko J, B Gwozdz, H Jedrzejowska-Szypulka, and S Hendryk (2000). Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. *Med Sci Monit* **6**: 1047-1052.
47. Berra E, J Milanini, DE Richard, M Le Gall, F Vinals, E Gothie, D Roux, G Pages, and J Pouyssegur (2000). Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. *Biochem Pharmacol* **60**: 1171-1178.
48. Fuh G, B Li, C Crowley, B Cunningham, and JA Wells (1998). Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. *J Biol Chem* **273**: 11197-11204.
49. Fujio Y and K Walsh (1999). Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. *J Biol Chem* **274**: 16349-16354.
50. Krumlauf R (1992). Evolution of the vertebrate Hox homeobox genes. *Bioessays* **14**: 245-252.
51. Ford HL, EN Kabingu, EA Bump, GL Mutter, and AB Pardee (1998). Abrogation of the G2 cell cycle checkpoint associated with overexpression of HSIX1: a possible mechanism of breast carcinogenesis. *Proc Natl Acad Sci USA* **95**: 12608-12613.

### DOD Career Development Award

52. Uyeno LA, JA Newman-Keagle, I Cheung, TK Hunt, DM Young, and N Boudreau (2001). Hox D3 expression in normal and impaired wound healing. *J Surg Res* **100**: 46-56.
53. Friedlander M, PC Brooks, RW Shaffer, CM Kincaid, JA Varner, and DA Cheresch (1995). Definition of two angiogenic pathways by distinct alpha v integrins. *Science* **270**: 1500-1502.
54. Gorski DH, DF LePage, and K Walsh (1994). Cloning and sequence analysis of homeobox transcription factor cDNAs with an inosine-containing probe. *Biotechniques* **16**: 856-865.
55. Unger RE, V Krump-Konvalinkova, K Peters, and CJ Kirkpatrick (2002). In Vitro Expression of the Endothelial Phenotype: Comparative Study of Primary Isolated Cells and Cell Lines, Including the Novel Cell Line HPMEC-ST1.6R. *Microvasc Res* **64**: 384-397.
56. Ades EW, FJ Candal, RA Swerlick, VG George, S Summers, DC Bosse, and TJ Lawley (1992). HMEC-1: establishment of an immortalized human microvascular endothelial cell line. *J Invest Dermatol* **99**: 683-690.
57. O'Reilly MS, L Holmgren, Y Shing, C Chen, RA Rosenthal, M Moses, WS Lane, Y Cao, EH Sage, and J Folkman (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. *Cell* **79**: 315-328.
58. O'Reilly MS, T Boehm, Y Shing, N Fukai, G Vasios, WS Lane, E Flynn, JR Birkhead, BR Olsen, and J Folkman (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. *Cell* **88**: 277-285.
59. Chan FK, J Zhang, L Cheng, DN Shapiro, and A Winoto (1995). Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. *Mol Cell Biol* **15**: 2682-2688.
60. Tsugu A, K Sakai, PB Dirks, S Jung, R Weksberg, YL Fei, S Mondal, S Ivanchuk, C Ackerley, PA Hamel, and JT Rutka (2000). Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. *Am J Pathol* **157**: 919-932.
61. Klein S, AR de Fougères, P Blaikie, L Khan, A Pepe, CD Green, V Kotliansky, and FG Giancotti (2002). Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. *Mol Cell Biol* **22**: 5912-5922.
62. Isaji M, H Miyata, Y Ajisawa, Y Takehana, and N Yoshimura (1997). Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. *Br J Pharmacol* **122**: 1061-1066.
63. Kim HS, C Skurk, SR Thomas, A Bialik, T Suhara, Y Kureishi, M Birnbaum, JF Keaney, Jr., and K Walsh (2002). Regulation of angiogenesis by glycogen synthase kinase-3beta. *J Biol Chem* **277**: 41888-41896.
64. Nagata D, M Mogi, and K Walsh (2003). AMP-activated protein kinase (AMPK) signaling in endothelial cells is essential for angiogenesis in response to hypoxic stress. *J Biol Chem* **278**: 31000-31006.
65. Riccioni T, C Cirielli, X Wang, A Passaniti, and MC Capogrossi (1998). Adenovirus-mediated wild-type p53 overexpression inhibits endothelial cell differentiation in vitro and angiogenesis in vivo. *Gene Ther* **5**: 747-754.



### **DOD Career Development Award**

66. Krump-Konvalinkova V, F Bittinger, RE Unger, K Peters, HA Lehr, and CJ Kirkpatrick (2001). Generation of human pulmonary microvascular endothelial cell lines. *Lab Invest* **81**: 1717-1727.
67. Dias S, M Choy, and S Rafii (2001). The role of CXC chemokines in the regulation of tumor angiogenesis. *Cancer Invest* **19**: 732-738.
68. Dias S, M Choy, K Alitalo, and S Rafii (2002). Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. *Blood* **99**: 2179-2184.
69. Kim II, SO Moon, SH Kim, HJ Kim, YS Koh, and GY Koh (2000). VEGF stimulates expression of ICAM-1, VCAM-1 and E-selectin through nuclear factor-kappaB activation in endothelial cells. *J Biol Chem* **275**: 6.
70. Yasuda M, S Shimizu, K Ohhina, S Naito, S Tokuyama, Y Mori, Y Kiuchi, and T Yamamoto (2002). Differential roles of ICAM-1 and E-selectin in polymorphonuclear leukocyte-induced angiogenesis. *Am J Physiol Cell Physiol* **282**: C917-925.
71. Doniger SW, N Salomonis, KD Dahlquist, K Vranizan, SC Lawlor, and BR Conklin (2003). MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. *Genome Biol* **4**: R7.
72. Ghosh S and M Karin (2002). Missing pieces in the NF-kappaB puzzle. *Cell* **109** Suppl: S81-96.
73. Ko HM, KH Seo, SJ Han, KY Ahn, IH Choi, GY Koh, HK Lee, MS Ra, and SY Im (2002). Nuclear factor kappaB dependency of platelet-activating factor-induced angiogenesis. *Cancer Res* **62**: 1809-1814.
74. Scatena M and C Giachelli (2002). The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. *Trends Cardiovasc Med* **12**: 83-88.
75. Hu MC, TD Piscione, and ND Rosenblum (2003). Elevated SMAD1/beta-catenin molecular complexes and renal medullary cystic dysplasia in ALK3 transgenic mice. *Development* **130**: 2753-2766.
76. Goumans MJ, G Valdimarsdottir, S Itoh, A Rosendahl, P Sideras, and P ten Dijke (2002). Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. *EMBO J* **21**: 1743-1753.
77. Goumans MJ, G Valdimarsdottir, S Itoh, F Lebrin, J Larsson, C Mummery, S Karlsson, and P ten Dijke (2003). Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. *Mol Cell* **12**: 817-828.
78. Cheng CW, SK Smith, and DS Charnock-Jones (2003). Wnt-1 signaling inhibits human umbilical vein endothelial cell proliferation and alters cell morphology. *Exp Cell Res* **291**: 415-425.
79. Goodwin AM and PA D'Amore (2002). Wnt signaling in the vasculature. *Angiogenesis* **5**: 1-9.

### DOD Career Development Award

80. Oitzinger W, R Hofer-Warbinek, JA Schmid, Y Koshelnick, BR Binder, and R de Martin (2001). Adenovirus-mediated expression of a mutant IkappaB kinase 2 inhibits the response of endothelial cells to inflammatory stimuli. *Blood* **97**: 1611-1617.
81. Malyankar UM, M Scatena, KL Suchland, TJ Yun, EA Clark, and CM Giachelli (2000). Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. *J Biol Chem* **275**: 20959-20962.
82. Scatena M, M Almeida, ML Chaisson, N Fausto, RF Nicosia, and CM Giachelli (1998). NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival. *J Cell Biol* **141**: 1083-1093.
83. Shono T, M Ono, H Izumi, SI Jimi, K Matsushima, T Okamoto, K Kohno, and M Kuwano (1996). Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. *Mol Cell Biol* **16**: 4231-4239.
84. Min JK, YM Kim, EC Kim, YS Gho, IJ Kang, SY Lee, YY Kong, and YG Kwon (2003). Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. *J Biol Chem* **278**: 39548-39557.
85. Tian Y, S Ke, MS Denison, AB Rabson, and MA Gallo (1999). Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. *J Biol Chem* **274**: 510-515.
86. Kim SP, JW Park, SH Lee, JH Lim, BC Jang, IH Jang, JN Freund, SI Suh, KC Mun, DK Song, EM Ha, WJ Lee, and TK Kwon (2004). Homeodomain protein CDX2 regulates COX-2 expression in colorectal cancer. *Biochem Biophys Res Commun* **315**: 93-99.
87. Krumlauf R (2002). Spring forward and fall back: dynamics in formation of somite boundaries. *Dev Cell* **3**: 605-606.
88. Patel CV, R Sharangpani, S Bandyopadhyay, and PE DiCorleto (1999). Endothelial cells express a novel, tumor necrosis factor-alpha-regulated variant of HOXA9. *J Biol Chem* **274**: 1415-1422.
89. Nor JE, MC Peters, JB Christensen, MM Sutorik, S Linn, MK Khan, CL Addison, DJ Mooney, and PJ Polverini (2001). Engineering and characterization of functional human microvessels in immunodeficient mice. *Lab Invest* **81**: 453-463.
90. Candia AF and CV Wright (1996). Differential localization of *Mox-1* and *Mox-2* proteins indicates distinct roles during development. *Int J Dev Biol* **40**: 1179-1184.
91. De Martin R, M Hoeth, R Hofer-Warbinek, and JA Schmid (2000). The transcription factor NF-kappa B and the regulation of vascular cell function. *Arterioscler Thromb Vasc Biol* **20**: E83-88.
92. Vanderslice P, CL Munsch, E Rachal, D Erichsen, KM Sughrue, AN Truong, JN Wygant, BW McIntyre, SG Eskin, RG Tilton, and PJ Polverini (1998). Angiogenesis induced by tumor necrosis factor-alpha is mediated by alpha4 integrins. *Angiogenesis* **2**: 265-275.
93. Goto D, H Izumi, M Ono, T Okamoto, K Kohno, and M Kuwano (1998). Tubular morphogenesis by genotoxic therapeutic agents that induce NF-kappaB activation in human vascular endothelial cells. *Angiogenesis* **2**: 345-356.

### **DOD Career Development Award**

94. Yoshida A, S Yoshida, T Ishibashi, M Kuwano, and H Inomata (1999). Suppression of retinal neovascularization by the NF-kappaB inhibitor pyrrolidine dithiocarbamate in mice. *Invest Ophthalmol Vis Sci* **40**: 1624-1629.
95. Bushdid PB, CL Chen, DM Brantley, F Yull, R Raghow, LD Kerr, and JV Barnett (2001). NF-kappaB mediates FGF signal regulation of msx-1 expression. *Dev Biol* **237**: 107-115.
96. Chariot A, F Princen, J Gielen, MP Merville, G Franzoso, K Brown, U Siebenlist, and V Bours (1999). IkappaB-alpha enhances transactivation by the HOXB7 homeodomain-containing protein. *J Biol Chem* **274**: 5318-5325.
97. Viatour P, S Legrand-Poels, C van Lint, M Warnier, MP Merville, J Gielen, J Piette, V Bours, and A Chariot (2003). Cytoplasmic IkappaBalpha increases NF-kappaB-independent transcription through binding to histone deacetylase (HDAC) 1 and HDAC3. *J Biol Chem* **278**: 46541-46548.
98. van Heel DA, IA Udalova, AP De Silva, DP McGovern, Y Kinouchi, J Hull, NJ Lench, LR Cardon, AH Carey, DP Jewell, and D Kwiatkowski (2002). Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors. *Hum Mol Genet* **11**: 1281-1289.

### **APPENDICES**

Publications during period of report:

1. **Gorski DH** and AD Leal (2003). Inhibition of endothelial cell activation by the homeobox gene *Gax*. *J. Surg. Res.* **111**: 91-99.
2. **Gorski DH** and K Walsh (2003). Control of vascular cell differentiation by homeobox transcription factors. *Trends Cardiovasc Med* **13**: 213-220.
3. Patel, S, Leal, AD, and **DH Gorski** (2004). The homeobox gene *Gax* inhibits endothelial cell activation, angiogenesis, and nuclear factor kB activity. *Mol. Cell. Biol.* *In review.*

## Inhibition of Endothelial Cell Activation by the Homeobox Gene *Gax*

David H. Gorski, M.D., Ph.D., F.A.C.S.<sup>1</sup> and Alejandro D. Leal, B.S.

Division of Surgical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey,  
New Brunswick, New Jersey 08901, USA

Submitted for publication July 1, 2002

**Background.** Angiogenesis is critical to tumor growth. *Gax*, a homeobox transcription factor whose expression in the adult is restricted mainly to the cardiovascular system, strongly inhibits growth factor-stimulated phenotypic modulation of vascular smooth muscle cells *in vitro* and *in vivo*. The function of *Gax* in vascular endothelium is unknown, but we hypothesized that it may play a similar role there. We therefore studied *Gax* expression in vascular endothelial cells and its effects on proliferation and tube formation.

**Materials and methods.** *Gax* expression in normal endothelial cells was examined *in vitro* by Northern blot and reverse transcriptase polymerase chain reaction and *in vivo* by immunohistochemistry. A replication-deficient adenovirus was then used to express *Gax* in human umbilical vein endothelial cells (HUVECs). HUVEC proliferation, <sup>3</sup>H-thymidine uptake, p21 expression, and tube formation on reconstituted basement membrane were measured at different viral multiplicities of infection.

**Results.** *Gax* mRNA was detected in HUVECs by reverse transcriptase polymerase chain reaction and Northern blot analysis and in normal vascular endothelium by immunohistochemistry. Compared with controls transduced with a virus expressing  $\beta$ -galactosidase, *Gax* strongly inhibited HUVEC proliferation and mitogen-stimulated <sup>3</sup>H-thymidine uptake. p21 expression in HUVECs transduced with *Gax* was increased up to 5-fold as measured by Northern blot, and p21 promoter activity was activated by 4- to 5-fold. Tube formation on Matrigel was strongly inhibited by *Gax* expression.

**Conclusions.** *Gax* is expressed in vascular endothelium and strongly inhibits endothelial cell activation

in response to growth factors and tube formation *in vitro*. These observations suggest that *Gax* inhibits endothelial cell transition to the angiogenic phenotype in response to proangiogenic growth factors and, as a negative regulator of angiogenesis, may represent a target for the antiangiogenic therapy of cancer. © 2003 Elsevier Inc. All rights reserved.

**Key Words:** angiogenesis; homeobox genes; transcription factors; vascular endothelium.

### INTRODUCTION

Vascular remodeling plays a critical role in the biology of tumors, whose growth without a blood supply is limited to less than 1 mm in diameter by diffusion of oxygen and nutrients through the interstitial fluids [1]. To overcome this limitation, tumors secrete proangiogenic factors, such as vascular endothelial growth factor (VEGF) [2] and basic fibroblast growth factor (bFGF) [3], to stimulate the ingrowth of new blood vessels [1, 4]. To form new tumor vasculature, endothelial cells undergo profound phenotypic changes, many of which are similar to the phenotypic changes tumor cells undergo when invading the surrounding stroma [1, 5, 6]. They degrade their basement membrane and invade the surrounding tissue, migrate towards the proangiogenic stimulus secreted by the tumor, and then form tubular structures and finally neovasculature [1, 7]. Although the receptors and signaling pathways activated by proangiogenic factors and cytokines have been extensively studied in endothelial cells [8, 9], much less is known about the molecular biology of the downstream transcription factors that regulate the tissue-specific gene expression controlling endothelial cell growth and differentiation and are activated by these signaling pathways. These transcription factors represent a common mechanism that can be influenced by the interaction of multiple signal-

<sup>1</sup> To whom correspondence should be addressed at Division of Surgical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ 08901. Fax: +1-732-235-8098. E-mail: gorskidh@umdnj.edu.

ing pathways and therefore might represent targets for the antiangiogenic therapy of cancer.

To understand the transcriptional control of tumor-induced angiogenesis and thereby potentially identify new ways to target it therapeutically, we decided to study the role of homeobox transcription factors in regulating the phenotypic changes that occur in endothelial cells when stimulated with proangiogenic factors. Because of their ubiquitous role as regulators of cell proliferation, migration, and differentiation, as well as body plan formation and organogenesis during embryogenesis in vertebrates and invertebrates [10, 11] and as oncogenes and tumor suppressors in various human cancers [12, 13], of all the various classes of transcription factors, we considered homeobox genes as especially likely to be important in regulating endothelial cell phenotype during angiogenesis.

Among homeobox genes, *Gax* (Growth Arrest-specific homeobox) has several characteristics that suggest it as a candidate for a role as an inhibitor of the endothelial cell phenotypic changes that occur as a result of stimulation by proangiogenic factors. Originally isolated from vascular smooth muscle [14], in the adult *Gax* expression is largely restricted to the cardiovascular system [14, 15]. In vascular smooth muscle cells, *Gax* expression is downregulated by mitogens [14, 16] and upregulated by growth arrest signals [14, 17]. Consistent with this observation, *Gax* expression induces G<sub>1</sub> cell cycle arrest [18] and inhibits vascular smooth muscle cell migration, downregulating the expression of integrins,  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  [19], both of which are associated with the synthetic state in vascular smooth muscle cells and the angiogenic phenotype in endothelial cells [19, 20]. *In vivo*, *Gax* expression in arteries inhibits proliferative restenosis of the arterial lumen after injury [21]. Because *Gax* expression is largely confined to the cardiovascular system and mesoderm-derived structures [15, 22], we considered it likely that *Gax* is also expressed in endothelial cells because endothelial cells are also derived from mesoderm. Because of its activities in vascular smooth muscle cells, we further hypothesized that *Gax* may be involved in inhibiting the phenotypic changes that occur in endothelial cells in response to stimulation with proangiogenic factors. In this report, we show that *Gax* is also expressed in vascular endothelial cells and inhibits endothelial cell cycle activation and tube formation in response to proangiogenic factors, suggesting that it has a role as a negative regulator of angiogenesis.

## MATERIALS AND METHODS

### Cells and Cell Culture

Human umbilical vein endothelial cells were obtained from Cambrex Biosciences (Walkersville, MD) and cultured as previously described [23] according to manufacturer's instructions in EGM-2 me-

dium (Cambrex Biosciences, Walkersville, MD). For experiments, recombinant VEGF<sub>165</sub> (R & D Systems, Minneapolis, MN) was substituted in the media at the concentrations indicated for the proprietary VEGF solution.

### Plasmid and Adenoviral Constructs

The *Gax* cDNA was maintained in pBluescript SK+ vectors and excised as needed for use as probes for Northern blots. Adenoviral constructs expressing the human and rat homologs of *Gax* (*Ad.hGax* and *Ad.rGax*, respectively) conjugated to the  $\alpha$ -hemagglutinin (HA) epitope were a kind gift of Dr. Kenneth Walsh (Boston University, Boston, MA) [18], as was the control adenoviral vector expressing  $\beta$ -galactosidase (*Ad. $\beta$ -Gal*). Both human and rat isoforms of *Gax* were used to verify that both isoforms have similar activity. The control adenoviral vector expressing green fluorescent protein (*Ad.GFP*) was a kind gift of Dr. Daniel Medina (The Cancer Institute of New Jersey, New Brunswick, NJ). Viral titers were determined by plaque assay. Prior to the use of *Ad.hGax* or *Ad.rGax* in HUVECs, expression of *Gax* mRNA and protein in cells transduced with these adenoviral constructs were verified by Northern and Western blot (not shown). The p21 cDNA and p21 promoter constructs were also obtained from Dr. Kenneth Walsh and are the same constructs used in other studies [18]. The glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA used as a probe for Northern blots was the same construct used in another study [14].

### Immunohistochemistry

Tissue sections were obtained from human surgical specimens and fixed and imbedded in paraffin according to standard procedures, with sections dehydrated through xylenes and then rehydrated through graded ethanols [15]. Staining with a polyclonal rabbit anti-*Gax* antibody, which labels rat, human, and mouse *Gax* protein, was performed according to previously described methods, except that the dilution used was 1:1000 [15]. A biotin-labeled goat anti-rabbit IgG (Sigma Corporation, St. Louis, MO) was used as a secondary antibody, and *Gax* staining was visualized using Vectastain ABC (Vector Laboratories, Burlingame, CA). Background staining was assessed by staining sections without primary antibody. All tissue specimens were obtained from a protocol approved by the Institutional Review Board of the University that protects the privacy of the patients from which the samples were obtained.

### Northern Blots

Northern blots measuring *Gax* expression were performed as previously described [14]. Briefly, total RNA (30  $\mu$ g) was isolated from cultured cells using the guanidinium thiocyanate method [24] subjected to electrophoresis through formaldehyde-containing agarose gels, capillary blotted to nylon membranes using 10 $\times$  SSC as the transfer buffer, fixed to the membrane using ultraviolet crosslinking, and then hybridized to the *Gax* cDNA labeled with <sup>32</sup>P by random priming in Church buffer [25]. Blots were exposed to Kodak XAR-5 X-ray film with an intensifying screen at -80° C. Blots were then stripped with 0.1 $\times$  SSC plus 0.1% SDS at 95°C and reprobed with the GAPDH cDNA to verify equal RNA loading. Hybridization temperatures were 55°C for *Gax*, p21, and GAPDH probes, and all blots were washed to a stringency of 0.2 $\times$  SSC at 65°C. For p21 Northern blots, autoradiographs were scanned and band intensities determined with NIH Image v.1.6 p21 message levels were then normalized to GAPDH levels, and the fold-induction of p21 determined.

### Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)

RNA was isolated as described above from HUVECs and used in RT-PCR to detect *Gax* transcripts. Total RNA (5  $\mu$ g) was subjected to

reverse transcriptase reaction with MMLV-reverse transcriptase (Invitrogen, Carlsbad, CA) using random hexamers (Invitrogen, Carlsbad, CA). Because *Gax* has a single exon [26], all samples were treated with RNase-free DNase I (Ambion, Austin, TX) before being subjected to reverse transcription. As a further means of verifying that there was no genomic DNA contamination, control reactions with no reverse transcriptase were also subjected to PCR. To check the integrity of the RNA, the same reverse transcriptase reactions used to detect *Gax* were subjected to PCR using  $\beta$ -actin-specific primers. Human *Gax* primer sequences were: 5'-GTCAGAACT-CAACAGCAAACCCAG-3', sense; 5'-CACATTCACCAGTTCCTTTT-CCCGAGCC-3', antisense; product size 247 bp, from nucleotides 566 to 812 [26]. Human  $\beta$ -actin primer sequences were: 5'-ATCCG-CAAAGACCTGT-3',  $\beta$ -actin sense; and 5'-GTCCGCCTAGAAGC-AT-3'  $\beta$ -actin antisense; product size 270 bp, from nucleotides 906 to 1175 [27]. Before *Gax* primers were synthesized, their sequences were subjected to a BLAST [28] search against the Genbank database to detect any possibility that they might bind to or amplify genes other than *Gax*. Before running assays on experimental samples, each primer set, annealing conditions,  $Mg^{2+}$  concentration, and primer and probe concentration were optimized using plasmids containing the cDNA of interest. Reaction mixtures (25  $\mu$ l) were used containing 0.75 U *Taq* polymerase (Gibco BRL), reaction buffer, 0.2 mM dNTPs, plus the optimized concentrations of  $MgCl_2$ , probe, and primers for each primer set. The PCR cycle consisted of an initial 5-min denaturation step at 95°C, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 56°C (*Gax*) or 54°C ( $\beta$ -actin) for each primer for 60 s, and extension at 72°C for 60 s.

#### Cell Proliferation and $^3H$ -Thymidine Incorporation

The effect of *Gax* overexpression on mitogen-stimulated  $^3H$ -thymidine incorporation was examined in HUVECs. For cell proliferation, randomly cycling HUVECs in 6-well plates (20,000 cells/plate) were transduced for 12 h with Ad.*Gax* or Ad. $\beta$ -gal at varying MOIs, after which they were washed 3 times with phosphate-buffered saline and then placed in fresh medium EGM-2 supplemented with 10 ng/ml VEGF<sub>165</sub>. After infection, every day 3 wells for each experimental group were trypsinized and viable cells counted, with cell viability determined by Trypan blue exclusion. For  $^3H$ -thymidine uptake studies, HUVECs were made quiescent by serum starvation for 24 h in medium containing 0.1% fetal bovine serum (FBS) at which point the cells were transduced with Ad.*Gax* or Ad. $\beta$ -gal and incubated in 0.1% FBS for an additional 24 h. The cells were then stimulated with medium containing 10% FBS and 10 ng/ml VEGF<sub>165</sub> for 24 h in the presence of 0.2  $\mu$ Ci/ml  $^3H$ -thymidine (Amersham, Piscataway, NJ), after which trichloroacetic acid precipitable counts were measured.

#### Transactivation of the p21 Promoter

Subconfluent HUVECs were plated in 6-well plates and allowed to attach for 4 h. They were then infected with different MOIs of Ad.*hGax*, Ad.*rGax*, or Ad.*GFP* overnight, then transfected with p21 promoter Luciferase reporter construct. Transfection was performed using 2  $\mu$ g p21-Luciferase plasmid per well, plus 0.2  $\mu$ g pRL-SV (Promega, Madison, WI), which contains the cDNA for *Renilla reniformis* Luciferase downstream from the SV40 promoter as its reporter instead of the cDNA for firefly Luciferase, as a control for transfection efficiency. Firefly and *Renilla* Luciferase activities were measured using the Dual Luciferase Assay Kit (Promega, Madison, WI), and the firefly Luciferase activity from the p21-Luciferase promoter construct normalized to the constitutive *Renilla* Luciferase activity from the pRL-SV plasmid.

#### Tube Formation Assay

Tube formation assays were performed essentially as described [29]. Briefly, HUVECs were infected with adenoviruses expressing either human *Gax* (Ad.*hGax*), rat *Gax* (Ad.*rGax*), or GFP (Ad.*GFP*) at various multiplicity of infection (MOI). Eighteen hours later  $5 \times 10^5$  cells were plated on 6 well plates whose surfaces had been coated with reconstituted basement membrane, Low Growth Factor Matrigel, (BD Biosciences, San Jose, CA) and incubated overnight in the presence of serum and 10 ng/ml VEGF<sub>165</sub>. After this, the number of tubes per high-powered field were counted for 10 high-powered fields, with tubes being defined as a completed connection between cells. Ad.*GFP*-transduced cells were also examined using a fluorescence microscope to demonstrate that GFP was being expressed in the HUVECs forming tubes.

#### Data Analysis and Statistics

Experiments were repeated 3 or more times. For cell culture experiments, at least three wells per experimental group were measured and the mean  $\pm$  standard deviation determined. Statistical significance between the various groups was determined by 2-way ANOVA and the appropriate post-test, with the results being considered statistically significant when  $P < 0.05$ .

### RESULTS


#### *Gax* is Expressed in Human Vascular Endothelium

Because we hypothesized that *Gax* is expressed in endothelial cells as well as vascular smooth muscle cells, we first examined *Gax* expression in cultured human vascular endothelial cells and detected *Gax* expression in HUVECs by Northern blot (Fig. 1A) and by RT-PCR using human *Gax*-specific primers (Fig. 1B). Next, to verify that *Gax* protein is expressed in the endothelium of normal human blood vessels, we subjected a section of human kidney from a nephrectomy specimen to immunohistochemistry with a polyclonal rabbit anti-*Gax* antibody [15] (Fig. 2). As expected, *Gax* was expressed in vascular smooth muscle cells. In addition, it was also expressed in the endothelial cells lining the lumen of arteries, as evidenced by nuclear staining of the cells of the intima. From these observations, we conclude that *Gax* is expressed in normal endothelial cells, both *in vitro* and *in vivo*.

#### *Gax* Inhibits HUVEC Proliferation *in Vitro*

To test the hypothesis that *Gax* expression inhibits proliferation of endothelial cells, we transduced HUVECs that had been sparsely plated on plastic in 6-well plates with Ad.*hGax* at increasing MOI. Viable cells were counted from each experimental group every 24 h for 4 days. Control cells were transduced with Ad. $\beta$ -gal. Up to MOI = 1000, Ad. $\beta$ -gal did not inhibit HUVEC proliferation (data not shown). Both Ad.*hGax* and Ad.*rGax*, however, inhibited HUVEC proliferation in a dose-dependent fashion compared to Ad. $\beta$ -gal (Fig. 3A and B;  $P < 0.05$  for all MOI of virus). Quiescent HUVECs were then transduced with either





**FIG. 1.** *Gax* expression in vascular endothelial cells. Total RNA from HUVECs was subjected to Northern blot with the *Gax* cDNA labeled with  $^{32}\text{P}$  by random priming. (A) Northern blots. Two different HUVEC preparations were studied and compared to mouse heart (MH), which is known to express *Gax*. (B) RT-PCR. Total RNA from HUVECs was subjected to RT-PCR using primers that amplify a 247-bp fragment (base 566 to 812) of the human *Gax* cDNA. The same RT reactions were also subjected to PCR using  $\beta$ -actin primers. See Materials and Methods for details. (G = *Gax*; A =  $\beta$ -actin).

Ad.*hGax* or Ad. $\beta$ -gal, maintained in low serum medium for 24 h, then stimulated with 10% FBS and VEGF<sub>165</sub> = 10 ng/ml, and 24-h  $^3\text{H}$ -thymidine uptakes measured (Fig. 4). For comparison, one experimental


group was left in low serum medium and is labeled "Quiescent." Consistent with its effect on randomly cycling HUVECs, *Gax* strongly inhibited mitogen-stimulated  $^3\text{H}$ -thymidine uptake ( $P < 0.05$  for all MOI of virus). From these results, we conclude that *Gax* expression results in inhibition of HUVEC proliferation, as well as cell cycle arrest.

#### *Gax* Activates p21 Promoter Activity in Endothelial Cells


Because *Gax* induces p21 in vascular smooth muscle cells and *Gax* expression inhibited HUVEC proliferation as measured both by cell counts and  $^3\text{H}$ -thymidine uptake, we tested whether *Gax* could induce p21 expression in endothelial cells. HUVECs were transduced with Ad.*hGax* and Ad.*rGax* at varying MOIs. Cells transduced with an adenovirus expressing green fluorescent protein (Ad.*GFP*) served as controls. By Northern blot, p21 levels were strongly induced in a viral MOI-dependent fashion (Fig. 5A). When cells transduced with Ad.*hGax* in a similar fashion were transfected with a plasmid containing the p21 promoter fused upstream to the firefly Luciferase gene, it was similarly observed that p21 promoter activity was increased by up to 7-fold (Fig. 5B;  $P < 0.05$  for all MOI). Transduction with Ad.*GFP* did not affect p21 promoter activity (Fig. 5A and B), nor did transduction with Ad. $\beta$ -Gal (data not shown).

#### *Gax* Inhibits Endothelial Cell Tube Formation on Reconstituted Basement Membranes

We next studied the effect of *Gax* expression on angiogenesis *in vitro*. HUVECs were transduced with



**FIG. 2.** *Gax* is expressed in both the vascular smooth muscle cells and the endothelial cells of normal human arteries. A section from human kidney obtained from a nephrectomy specimen for renal cell carcinoma was stained with rabbit polyclonal anti-*Gax* antibody. In the section containing normal kidney, *Gax* expression was noted in both the media, containing vascular smooth muscle cells (VSMC), as expected from previous studies, but there was also strong staining in the endothelial cells (EC) in the intima lining the lumen.




**FIG. 3.** Inhibition of HUVEC proliferation by *Gax*. Randomly cycling HUVECs growing in 6-well plates in EGM-2 medium were infected with varying MOI of either Ad.h*Gax*, Ad.r*Gax*, or Ad.β-Gal. After infection, 3 wells for each experimental group were trypsinized and counted, with cell viability determined by Trypan blue exclusion, and results were counted as mean number of cells  $\pm$  standard deviation. Inhibition of proliferation was statistically significant for all experimental groups at all time points from 48 hours on ( $P < 0.05$ ). (A) Effect of Ad.h*Gax* on HUVEC proliferation (B) Effect of Ad.r*Gax* on HUVEC proliferation.

Ad.h*Gax* and Ad.r*Gax* at varying MOIs and plated on reconstituted basement membrane (Matrigel) in the presence of serum and 10 ng/ml VEGF<sub>165</sub>, conditions that result in robust tube formation. Ad.*GFP* had no effect on tube formation up to MOI = 250, and ex-

pression of GFP was verified by fluorescence microscopy (Fig. 6). However, there was a dose-dependent decrease in tube formation beginning at relatively small doses of virus (MOI = 25) and becoming maximal at MOI = 100 (Fig. 6). Maximal inhibition oc-





**FIG. 4.** Inhibition of mitogen-induced  $^3\text{H}$ -thymidine uptake in HUVECs by *Gax*. Quiescent HUVECs were transduced with Ad.*hGax* at various MOI. Twenty-four hours later, the cells were stimulated with serum and VEGF<sub>165</sub> (10 ng/ml) and 24 h.  $^3\text{H}$ -thymidine uptakes measured after stimulation. *Gax* strongly inhibited  $^3\text{H}$ -thymidine uptake in response to mitogen stimulation.


curred at a lower MOI than is necessary to maximally inhibit endothelial cell proliferation and activate p21 expression and became maximal at MOI = 50 to 100. We note that is the dose range of virus that we have determined to be necessary to transduce 100% of HUVECs (not shown), implying that few viral particles per cell are necessary to produce sufficient *Gax* protein to inhibit the cellular machinery that causes tube formation. This is in contrast to the higher viral MOI necessary to produce maximal inhibition of cell cycle progression and induction of p21 expression, implying that more viral particles per cell and therefore a higher level of *Gax* protein are required to mediate these effects.

#### DISCUSSION

The primary target of proangiogenic factors secreted by tumor cells, and many antiangiogenic factors, is the vascular endothelial cell [1, 30]. During angiogenesis, whether physiologic or tumor-induced, endothelial cells undergo distinct changes in phenotype and gene expression, including activation of proteolytic enzymes to degrade basement membrane, sprouting, proliferation, tube formation, and production of extracellular matrix [1, 4, 31]. Endothelial proliferation accompanies cell invasion and migration, and lumens of new capillaries are formed when endothelial cells adhere to one another and form tubes. Homeobox genes are master regulatory genes with diverse functions in many

cell types, both during embryogenesis and in the adult [10–13]. It is therefore not surprising that recently they have been implicated as important transcriptional regulators controlling endothelial cell phenotype during angiogenesis.

Until recently, little was known about how homeobox genes might influence endothelial cell phenotype and behavior during angiogenesis. However, evidence for their involvement in the phenotypic changes endothelial cells undergo during angiogenesis is now accumulating. For instance, Patel *et al.* reported an endothelial cell-specific variant of *HOXA9* whose expression is regulated by tumor necrosis factor- $\alpha$ , which is proangiogenic [32]. More direct evidence for the importance of homeobox genes in angiogenesis exists for *HOXD3*. Stimulation of endothelial cells with bFGF induces *HOXD3* expression, as well as integrin  $\alpha_v\beta_3$  and the urokinase plasminogen activator, effects that are blocked by *HOXD3* antisense. *In vivo*, sustained expression of *HOXD3* on the chick chorioallantoic membrane retains endothelial cells in an invasive state and prevents vessel maturation, leading to vascular malformations and endotheliomas [33]. In diabetic mice, *HOXD3* expression is impaired in endothelial cells, as is its upregulation after wounding [34]. More recently, overexpression of another homeobox gene, *HOXB3*, in the chick chorioallantoic has been shown to result in an increase in capillary vascular density and angiogenesis, and its blockade by antisense results in impaired capillary morphogenesis [35].




**FIG. 5.** *Gax* overexpression induces p21 expression. (A) *Gax* expression induces p21 expression in HUVECs. Randomly cycling HUVECs were infected with either Ad.h*Gax* at varying MOIs, Ad.r*Gax* at MOI = 100(\*), or Ad.GFP = 300 MOI (C) and then were harvested 24 h later, and Northern blots performed using a p21 probe. (B) *Gax* expression induces p21 promoter activity. HUVECs were infected with Ad.r*Gax* and then transfected with a plasmid containing the p21 promoter driving the firefly Luciferase gene. Luciferase activity was measured 24 h later and normalized to *Renilla* Luciferase activity. Error bars represent standard deviation of 3 wells.

Taken together, these data suggest significant roles for specific homeobox genes in responding to extracellular signals and activating batteries of downstream genes to induce the phenotypic changes in endothelial cells associated with angiogenesis. These observations are what initially led us to look for additional homeobox genes likely to be involved in the final transcriptional control of genes determining angiogenic phenotype.

In this study, we have reported data strongly suggesting a role for another homeobox gene, the growth arrest homeobox gene *Gax*, in regulating the phenotypic changes that occur in vascular endothelial cells during angiogenesis. Moreover, unlike cell cycle regu-

lators such as p21 or p53, the expression of this gene is relatively restricted to the cardiovascular system [14, 15]. We suspected such a role for *Gax* in endothelial cells during angiogenesis because of its activities in vascular smooth muscle cells, which include G<sub>1</sub> cell cycle arrest [18]; p21 activation [18]; and inhibition of migration towards cytokines and mitogens [19]. We therefore looked for its expression in vascular endothelial cells using RT-PCR, Northern blot, and immunohistochemistry and found that *Gax* is indeed expressed in endothelial cells, both *in vitro* (Fig. 1) and *in vivo* in normal human blood vessels (Fig. 2). Moreover, its expression blocks endothelial cell proliferation, with this inhibition being associated with an upregulation of p21. This upregulation is proportional to the level of expression of *Gax*, and appears to be caused by the activation of the p21 promoter.

Tumor angiogenesis represents a promising new target for anticancer therapy. Given that the most important cell in this process is the vascular endothelial cell, targeting angiogenesis implies targeting vascular endothelial cell processes important to angiogenesis. Specific transcription factors such as *Ets-1* [36] are known to integrate the signals coming from the pathways activated by pro- and antiangiogenic factors and translate these signals to changes in endothelial cell gene expression and phenotype. As such, endothelial cell transcription factors represent both a tool for understanding the phenotypic changes endothelial cells undergo in response to proangiogenic factors secreted by tumor cells that result in angiogenesis and potential targets for the anti-angiogenic therapy of cancer. *Gax* is a homeobox transcription factor originally isolated in vascular smooth muscle cells that has previously been shown to be involved in cardiovascular remodeling [19, 21, 37], inhibiting vascular smooth muscle cell proliferation [18] and migration [19]. We have now shown that *Gax* is also expressed in vascular endothelial cells (Figs. 1 and 2). Moreover, *Gax* inhibits endothelial cell proliferation (Figs. 3 and 4) as well, activating p21 expression (Fig. 5). Of most interest, *Gax* also strongly inhibits tube formation on reconstituted basement membranes (Fig. 6), suggesting that, in addition to its role in inhibiting vascular smooth muscle cell-dependent vascular remodeling processes such as intimal hyperplasia [18, 19], it may also have a role inhibiting vascular remodeling processes that depend mainly on endothelial cells, such as angiogenesis. We therefore conclude that *Gax* may represent an important negative regulator of angiogenesis in vascular endothelial cells, and as such may represent a new molecular tool to understand the transcriptional control of changes in gene expression that occur in endothelial cells during angiogenesis and, more importantly, a potential target for the antiangiogenic therapy of cancer.



**FIG. 6.** *Gax* inhibits VEGF-induced endothelial cell tube formation on Matrigel. HUVECs were infected with adenoviruses expressing either human *Gax* (Ad.h*Gax*), rat *Gax* (Ad.r*Gax*), or *GFP* (Ad.*GFP*) at the MOI indicated. Eighteen hours later,  $5 \times 10^5$  cells were plated on Matrigel in 6-well plates and incubated overnight in the presence of serum and 10 ng/ml VEGF. Tube formation was strongly inhibited by both Ad.h*Gax* and Ad.r*Gax* ( $P < 0.05$  at MOI = 25). (A) HUVECs in culture demonstrating the inhibition of tube formation by increasing MOI of Ad.h*Gax* and Ad.r*Gax* and Ad. $\beta$ -gal was the control. (B) Tube counts for an experiment in which Ad.h*Gax* was used to inhibit endothelial cell tube formation.

#### ACKNOWLEDGMENTS

The authors would like to thank Dr. Kenneth Walsh (Boston University) for supplying the adenoviral constructs expressing *Gax* and  $\beta$ -galactosidase, as well as the p21 promoter-Luciferase constructs and the p21 cDNA. Thanks are also due to Dr. Daniel Medina (UMDNJ-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey) for supplying the adenoviral construct expressing GFP. The work described in this article was supported by

grants from the Foundation of UMDNJ, the New Jersey Commission on Cancer Research (0139CCRS1), and a Department of Defense Career Development Award (DAMD17-02-1-0511).

#### REFERENCES

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat. Med.* 1: 27, 1995.

2. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J.* **13**: 9, 1999.
3. Kandel, J., Bossy-Wetzel, E., Radvanyi, F., Klagsbrun, M., Folkman, J., and Hanahan, D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. *Cell* **66**: 1095, 1991.
4. Folkman, J. Fighting cancer by attacking its blood supply. *Sci. Am.* **275**: 150, 1996.
5. Juczewska, M., and Chyczewski, L. Angiogenesis in cancer. *Rocz. Akad. Med. Białymst.* **42**(Suppl 1): 86, 1997.
6. Pluda, J. M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. *Semin. Oncol.* **24**: 203, 1997.
7. Bachetti, T., and Morbidelli, L. Endothelial cells in culture: a model for studying vascular functions. *Pharmacol. Res.* **42**: 9, 2000.
8. Fujio, Y., and Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. *J. Biol. Chem.* **274**: 16349, 1999.
9. Ilan, N., Mahooti, S., and Madri, J. A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. *J. Cell. Sci.* **111**: 3621, 1998.
10. Garcia-Fernandez, J., and Holland, P. W. Amphioxus Hox genes: insights into evolution and development. *Int. J. Dev. Biol. Suppl* **1**: 71S, 1996.
11. Krumlauf, R. Hox genes in vertebrate development. *Cell* **78**: 191, 1994.
12. Cillo, C., Faiella, A., Cantile, M., and Boncinelli, E. Homeobox genes and cancer. *Exp. Cell. Res.* **248**: 1, 1999.
13. Ford, H. L. Homeobox genes: a link between development, cell cycle, and cancer? *Cell. Biol. Int.* **22**: 397, 1998.
14. Gorski, D. H., LePage, D. F., Patel, C. V., Copeland, N. G., Jenkins, N. A., and Walsh, K. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G<sub>0</sub>/G<sub>1</sub> transition in vascular smooth muscle cells. *Mol. Cell. Biol.* **13**: 3722, 1993.
15. Skopicki, H. A., Lyons, G. E., Schatteman, G., Smith, R. C., Andres, V., Schirm, S., Isner, J., and Walsh, K. Embryonic expression of the Gax homeodomain protein in cardiac, smooth, and skeletal muscle. *Circ. Res.* **80**: 452, 1997.
16. Weir, L., Chen, D., Pastore, C., Isner, J. M., and Walsh, K. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. *J. Biol. Chem.* **270**: 5457, 1995.
17. Yamashita, J., Itoh, H., Ogawa, Y., Tamura, N., Takaya, K., Igaki, T., Doi, K., Chun, T. H., Inoue, M., Masatsugu, K., and Nakao, K. Opposite regulation of Gax homeobox expression by angiotensin II and C-type natriuretic peptide. *Hypertension* **29**: 381, 1997.
18. Smith, R. C., Branellec, D., Gorski, D. H., Guo, K., Perlman, H., Dedieu, J. F., Pastore, C., Mahfoudi, A., Deneffe, P., Isner, J. M., and Walsh, K. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. *Genes Dev.* **11**: 1674, 1997.
19. Witzensbichler, B., Kureishi, Y., Luo, Z., Le Roux, A., Branellec, D., and Walsh, K. Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. *J. Clin. Invest.* **104**: 1469, 1999.
20. Friedlander, M., Brooks, P. C., Shaffer, R. W., Kincaid, C. M., Varner, J. A., and Cheresh, D. A. Definition of two angiogenic pathways by distinct alpha v integrins. *Science* **270**: 1500, 1995.
21. Maillard, L., Van Belle, E., Smith, R. C., Le Roux, A., Deneffe, P., Steg, G., Barry, J. J., Branellec, D., Isner, J. M., and Walsh, K. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. *Cardiovasc. Res.* **35**: 536, 1997.
22. Candia, A. F., and Wright, C. V. The expression pattern of *Xenopus Mox-2* implies a role in initial mesodermal differentiation. *Mech. Dev.* **52**: 27, 1995.
23. Gorski, D. H., Beckett, M. A., Jaskowiak, N. T., Calvin, D. P., Maureri, H. J., Salloum, R. M., Seetharam, S., Koons, A., Hari, D. M., Kufe, D. W., and Weichselbaum, R. R. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. *Cancer Res.* **59**: 3374, 1999.
24. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal. Biochem.* **162**: 156, 1987.
25. Church, G. M., and Gilbert, W. Genomic sequencing. *Proc. Natl. Acad. Sci. USA* **81**: 1991, 1984.
26. LePage, D. F., Altomare, D. A., Testa, J. R., and Walsh, K. Molecular cloning and localization of the human GAX gene to 7p21. *Genomics* **24**: 535, 1994.
27. Ponte, P., Ng, S. Y., Engel, J., Gunning, P., and Kedes, L. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. *Nucleic Acids Res.* **12**: 1687, 1984.
28. Altschul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.* **215**: 403, 1990.
29. Colorado, P. C., Torre, A., Kamphaus, G., Maeshima, Y., Hopfer, H., Takahashi, K., Volk, R., Zamborsky, E. D., Herman, S., Sarkar, P. K., Ericksen, M. B., Dhanabal, M., Simons, M., Post, M., Kufe, D. W., Weichselbaum, R. R., Sukhatme, V. P., and Kalluri, R. Anti-angiogenic cues from vascular basement membrane collagen. *Cancer Res.* **60**: 2520, 2000.
30. Bell, S. E., Mavila, A., Salazar, R., Bayless, K. J., Kanagala, S., Maxwell, S. A., and Davis, G. E. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. *J. Cell. Sci.* **114**: 2755, 2001.
31. Folkman, J. New perspectives in clinical oncology from angiogenesis research. *Eur. J. Cancer* **32A**: 2534, 1996.
32. Patel, C. V., Sharangpani, R., Bandyopadhyay, S., and DiCorleto, P. E. Endothelial cells express a novel, tumor necrosis factor-alpha-regulated variant of HOXA9. *J. Biol. Chem.* **274**: 1415, 1999.
33. Boudreau, N., Andrews, C., Srebrow, A., Ravanpay, A., and Cheresh, D. A. Induction of the angiogenic phenotype by Hox D3. *J. Cell. Biol.* **139**: 257, 1997.
34. Uyeno, L. A., Newman-Keagle, J. A., Cheung, I., Hunt, T. K., Young, D. M., and Boudreau, N. Hox D3 expression in normal and impaired wound healing. *J. Surg. Res.* **100**: 46, 2001.
35. Myers, C., Charboneau, A., and Boudreau, N. Homeobox B3 promotes capillary morphogenesis and angiogenesis. *J. Cell. Biol.* **148**: 343, 2000.
36. Oda, N., Abe, M., and Sato, Y. ETS-1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin beta3. *J. Cell. Physiol.* **178**: 121, 1999.
37. Perlman, H., Luo, Z., Krasinski, K., Le Roux, A., Mahfoudi, A., Smith, R. C., Branellec, D., and Walsh, K. Adenoviral-mediated delivery of the Gax transcription factor to rat carotid arteries inhibits smooth muscle proliferation and induces apoptosis. *Gene Ther.* **6**: 758, 1999.

## **Control of Vascular Cell Differentiation by Homeobox Transcription Factors**

David H. Gorski\* and Kenneth Walsh

*Homeobox genes are a family of transcription factors with a highly conserved DNA-binding domain that regulate cell proliferation, differentiation, and migration in many cell types in diverse organisms. These properties are responsible for their critical roles in regulating pattern formation and organogenesis during embryogenesis. The cardiovascular system undergoes extensive remodeling during embryogenesis, and cardiovascular remodeling in the adult is associated with normal physiologic processes such as wound healing and the menstrual cycle, and disease states such as atherosclerosis, tumor-induced angiogenesis, and lymphedema. Aside from their roles in the formation of the embryonic vascular system, homeobox genes recently have been implicated in both physiologic and pathologic processes involving vascular remodeling in the adult, such as arterial restenosis after balloon angioplasty, physiologic and tumor-induced angiogenesis, and lymph-angiogenesis. Understanding how homeobox genes regulate the phenotype of smooth muscle and endothelium in the vasculature will improve insight into the molecular mechanisms behind vascular cell differentiation and may suggest therapeutic interventions in human disease. (Trends Cardiovasc Med 2003;13:213–220)*

© 2003, Elsevier Inc.

David H. Gorski is at the Division of Surgical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey, USA. Kenneth Walsh is at the Division of Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University, Boston, Massachusetts, USA.

\*Address correspondence to: David H. Gorski, MD, PhD, Division of Surgical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA. Tel.: (+1) 732-235-8524; fax: (+1) 732-235-8098; e-mail: gorskidh@umdnj.edu.

© 2003, Elsevier Inc. All rights reserved.  
1050-1738/03/\$-see front matter

Changes in cellular phenotype leading to remodeling in the vascular system occur during normal development and in pathologic states. During embryogenesis, vascular endothelial cell (EC) precursors converge into blood islands, which ultimately develop into the aortic arches and capillary networks that provide oxygen and nutrients to the developing organs and limbs. From this, lymphatic EC precursors bud from embryonic veins to form the lymphatic vascular system. In the adult, examples of changes in vascular cell phenotype leading to vascular remodeling include wound healing and the

menstrual cycle, during which both angiogenesis and regression of blood vessels are tightly regulated. Examples of pathologic remodeling include atherosclerosis and arterial restenosis after balloon angioplasty. In both processes, vascular smooth muscle cells (VSMCs) migrate from the media to the intima and proliferate, leading to narrowing of the arterial lumen and the subsequent complications, including hypoxia or even anoxia in downstream tissues (Ross 1993)—quickly in the case of restenosis and slowly in the case of atherosclerosis. In addition, phenotypic changes in vascular ECs leading to vascular remodeling play a critical role in tumor biology because diffusion of oxygen and nutrients limits tumor growth to within 1 mm of a capillary. To overcome this limitation, tumors secrete proangiogenic factors to stimulate the ingrowth of new blood vessels (Folkman 1995), which develop from ECs with an immature phenotype (Eberhard et al. 2000). Similarly, tumors also secrete prolymph-angiogenic factors, which allow for the ingrowth of lymphatics and subsequent metastasis to regional lymph nodes (Skobe et al. 2001). Thus, understanding the mechanisms underlying the phenotypic changes that lead to vascular remodeling could produce insights into diseases as diverse as atherosclerosis or restenosis, lymphedema, and cancer.

Although the receptors and signaling pathways activated by growth factors and cytokines have been studied extensively in the vascular system, much less is known about the molecular biology of the downstream transcription factors activated by these pathways to regulate tissue-specific gene expression controlling the growth and differentiation of these cells. Transcription factors represent a common mechanism that can integrate multiple signaling pathways to produce the necessary changes in gene expression and phenotype for vascular cells to perform their functions. Homeobox genes encode a family of transcription factors




containing a common 60-amino-acid DNA-binding motif known as the homeo-domain, containing a helix–turn–helix motif similar to that found in prokaryotic regulatory proteins such as Cro, CAP, and the  $\lambda$  repressor in *Escherichia coli* (Scott et al. 1989). They are regulators of cell differentiation, proliferation, and migration in both vertebrates and invertebrates, controlling pattern formation in the embryo and organogenesis, as well as oncogenesis in the adult (Cillo et al. 1999, Ford 1998, Krumlauf 1994). Given these characteristics, homeobox genes are excellent candidates for important roles in the final transcriptional regulation of genes responsible for vascular remodeling and angiogenesis in normal physiology and disease. Recently several homeobox genes have been implicated in the phenotypic changes in vascular cells that lead to intimal hyperplasia, arterial restenosis after angioplasty, angiogenesis, and lymphangiogenesis. It is therefore an opportune time to review briefly what is currently known about homeobox gene expression and activity during vasculogenesis and vascular remodeling in the adult.

## • Homeobox Gene Expression and Function During Vascular Development

### HOX Cluster Genes

In *Drosophila melanogaster* and vertebrates, many, but not all, homeobox genes are arranged in gene clusters. In mice and humans, there are four unlinked complexes—HOX A through HOX D—that arose from gene duplication (Krumlauf 1994). Because of this, each HOX gene may have as many as three paralogues. The location of each HOX gene in the cluster corresponds to its axial pattern of expression in the developing embryo, with 5' genes expressed more toward the caudal region and 3' genes expressed more toward the rostral region (Figure 1), with specific embryonic defects due to knockouts of specific HOX genes occurring in the axial region of their expression. HOX genes have been studied widely with regard to their ability to control pattern formation in the developing embryo. They are powerful regulators of pattern formation, as evidenced by the homeotic mutations (i.e., mutations in which one normal body part is substi-



**Figure 1.** Organization of the HOX clusters. The four HOX clusters in the human and mouse are believed to have evolved through gene duplication. In the human, there are 39 homeobox genes in the HOX clusters (Kosaki et al. 2002). In the mouse, as shown in this figure, the 3' genes are expressed early in embryogenesis in the more rostral regions of the embryo, whereas the 5' genes are expressed later in embryogenesis in the caudal regions of the embryo (Cillo et al. 1999). The 3' rostral genes are highly responsive to retinoic acid (RA), whereas the 5' caudal genes are less sensitive. Each homeobox gene can have as many as three paralogues in the same position in other HOX clusters. Each HOX cluster is located on a different chromosome. The arrangement of the human HOX clusters, HOX A through D, is nearly identical to the mouse. See text for details.

tuted for another normal body part, as in *Antennapedia*).

Several members of the HOX clusters are expressed in the cardiovascular system during embryogenesis, including *HOXA5*, *HOXA11*, *HOXB1*, *HOXB7*, and *HOXC9* (Miano et al. 1996). Moreover, there is functional evidence for involvement of HOX genes in vasculogenesis. For example, transgenic mice with null mutations of the *HOXA3* gene die shortly after birth, suffering from defects in the cardiovascular system that include heart-wall malformations, persistent patent ductus arteriosus, and aortic stenosis (Chisaka and Capecchi 1991). In some of these mice, the right carotid artery fails to form, and in all mice the aorta is thin walled and poorly developed. The overall constellation of defects in *HOXA3* null mice is similar to that observed in the human congenital disorder DiGeorge syndrome (Chisaka and Capecchi 1991).

Because paralogous HOX genes have similar DNA-binding domains and axial expression patterns during embryogenesis, it has been hypothesized that they may have overlapping or complemen-

tary functions. Thus, targeting one paralogue may not produce an observable phenotype. This has been demonstrated by antisense targeting of the messages for the paralogous HOX 3 group (*HOXA3* and *HOXB3*), which results in the regression of aortic arch 3 in a manner similar to that of arch 2 (Kirby et al. 1997). Similarly, targeting paralogous group 5 genes (*HOXA5*, *HOXB5*, and *HOXC5*) causes the appearance of an additional pharyngeal arch containing a novel and aortic arch artery (Kirby et al. 1997). These observations suggest that paralogues probably have overlapping functions in vascular development and that in at least some cases they can compensate for each other when the function of one is impaired.

### Paired-Related Genes

The expression of two genes not located in the HOX clusters—*Prx1* (formerly known as *MHox* or *Phox*) (Cserjesi et al. 1992) and *Prx2* (formerly known as *S8*) (Opstelten et al. 1991)—during embryogenesis suggests that they have an important role in vasculogenesis. In the vascular



system, expression of *Prx1* and *Prx2* is associated with the primary vessel wall and becomes increasingly restricted to the adventitial and outer medial cell layers as development proceeds (Bergwerff et al. 1998). *Prx1* expression colocalizes with procollagen I and fibrillin 2 but not with smooth muscle  $\alpha$  actin, whereas *Prx2* expression is highly associated with the developing ductus arteriosus and is one of the earliest markers of its differentiation. Transgenic mice with null mutations *Prx1* and *Prx2* suggest their relative importance in vascular patterning in the embryo. *Prx2*<sup>-/-</sup> mutants do not show cardiovascular malformations. In contrast, *Prx1*<sup>-/-</sup> mutants display abnormal positioning and awkward curvature of the aortic arch, in addition to a misdirected and elongated ductus arteriosus (Bergwerff et al. 2000). However, *Prx1*<sup>-/-</sup>/*Prx2*<sup>-/-</sup> double mutants demonstrate a more severe form of these abnormalities, some of them possessing an anomalous retroesophageal right subclavian artery, as well as excessive tortuosity of all great vessels as they run through the mesenchyme, although they do not have cardiac anomalies (Chesterman et al. 2001). Thus, the loss of *Prx2* function exacerbates anomalies due to the loss of *Prx1*, suggesting functional overlap between these two genes in vascular development.

#### *Hex: An Early Marker of EC Precursors and Regulator of EC and VSMC Differentiation*

*Hex* is a proline-rich divergent homeobox gene originally isolated from hematopoietic tissues (Crompton et al. 1992). Expressed in a range of hematopoietic progenitor cells and cell lines (Crompton et al. 1992), *Hex* is an early marker of EC precursors and is transiently expressed in the nascent blood islands of the visceral yolk sac and later in embryonic angioblasts and endocardium (Thomas et al. 1998). The *Xenopus laevis* homologue *XHex* is expressed in vascular ECs throughout the developing vascular network, and its overexpression leads to disruption of vascular structures and an overall increase in EC number (Newman et al. 1997). These observations suggest an important role for *Hex* in the vascular patterning due to the migration and proliferation of EC precursors. In addition, it has been reported recently that *Hex* also is expressed in VSMCs (Sekiguchi et al. 2001).

Its expression is upregulated in neointimal VSMCs after balloon injury in the rat, and *Hex* activates the promoter of NMHC-B/SMemb, a nonmuscle-specific isoform of the smooth muscle myosin heavy chain that is expressed during embryonic development of the aorta, declines in the neonate and adult, and is re-induced in vascular lesions.

Given the above experimental observations, it has been assumed that *Hex* promotes the conversion of ECs to the angiogenic phenotype. However, recent evidence does not support that assumption and suggests that the role of *Hex* in controlling vascular phenotype may be more complex than first thought. First, disruption of the *Hex* gene in mouse embryos does not produce a detectable change in the vascular phenotype (Barbera et al. 2000), suggesting that other factors—perhaps the transcription factor *Scl* (Liao et al. 2000)—may compensate for the loss of *Hex* function. Also, it has been reported recently that *Hex* overexpression in human umbilical vein ECs (HUVECs) inhibits in vitro surrogates for angiogenesis, including migration toward vascular endothelial growth factor (VEGF), invasion, proliferation, and tube formation on reconstituted basement membrane (Matrigel) (Nakagawa et al. 2003). In addition, *Hex* was shown to inhibit the expression of angiogenesis-related membrane genes, including those encoding VEGFR-1, VEGFR-2, neuropilin 1, integrin subunit  $\alpha_v$ , Tie-1, and Tie-2. It remains to be clarified whether *Hex* inhibits angiogenesis in vivo, but, taken together with previous reports, these observations suggest a complex role for *Hex* in regulating the proliferation and development of the vascular tree and the differentiation of ECs and VSMCs.

#### *Prox1 and Development of the Lymphatic System*

The lymphatic system is a vascular network of thin-walled capillaries and larger vessels lined by a layer of ECs that drain lymph from the tissue spaces of most organs and return it to the venous system for recirculation. Early in development, primitive lymph sacs develop from endothelial budding from the veins to form the lymphatic system. The homeobox gene *Prox1* has been implicated in the development of the lymphatic system. Originally isolated by its homology to the *Drosophila* gene *prospero* (Oliver et al. 1993), *Prox1* has an expression pattern that suggests a functional role in a variety of tissues, including eye lens, central nervous system, and liver, with null mutations leading to embryonic lethality (Wigle and Oliver 1999). Supporting a role in lymphatic development is the observation that *Prox1* is the earliest marker of lymphatic EC precursors, and in *Prox1*<sup>-/-</sup> knockout mice, budding of ECs that give rise to the lymphatic system is arrested at embryonic day 11.5, resulting in mice without lymphatic vasculature (Wigle and Oliver 1999). In contrast, vasculogenesis and angiogenesis are unaffected by the loss of *Prox1* function (Wigle and Oliver 1999, Wigle et al. 2002). In addition, expression of *Prox1* in vascular ECs results in proliferation and a reprogramming of these cells to a lymphatic EC phenotype, inducing expression of lymphatic genes such as *VEGFR-3*, *p57<sup>kip2</sup>*, and *desmoplakin I/II* and downregulating vascular EC genes such as *STAT6* and *neuropilin 1* (Hong et al. 2002, Petrova et al. 2002). Moreover, this lymphatic reprogramming due to *Prox1* expression occurs only in vascular ECs, although *Prox1* is still able to induce cyclin expression and proliferation in other cell types (Petrova et al. 2002). Together, these data suggest a role for *Prox1* as a general inducer of proliferation and a key regulatory gene in the developing lymphatic system.

• **Homeobox Gene Expression and Function in Mature Blood Vessels**

#### *Homeobox Gene Expression during VSMC Phenotypic Modulation and Vascular Disease*

VSMCs exist within a spectrum of phenotypes ranging from the "contractile" to the "synthetic" state (Ross 1993). Cells in the contractile state are quiescent; do not migrate; are relatively insensitive to mitogens; express contractile proteins, including smooth muscle-specific isoforms of actin and myosin; and are associated with normal vessel wall. Synthetic state cells, on the other hand, are able to migrate; express lower levels of contractile proteins, with higher levels of nonmuscle isoforms of myosin and actin; secrete extracellular matrix components; and generally resemble less-differentiated VSMCs found in fetal blood vessels. Over the last decade, evidence has been accu-

mutating that homeobox genes are involved in regulating the transition between these two phenotypes.

In the adult, several members of the HOX clusters are expressed in the cardiovascular system. Homeobox sequences isolated from adult rat aorta include *HOXA2*, *HOXA4*, *HOXA5*, and *HOXB7*, and *HOXA11* (Gorski et al. 1994, Patel et al. 1992). Other groups have reported the expression of *HOXA5*, *HOXA11*, *HOXB1*, *HOXB7*, and *HOXC9* in human adult and fetal aortic smooth muscle (Miano et al. 1996, Patel et al. 1992). Of these, *HOXB7* and *HOXC9* are expressed at markedly higher levels in embryonic VSMCs compared with adult VSMCs, suggesting a role in the proliferation and remodeling that occur during embryogenesis (Miano et al. 1996). In addition, overexpression of *HOXB7* in C3H10T1/2 cells results in increased proliferation; the induction of a VSMC-like morphology; and the expression of early, but not intermediate, VSMC markers. Moreover, *HOXB7* mRNA was detected in human atherosclerotic plaques at a higher level than in normal human arterial media (Bostrom et al. 2000). These observations suggest a role for *HOXB7* and perhaps *HOXC9* in vascular remodeling, either in the expansion of immature VSMCs or the change of vascular myocytes to a more immature phenotype, both of which occur in human vascular diseases, such as atherosclerosis and restenosis after balloon angioplasty.

#### *Gax and Control of Smooth Muscle Phenotype*

Originally isolated from a rat aorta cDNA library with the use of degenerate oligonucleotide probes directed at the most conserved protein sequence of the *Antennapedia* homeodomain (Gorski et al. 1993a), *Gax* (also known as *Mox-2*) encodes a homeodomain-containing transcription factor whose expression has multiple effects on vascular phenotype. Although its expression is more widespread in the embryo, including all three muscle lineages and brain (Skopicki et al. 1997), *Gax* expression in the adult is more narrowly confined to cardiovascular tissues, including heart, medial smooth muscle cells of arteries, lung, and mesangial cells in the kidney (Gorski et al. 1993a). In VSMCs, *Gax* expression is downregulated rapidly by mitogenic sig-

nals such as serum, platelet-derived growth factor (Gorski et al. 1993a), and angiotensin II (Yamashita et al. 1997), and more slowly upregulated by growth arrest signals such as serum deprivation (Gorski et al. 1993a) and C-type natriuretic peptide (Yamashita et al. 1997). Moreover, *Gax* expression is also downregulated in the proliferating VSMCs of the rat carotid artery after balloon injury (Weir et al. 1995). *Gax* expression induces G<sub>0</sub>/G<sub>1</sub> cell-cycle arrest and upregulates p21 expression by a p53-independent mechanism, and it is this upregulation of p21 that accounts for its antiproliferative activity (Smith et al. 1997). *Gax* also controls the migration of VSMCs toward chemotactic growth factors through its ability to alter integrin expression, downregulating integrins  $\alpha_v\beta_3$  and  $\alpha_v\beta_5$  through the specific suppression of the  $\beta_3$  and  $\beta_5$  subunits, both in vitro and in vivo (Witzenbichler et al. 1999). Cell-cycle arrest, which does not by itself suppress VSMC migration, is essential for the antimigratory activity of *Gax*, as *Gax* overexpression has no effect on p21<sup>-/-</sup> cells. Collectively, these data suggest that *Gax* may function to coordinate vascular cell growth and motility through its ability to regulate integrin expression in a cell-cycle-dependent manner. The ability of *Gax* to induce apoptosis in proliferating VSMCs (Perlman et al. 1998) is consistent with these observations, because integrin signaling is an important regulator of cell viability.

#### *Control of Smooth Muscle Phenotype by Prx*

The expression of *Prx1* and *Prx2* cannot be detected in the vasculature of adult rats, but they are upregulated in rat pulmonary arteries in which pulmonary hypertension was induced by the injection of monocrotaline (Jones et al. 2001). Induction of *Prx1* and *Prx2* expression in vitro and in vivo is coincident with induction of the extracellular matrix protein tenascin C, which promotes growth and survival of cultured VSMCs. *Prx1* activates the tenascin-C promoter and induces VSMC proliferation in vitro. Consistent with these observations, *Prx1* is upregulated by angiotensin II and, along with the serum response factor, mediates angiotensin II-induced smooth muscle  $\alpha$ -actin expression in VSMCs (Hautmann et al. 1997). Collectively, it appears

that *Prx1* and *Prx2* genes have roles both in regulating the proliferation of embryonic VSMCs during the formation of the vascular system and in controlling the change of mature VSMCs to a more immature phenotype that occurs in some vascular diseases.

#### *Homeobox Genes and Postnatal Angiogenesis*

Functional evidence for the involvement of HOX cluster genes in the regulation of the angiogenic phenotype comes from the study of the paralogous HOX genes *HOXD3* and *HOXB3*, each of which appears to have distinct and complementary roles in this process. *HOXD3* is expressed at high levels in proliferating ECs induced to form tubes on Matrigel but not in quiescent ECs, and its expression is induced by basic fibroblast growth factor (bFGF) (Boudreau et al. 1997). Functionally, blocking *HOXD3* expression with antisense inhibits the bFGF-stimulated upregulation of integrin  $\alpha_v\beta_3$  and urokinase plasminogen activator (uPA) without affecting EC proliferation. In contrast, overexpressing *HOXD3* leads to expression of these genes and a morphologic change to the angiogenic phenotype, resulting in the formation of endotheliomas in vivo. In diabetic mice, *HOXD3* expression is impaired in ECs, as is its upregulation after wounding, suggesting that impaired *HOXD3* expression might be involved in the impaired wound healing observed in diabetics (Uyeno et al. 2001). In addition, the *HOXD3* paralogue, *HOXB3*, has been reported to influence angiogenic behavior in a manner distinct from *HOXD3*. Antisense against *HOXB3* impairs the capillary morphogenesis of dermal microvascular ECs and decreases the phosphorylation of the Eph A2 receptor (Myers et al. 2000). Consistent with this result, constitutive expression of *HOXB3* results in an increase in capillary vascular density and angiogenesis, but does not produce endotheliomas. Taken together, these results suggest overlapping and complementary roles for *HOXB3* and *HOXD3* in angiogenesis, with *HOXD3* promoting the invasive or migratory behavior of ECs in response to angiogenic signals and *HOXB3* promoting capillary morphogenesis of these new vascular sprouts.

In contrast to *HOXB3* and *HOXD3*, another HOX cluster gene—*HOXD10*—

inhibits EC conversion to the angiogenic phenotype. Expression of *HOXD10* is higher in quiescent endothelium as compared with tumor-associated vascular endothelium. Moreover, sustained expression of *HOXD10* inhibits EC migration and blocks bFGF- and VEGF-induced angiogenesis in the chick chorioallantoic membrane assay in vivo. Consistent with these observations, human ECs overexpressing *HOXD10* fail to form new blood vessels (Myers et al. 2002) when embedded in Matrigel-containing sponges (Nor et al. 2001) in nude mice. In addition, human ECs overexpressing *HOXD10* express a gene profile consistent with a quiescent, nonangiogenic state, with decreased expression of genes that influence remodeling of the extracellular matrix and cell migration during angiogenesis, such as the uPA receptor and the  $\alpha_3$  and  $\beta_4$  integrin subunits (Myers et al. 2002). Based on these observations, coupled with the proangiogenic activity of *HOXB3* and *HOXD3*, it has been proposed that the 5' and 3' HOX genes have distinct influences on EC behavior, with the more 3' genes tending to promote the angiogenic phenotype and the more 5' HOX genes such as *HOXD10* tending to be inhibitory to the angiogenic phenotype and dominant.

The expression of other members of the HOX clusters also have been detected in vascular ECs. One example is *HOXA9EC*, an alternatively spliced variant of *HOXA9* whose expression is downregulated by tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), which, in addition to its numerous other activities, is proangiogenic (Patel et al. 1999). Also, the expression of several members of the HOX B cluster in HUVECs is regulated by VEGF and tissue plasminogen activator, but not bFGF (Belotti et al. 1998). Because HOX B cluster gene expression does not correlate with the mitogenic state of the cell but rather is altered with the state of cellular differentiation, it has been suggested that these genes are involved in the morphogenic changes associated with the angiogenic phenotype.

Recently it has been reported that *Gax* also is expressed in vascular ECs (Gorski and Leal 2003). As in VSMCs, in ECs, *Gax* expression results in cell-cycle arrest and induces p21 expression and promoter activity. Of note, it also strongly inhibits EC tube formation in response to VEGF on Matrigel (Gorski and Leal

2003) in a manner similar to that of *Hex* (Nakagawa et al. 2003). These additional observations suggest that in addition to its likely role in maintaining VSMCs in the contractile phenotype, *Gax* may also have a role in EC differentiation. Taken together, all of the above observations suggest that *Gax* may be a global inhibitor of vascular cell activation. However, like *Hex* knockout mice (Barbera et al. 2000), mice transgenic for a null mutation in *Gax* have not been reported to show vascular anomalies (Mankoo et al. 1999). Rather, they show skeletal muscle anomalies in the limbs and die shortly after birth from unknown causes. This would tend to suggest that other homeobox factors, such as *Mox-1* (Candia and Wright 1996) or possibly *Pax3* (Stamataki et al. 2001), might compensate for a lack of *Gax/Mox-2* expression in the developing cardiovascular system. It would be of great interest to determine whether *Gax* knockout mice demonstrate increased angiogenesis in response to proangiogenic stimuli, but such studies would be difficult because of their very brief life span. Similar studies would also be of interest in *Hex* knockout mice.

Other homeobox genes also are likely to be involved in regulating angiogenesis, whether physiologic or tumor induced. For example, St. Croix et al. (2000) used serial analysis of gene expression to look for expressed sequence tags (ESTs) whose expression is at least 10-fold greater in tumor endothelium compared with normal endothelium. Not surprisingly, many of the ESTs they reported derive from extracellular matrix proteins. However, one EST was similar to the homeobox gene *Dlx-3*, a member of the *Distal-less* family of homeobox genes. This EST was not detectable in the developing corpus luteum, implying a distinction between tumor angiogenesis and physiologic angiogenesis. Interestingly, *Dlx-3* has been implicated in placental function (Beanan and Sargent 2000). Other placental homeobox genes include *Dlx-4*, *Gax/Mox-2*, *HB24*, and *Msx2* (Quinn et al. 1997). Given the critical importance of angiogenesis and blood vessel regression in placental function, it is reasonable to predict that some of these genes are involved in vascular remodeling in the placenta. It is also reasonable to postulate that homeobox genes previously demonstrated to be important in inducing proliferation and migration of ECs and EC

precursors during angiogenesis—such as *Hex*—also may be important in inducing angiogenesis in the adult vasculature.

## • Conclusions

Although much more is known since the last time we reviewed the expression and function of homeobox genes in the vasculature (Gorski et al. 1993b), knowledge of the transcriptional regulation of VSMC and EC phenotype still is not as detailed as is the understanding of the cytokines and growth factors that act on ECs and VSMCs to regulate their phenotype, the receptors these factors activate, and the downstream signaling pathways activated in turn by these receptors. However, a growing number of homeobox genes have been implicated in vascular development in the embryo and vascular remodeling, angiogenesis, and vascular diseases in the adult. Moreover, with the description of *Prox1* (Hong et al. 2002, Petrova et al. 2002), it has become clear that homeobox genes participate in the development of the lymphatic vascular system as well. Given the sheer number of homeobox genes and potential interactions between them and vascular remodeling, it is difficult to generalize too much about the roles of homeobox genes in these processes, some of which are listed in Table 1. It is possible, however, to come to three general conclusions with regard to how homeobox genes regulate vascular remodeling.

1. Pathways controlled by homeobox genes are redundant, especially during embryogenesis. This implies that it is more likely to be the overall pattern of homeobox gene expression rather than any one individual homeobox gene that regulates the phenotype of VSMCs and ECs during angiogenesis and vascular remodeling. The roles of *HOXB3*, *HOXD3*, and *HOXD10* in regulating EC phenotype during angiogenesis represent a good example of this principle. It may be the balance between pro- and antiangiogenic HOX cluster genes that determine whether an EC becomes angiogenic, and different proangiogenic HOX genes may control different stages or aspects of angiogenesis (e.g., *HOXB3* and *HOXD3*). It also can be postulated that *Gax* and *Hex* help to determine this balance. Similarly, in VSMCs, it can be postulated that the balance between *Gax* and *Prx1/Prx2* (and possibly *Hex*) plays a major role in

**Table 1. Homeobox genes expressed in the cardiovascular system**

Cell type	Gene	Function/observation	Reference
VSMC	<i>Gax (Mox-2)</i>	Downregulated upon mitogen stimulation and vascular injury Causes G <sub>1</sub> cell-cycle arrest and inhibits VSMC migration Inhibits integrin $\alpha_v\beta_3$ and $\alpha_v\beta_5$ expression Induces apoptosis in cycling cells Inhibits restenosis after balloon injury Interacts with <i>Pax3</i>	Gorski et al. 1993a, Perlman et al. 1998, Smith et al. 1997, Stamatakis et al. 2001, Weir et al. 1995, Witzensbichler et al. 1999, Yamashita et al. 1997
	<i>Hex</i>	Induces expression of immature actin isoform in VSMCs	Sekiguchi et al. 2001
	<i>HOX B7</i>	More highly expressed in fetal VSMCs than in adult VSMCs Induces differentiation of C3H10T1/2 cells into VSMC-like cells	Bostrom et al. 2000, Miano et al. 1996
	<i>HOX C9</i>	More highly expressed in fetal VSMCs than in adult VSMCs	Miano et al. 1996
	<i>HOX A3 and B3</i>	<i>HOX A3</i> knockout mice have vascular anomalies Blocking <i>HOX A3</i> and <i>B3</i> causes regression of aortic arch 3	Kirby et al. 1997
	<i>HOX A5, B5, and C5</i>	Blocking expression causes appearance of additional aortic arch artery	Kirby et al. 1997
	<i>HOX A2, A4, A11, and B1</i>	Isolated from vascular smooth muscle, functions in VSMC unknown	Gorski et al. 1993a and 1994, Patel et al. 1992
	<i>Prx1</i>	Interacts with serum response factor to activate binding Putative role in angiotensin II-mediated smooth-muscle $\alpha$ -actin expression <i>Prx1/Prx2</i> double-null mutants demonstrate vascular anomalies Activates proliferation and tenascin-C expression	Bergwerff et al. 1998 and 2000, Chesterman et al. 2001, Hautmann et al. 1997, Jones et al. 2001
	<i>Prx2</i>	Widely expressed in embryonic vasculature <i>Prx1/Prx2</i> double-null mutants demonstrate vascular anomalies	Bergwerff et al. 1998 and 2000, ten Berge et al. 1998
	<i>HOXA9EC</i>	EC specific, function presently unknown Expression modulated by tumor necrosis factor $\alpha$	Patel et al. 1999
	<i>HOX B cluster</i>	<i>HOX B</i> cluster induced by differentiating factors	Belotti et al. 1998
	<i>HOXB3</i>	Involved in regulating capillary morphogenesis	Myers et al. 2000
Vascular ECs	<i>HOXD3</i>	Induces expression of integrin $\alpha_v\beta_3$ Induces angiogenic phenotype in ECs Impaired function associated with impaired wound healing	Boudreau et al. 1997, Uyeno et al. 2001
	<i>HOXD10</i>	Inhibits angiogenesis and changes EC gene expression profile to the nonangiogenic state	Myers et al. 2002
	<i>Dlx-3</i>	Expressed sequence tags with homology to <i>Dlx-3</i> expressed at high levels in tumor endothelium Necessary for placental development	Quinn et al. 1997, St. Croix et al. 2000
	<i>Gax (Mox-2)</i>	Inhibits in vitro surrogates for angiogenesis May have function in placental-mesenchymal interactions	Gorski and Leal 2003, Quinn et al. 1997 and 2000
	<i>Hex</i>	Early marker of ECs during embryogenesis Expressed throughout the vascular network Overexpression increases EC number in embryos Overexpression blocks EC tube formation on Matrigel	Barbera et al. 2000, Liao et al. 2000, Nakagawa et al. 2003, Newman et al. 1997, Sekiguchi et al. 2001, Thomas et al. 1998
	<i>Prox1</i>	Specific to lymphatic ECs Induces expression of lymphatic EC-specific genes Null mutations prevent development of lymphatic system Master regulator of lymphatic vessel formation from embryonic venous system	Hong et al. 2002, Petrova et al. 2002, Wigle and Oliver 1999, Wigle et al. 1999 and 2002

EC, endothelial cell; VSMC, vascular smooth muscle cell.



determining whether VSMCs become contractile or synthetic.

2. Individual homeobox genes may function as master regulatory genes for parts of the vascular system. For instance, although a master regulatory gene controlling development of angioblasts into vascular ECs or VSMCs remains to be identified, *Prox1* represents a very good candidate for such a role in lymphatic endothelium. However, it must be remembered that most homeobox genes controlling vascular phenotype also are expressed in other tissues. Even *Prox1* is expressed in liver and eye lens during embryogenesis. Similarly, *Prx1* is clearly important in skeletal development (ten Berge et al. 1998), and *Gax* is important in skeletal muscle development (Mankoo et al. 1999). This implies that cell-type-specific factors influence the activities of homeobox genes in both ECs and VSMCs and that homeobox genes may be downstream from other, more global, master regulatory genes. Indeed, *Prox1* can only reprogram a vascular EC to take on the phenotype of lymphatic endothelium (Petrova et al. 2002). It cannot so reprogram other cell types.

3. Little is known about how homeobox genes implicated in angiogenesis and vascular remodeling exert their effects at the molecular level. However, it is clear that at least a subset of them appear to function by controlling the differentiation, proliferation, and/or migration of VSMCs and ECs. The mechanism behind these phenotypic changes must be the activation and repression of specific batteries of downstream genes. Because few downstream genes from homeobox genes are known, one of the most fertile areas of research for homeobox gene research is the identification of their downstream targets and the elucidation of the mechanisms by which homeobox genes regulate the expression of these target genes and these target genes in turn lead to the phenotypic changes observed. In the near future, it is likely that cDNA microarray technology will provide an excellent tool for identifying the global changes in gene expression occurring in response to homeobox gene expression in vascular cells.

Given their importance in cell-cycle control, cell migration, and cell adhesion, it is likely that many more homeobox genes will be implicated in the regulation of vascular remodeling and angiogenesis. The identification of the specific

homeobox genes involved in these processes, their downstream target genes, and the cell-signaling pathways activated and repressed by homeobox gene expression in vascular ECs and VSMCs will result in a better understanding of the basic cellular mechanisms by which the vascular system is remodeled in response to physiologic signals, tumors, or other stimuli. Such understanding has the potential to lead to the development of therapies that block tumor angiogenesis and lymphatic metastasis, reverse atherosclerosis, prevent restenosis after angioplasty, improve wound healing, and reverse lymphedema.

# • Acknowledgments

Dr. Gorski is supported by US Department of Defense Career Development Award DAMD17-02-1-0511 and US Department of Defense Idea Award DAMD17-03-1-0292. Dr. Walsh is supported by National Institutes of Health grant number AR40197.

# References

Barbera JPM, Clements M, Thomas P, et al.: 2000. The homeobox gene *Hex* is required in definitive endodermal tissues for normal forebrain, liver and thyroid formation. *Development* 127:2433-2445.

Beanan MJ, Sargent TD: 2000. Regulation and function of *dlx3* in vertebrate development. *Dev Dyn* 218:545-553.

Belotti D, Clausse N, Flagiello D, et al.: 1998. Expression and modulation of homeobox genes from cluster B in endothelial cells. *Lab Invest* 78:1291-1299.

Bergwerff M, Gittenberger-de Groot AC, DeRuiter MC, et al.: 1998. Patterns of paired-related homeobox genes *PRX1* and *PRX2* suggest involvement in matrix modulation in the developing chick vascular system. *Dev Dyn* 213:59-70.

Bergwerff M, Gittenberger-de Groot AC, Wisse LJ, et al.: 2000. Loss of function of the *Prx1* and *Prx2* homeobox genes alters architecture of the great elastic arteries and ductus arteriosus. *Virchows Arch* 436:12-19.

Bostrom K, Tintut Y, Kao SC, et al.: 2000. *HOXB7* overexpression promotes differentiation of C3H10T1/2 cells to smooth muscle cells. *J Cell Biochem* 78:210-221.

Boudreau N, Andrews C, Srebrow A, et al.: 1997. Induction of the angiogenic phenotype by *Hox D3*. *J Cell Biol* 139:257-264.

Candia AF, Wright CV: 1996. Differential localization of *Mox-1* and *Mox-2* proteins indicates distinct roles during development. *Int J Dev Biol* 40:1179-1184.

Chesterman ES, Gainey GD, Varn AC, et al.: 2001. Investigation of *Prx1* protein expression provides evidence for conservation of cardiac-specific posttranscriptional regulation in vertebrates. *Dev Dyn* 222:459-470.

Chisaka O, Capecchi MR: 1991. Regionally restricted developmental defects resulting from targeted disruption of the mouse homeobox gene *hox-1.5*. *Nature* 350:473-479.

Cillo C, Faiella A, Cantile M, Boncinelli E: 1999. Homeobox genes and cancer. *Exp Cell Res* 248:1-9.

Crompton MR, Bartlett TJ, MacGregor AD, et al.: 1992. Identification of a novel vertebrate homeobox gene expressed in haematopoietic cells. *Nucleic Acids Res* 20:5661-5667.

Cserjesi P, Lilly B, Bryson L, et al.: 1992. *MHox*: a mesodermally restricted homeodomain protein that binds an essential site in the muscle creatine kinase enhancer. *Development* 115:1087-1101.

Eberhard A, Kahlert S, Goede V, et al.: 2000. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. *Cancer Res* 60:1388-1393.

Folkman J: 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1:27-31.

Ford HL: 1998. Homeobox genes: a link between development, cell cycle, and cancer? *Cell Biol Int* 22:397-400.

Gorski DH, Leal AJ: 2003. Inhibition of endothelial cell activation by the homeobox gene *Gax*. *J Surg Res* 13:213-220.

Gorski DH, LePage DF, Patel CV, et al.: 1993a. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G<sub>0</sub>/G<sub>1</sub> transition in vascular smooth muscle cells. *Mol Cell Biol* 13:3722-3733.

Gorski DH, Patel CV, Walsh K: 1993b. Homeobox transcription factor regulation in the cardiovascular system. *Trends Cardiovasc Med* 3:184-190.

Gorski DH, LePage DF, Walsh K: 1994. Cloning and sequence analysis of homeobox transcription factor cDNAs with an inosine-containing probe. *Biotechniques* 16:856-865.

Hautmann MB, Thompson MM, Swartz EA, et al.: 1997. Angiotensin II-induced stimulation of smooth muscle alpha-actin expression by serum response factor and the homeodomain transcription factor *MHox*. *Circ Res* 81:600-610.

Hong YK, Harvey N, Noh YH, et al.: 2002. *Prox1* is a master control gene in the program specifying lymphatic endothelial cell fate. *Dev Dyn* 225:351-357.

- Jones FS, Meech R, Edelman DB, et al.: 2001. Prx1 controls vascular smooth muscle cell proliferation and tenascin-C expression and is upregulated with Prx2 in pulmonary vascular disease. *Circ Res* 89:131-138.
- Kirby ML, Hunt P, Wallis K, Thorogood P: 1997. Abnormal patterning of the aortic arch arteries does not evoke cardiac malformations. *Dev Dyn* 208:34-47.
- Kosaki K, Kosaki R, Suzuki T, et al.: 2002. Complete mutation analysis panel of the 39 human HOX genes. *Teratology* 65:50-62.
- Krumlauf R: 1994. Hox genes in vertebrate development. *Cell* 78:191-201.
- Liao W, Ho CY, Yan YL, et al.: 2000. Hhex and scl function in parallel to regulate early endothelial and blood differentiation in zebrafish. *Development* 127:4303-4313.
- Mankoo BS, Collins NS, Ashby P, et al.: 1999. Mox2 is a component of the genetic hierarchy controlling limb muscle development. *Nature* 400:69-73.
- Miano JM, Firulli AB, Olson EN, et al.: 1996. Restricted expression of homeobox genes distinguishes fetal from adult human smooth muscle cells. *Proc Natl Acad Sci USA* 93:900-905.
- Myers C, Charboneau A, Boudreau N: 2000. Homeobox B3 promotes capillary morphogenesis and angiogenesis. *J Cell Biol* 148:343-351.
- Myers C, Charboneau A, Cheung I, et al.: 2002. Sustained expression of homeobox d10 inhibits angiogenesis. *Am J Pathol* 161:2099-2109.
- Nakagawa T, Abe M, Yamazaki T, et al.: 2003. HEX acts as a negative regulator of angiogenesis by modulating the expression of angiogenesis-related gene in endothelial cells in vitro. *Arterioscler Thromb Vasc Biol* 23:231-237.
- Newman CS, Chia F, Krieg PA: 1997. The XHex homeobox gene is expressed during development of the vascular endothelium: overexpression leads to an increase in vascular endothelial cell number. *Mech Dev* 66:83-93.
- Nor JE, Peters MC, Christensen JB, et al.: 2001. Engineering and characterization of functional human microvessels in immunodeficient mice. *Lab Invest* 81:453-463.
- Oliver G, Sosa-Pineda B, Geisendorf S, et al.: 1993. Prox 1, a prospero-related homeobox gene expressed during mouse development. *Mech Dev* 44:3-16.
- Opstelten DJ, Vogels R, Robert B, et al.: 1991. The mouse homeobox gene, S8, is expressed during embryogenesis predominantly in mesenchyme. *Mech Dev* 34:29-41.
- Patel CV, Gorski DH, LePage DF, et al.: 1992. Molecular cloning of a homeobox transcription factor from adult aortic smooth muscle. *J Biol Chem* 267:26,085-26,090.
- Patel CV, Sharangpani R, Bandyopadhyay S, DiCorleto PE: 1999. Endothelial cells express a novel, tumor necrosis factor- $\alpha$ -regulated variant of HOXA9. *J Biol Chem* 274:1415-1422.
- Perlman H, Sata M, Le Roux A, et al.: 1998. Bax-mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity. *EMBO J* 17:3576-3586.
- Petrova TV, Makinen T, Makela TP, et al.: 2002. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. *EMBO J* 21:4593-4599.
- Quinn LM, Johnson BV, Nicholl J, et al.: 1997. Isolation and identification of homeobox genes from the human placenta including a novel member of the Distal-less family, DLX4. *Gene* 187:55-61.
- Quinn LM, Latham SE, Kalionis B: 2000. The homeobox genes MSX2 and MOX2 are candidates for regulating epithelial-mesenchymal cell interactions in the human placenta. *Placenta* 21(Suppl A):S50-S54.
- Ross R: 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 362:801-809.
- Scott MP, Tamkun JW, Hartzell GWI: 1989. The structure and function of the homeodomain. *Biochim Biophys Acta* 989:25-48.
- Sekiguchi K, Kurabayashi M, Oyama Y, et al.: 2001. Homeobox protein Hex induces SMemb/nonmuscle myosin heavy chain-B gene expression through the cAMP-responsive element. *Circ Res* 88:52-58.
- Skobe M, Hawighorst T, Jackson DG, et al.: 2001. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. *Nat Med* 7:192-198.
- Skopicki HA, Lyons GE, Schattman G, et al.: 1997. Embryonic expression of the Gax homeodomain protein in cardiac, smooth, and skeletal muscle. *Circ Res* 80:452-462.
- Smith RC, Branellec D, Gorski DH, et al.: 1997. p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. *Genes Dev* 11:1674-1689.
- St. Croix B, Rago C, Velculescu V, et al.: 2000. Genes expressed in human tumor endothelium. *Science* 289:1197-1202.
- Stamatkaki D, Kastrinaki M, Mankoo BS, et al.: 2001. Homeodomain proteins Mox1 and Mox2 associate with Pax1 and Pax3 transcription factors. *FEBS Lett* 499:274-278.
- ten Berge D, Brouwer A, Korving J, et al.: 1998. Prx1 and Prx2 in skeletogenesis: roles in the craniofacial region, inner ear and limbs. *Development* 125:3831-3842.
- Thomas PQ, Brown A, Beddington RS: 1998. Hex: a homeobox gene revealing peri-implantation asymmetry in the mouse embryo and an early transient marker of endothelial cell precursors. *Development* 125: 85-94.
- Uyeno LA, Newman-Keagle JA, Cheung I, et al.: 2001. Hox D3 expression in normal and impaired wound healing. *J Surg Res* 100:46-56.
- Weir L, Chen D, Pastore C, et al.: 1995. Expression of gax, a growth arrest homeobox gene, is rapidly down-regulated in the rat carotid artery during the proliferative response to balloon injury. *J Biol Chem* 270:5457-5461.
- Wigle JT, Oliver G: 1999. Prox1 function is required for the development of the murine lymphatic system. *Cell* 98:769-778.
- Wigle JT, Chowdhury K, Gruss P, Oliver G: 1999. Prox1 function is crucial for mouse lens-fibre elongation. *Nat Genet* 21:318-322.
- Wigle JT, Harvey N, Detmar M, et al.: 2002. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. *EMBO J* 21:1505-1513.
- Witzenbichler B, Kureishi Y, Luo Z, et al.: 1999. Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. *J Clin Invest* 104:1469-1480.
- Yamashita J, Itoh H, Ogawa Y, et al.: 1997. Opposite regulation of Gax homeobox expression by angiotensin II and C-type natriuretic peptide. *Hypertension* 29:381-387.

PII S1050-1738(03)00081-1

TCM

## LETTERS

**TCM** welcomes letters on topics of interest to cardiovascular researchers and clinical cardiologists. Letters to the Editor in response to published articles are also accepted. Please submit brief letters, with a minimum of references, to:

Elizabeth G. Nabel, MD, Editor-in-Chief  
*Trends in Cardiovascular Medicine*  
 The Curtis Center, Suite 300, Independence Square West  
 Philadelphia, PA 19106, USA



**The homeobox gene *Gax* inhibits angiogenesis through  
inhibition of nuclear factor- $\kappa$ B-dependent endothelial  
cell gene expression**

**Sejal Patel<sup>1</sup>, Alejandro D. Leal<sup>1</sup>, and David H. Gorski<sup>1,2</sup>**

<sup>1</sup>Division of Surgical Oncology  
UMDNJ-Robert Wood Johnson Medical School  
The Cancer Institute of New Jersey  
195 Little Albany St.  
New Brunswick, NJ 08901  
Phone: (732) 235-8070  
FAX: (732) 235-8098

**<sup>2</sup>Corresponding author:**

David H. Gorski, M.D., Ph.D.  
Assistant Professor of Surgery  
Division of Surgical Oncology  
UMDNJ-Robert Wood Johnson Medical School  
The Cancer Institute of New Jersey  
195 Little Albany St.  
New Brunswick, NJ 08901

Phone: (732) 235-8524  
FAX: (732) 235-8098  
e-mail: gorskidh@umdnj.edu

**KEY WORDS:** *Gax*, homeobox genes, angiogenesis, vascular endothelium, NF- $\kappa$ B,  
transcription factors

**ABSTRACT**

The growth and metastasis of tumors are heavily dependent on angiogenesis, but much of the transcriptional regulation of vascular endothelial cell (EC) gene expression responsible for angiogenesis remains to be elucidated. The homeobox gene *Gax* is expressed in vascular ECs and inhibits proliferation and tube formation *in vitro*. We hypothesized that *Gax* is a negative transcriptional regulator of the EC angiogenic phenotype and studied its regulation and activity in vascular ECs. Several pro-angiogenic factors caused a rapid downregulation of *Gax* mRNA in human umbilical vein endothelial cells (HUVECs), as did conditioned media from breast cancer cell lines. In addition, *Gax* expression using an replication-deficient adenoviral vector inhibited HUVEC migration towards proangiogenic factors *in vitro* and inhibited angiogenesis *in vivo* in Matrigel plugs. To identify potential downstream targets of *Gax*, we examined changes in global gene expression due to *Gax* activity using cDNA microarrays. *Gax* expression resulted in changes in HUVEC gene expression profiles consistent with a quiescent, non-angiogenic phenotype, with increased expression of cyclin kinase inhibitors and decreased expression of numerous genes implicated in EC activation and angiogenesis. Further analysis revealed that *Gax* downregulated numerous nuclear factor- $\kappa$ B (NF- $\kappa$ B) targets genes, and we observed that *Gax* decreases the binding of NF- $\kappa$ B to its target sequence in electrophoretic mobility shift assays. To our knowledge, *Gax* is the first homeobox gene described that influences NF- $\kappa$ B activity in vascular ECs. Because NF- $\kappa$ B has been implicated in EC activation and angiogenesis, the downregulation of NF- $\kappa$ B-dependent genes by *Gax* suggests one potential mechanism by which *Gax* inhibits the angiogenic phenotype.

## **INTRODUCTION**

The process of angiogenesis, critical in both normal physiology and in disease states such as cancer and inflammatory diseases, is normally tightly regulated by a balance between pro- and antiangiogenic factors, known as the “angiogenic balance” (32). Tumors hijack the process of angiogenesis in order to parasitize their host by secreting proangiogenic peptides, cytokines, and chemokines, tipping the “angiogenic balance” towards a proangiogenic state. The primary target of proangiogenic factors secreted by tumors is the vascular endothelial cell (EC). During angiogenesis, whether physiologic or tumor-induced, vascular ECs become “activated” and undergo distinct changes in phenotype and gene expression. These changes include activation of proteolytic enzymes to degrade basement membrane, EC sprouting, proliferation, tube formation, and production of extracellular matrix (3, 45, 60). Although the EC receptors and signaling pathways activated by proangiogenic factors, such as vascular endothelial growth factor (VEGF) (15, 16) or basic fibroblast growth factor (bFGF) (15), and proangiogenic and proinflammatory factors such as tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) (64) have been extensively studied, less is known about the molecular biology of the downstream transcription factors activated by these factors, which in turn activate and repress batteries of downstream genes necessary for the phenotypic changes that ECs must undergo in order for angiogenesis to occur. Nuclear transcription factors likely integrate these signals in order to produce the gene expression profile that results in the phenotypic changes resulting in angiogenesis. Thus, understanding the transcriptional mechanisms by which ECs become activated is likely to suggest new therapeutic strategies for inhibiting this process at a very distal point in its signaling cascade, with potential applications in the treatment of cancer and vascular diseases whose pathophysiology is significantly based on EC activation, such as atherosclerosis.

Because of their ubiquitous role as regulators of cellular differentiation and body plan formation during embryogenesis, as well as oncogenes and tumor suppressors, in various human cancers (1, 13), it is not surprising that homeobox genes have been implicated in regulating the phenotypic changes that ECs undergo when during angiogenesis (4-6, 25, 47-49, 51). In particular, one diverged homeobox genes, *Gax* (Growth Arrest-specific homeoboX, whose mouse homologue is known as *Mox-2*), has several characteristics that implicate it as potentially having an important role as an inhibitor of the EC phenotypic changes that occur in response to stimulation by proangiogenic or proinflammatory factors (10, 27, 54, 59, 66, 67). Originally isolated from vascular smooth muscle (27) and widely expressed in mesoderm and muscle precursors in the embryo (9, 25, 58), in the adult *Gax* expression is mostly restricted to the cardiovascular system and kidney (27, 58). In vascular smooth muscle cells, *Gax* expression is downregulated by mitogens and upregulated by growth arrest signals (27, 66, 68). Consistent with this observation, *Gax* expression induces G<sub>1</sub> cell cycle arrest (59) and inhibits vascular smooth muscle cell migration, modulating expression integrin expression (67). *In vivo*, *Gax* expression in arteries inhibits proliferative restenosis of the arterial lumen after injury (42, 54, 59). Recently, we have observed that *Gax* has similar effects on EC phenotype, such as inhibition of proliferation associated with the induction of p21 expression (25). In addition, *Gax* strongly inhibits VEGF-induced EC tube formation on reconstituted basement membrane (25), suggesting that *Gax* may be a negative regulator of the phenotypic changes that ECs undergo when they become activated or angiogenic.

Until now, we had not identified potential mechanisms by which *Gax* might accomplish its inhibition of EC activation, other than a general cell cycle arrest due to induction of p21 (25, 59). In this report, we now describe how *Gax* expression is regulated in ECs by proangiogenic

and proinflammatory factors and how its expression can block EC activation *in vitro* and angiogenesis *in vitro* and *in vivo*. Finally, we provide evidence that *Gax* inhibits nuclear factor- $\kappa$ B (NF- $\kappa$ B) signaling in ECs. Given that there is now considerable evidence that activation of NF- $\kappa$ B activity in ECs is proangiogenic (39, 40, 43, 46, 52, 56, 57), this interaction likely represents one potential mechanism by which *Gax* expression may inhibit angiogenesis. This interaction, to our knowledge the first described in ECs, may represent a new mechanism by which homeobox genes can interact with intracellular signaling pathways and thereby inhibit angiogenesis.

## **METHODS**

### ***Cell culture and expression constructs***

Human umbilical vein endothelial cells (HUVECs) were obtained from BioWhittaker (Walkersville, MD) and cultured according to the manufacturer's instructions in EGM-2 medium, also obtained from BioWhittaker. HMEC-1 cells were obtained from the Centers for Disease Control and were cultured as described (2).

The construction of replication-deficient adenoviral vectors expressing the rat and human homologs of *Gax* (Ad.*hGax* and Ad.*rGax*, respectively) conjugated to the  $\alpha$ -hemagglutinin (HA) epitope has been described previously (59). In this study, both human and rat isoforms of *Gax* were used, in order to verify that both isoforms have similar activity. The control replication-deficient adenoviral vector expressing green fluorescent protein (Ad.*GFP*) was a kind gift of Dr. Daniel Medina (The Cancer Institute of New Jersey, New Brunswick, NJ). As a positive control for inhibition of angiogenesis *in vivo* by a viral vector, we utilized an additional adenoviral construct expressing a form of Akt (T308A, S473A, adenoviral construct designated Ad.DN.Akt) that functions in a dominant negative fashion (22, 50), kindly provided by Dr.

Kenneth Walsh (Boston University). Viral titers were measured by plaque assay. Expression of *Gax* mRNA and protein in cells transduced with these adenoviral constructs were verified by quantitative real time PCR according to methods described below and Western blot utilizing anti-HA antibody (not shown).

***Quantitative reverse transcriptase real time polymerase chain reaction (QRT-PCR)***

After treatment as described individually for each experiment, total RNA was isolated from ECs using a spin-column with on-column DNase digestion to remove contaminating genomic DNA (RNAeasy, Qiagen). First strand synthesis was performed on the total RNA also using oligo-dT primers (Superscript kit, Invitrogen). Message levels for *Gax* and the endothelial cell adhesion molecules (E-selectin, VCAM-1, and ICAM-1) were then determined by quantitative real time RT-PCR utilizing TaqMan probes (8). QRT-PCR was carried out using a Cepheid SmartCycler thermocycler, with the associated SmartCycler v.2.0 software used to analyze the data and determine the threshold count ( $C_t$ ).

Primer and probe sets for each gene were designed using the MacVector 7.2 software package (Accelrys, San Diego, CA). The fluorophore used was 6-FAM and Black Hole Quencher-1 (BHQ-1, Biosearch Technologies, Novato, CA). Sequences of the primers and probes were: *Gax*: 5'-TCA GAA GTC AAC AGC AAA CCC AG-3' (forward), 5'-CCA GTT CCT TTT CCC GAG-3' (reverse), 5'-(6-FAM)-TGG TTC CAA AAC AGG CGG ATG-3'-(BHQ1) (TaqMan probe), amplicon = 238 bp; E-Selectin: 5'-CTC TGA CAG AAG AAG CCA AG-3' (forward), 5'-ACT TGA GTC CAC TGA AGT CA -3' (reverse), 5'-(6-FAM)-CCA CGC AGT CCT CAT CTT TTT G-3'-(BHQ1) (TaqMan probe), amplicon = 255 bp; VCAM-1: 5'-ATG ACA TGC TTG AGC CAG G -3' (forward), 5'-GTG TCT CCT TCT TTG ACA CT-3' (reverse), 5'-(6-FAM)-CAC TTC CTT TCT GCT TCT TCC AGC-3'-(BHQ1) (TaqMan probe),



**The homeobox gene *Gax* inhibits endothelial cell activation and nuclear factor  $\kappa$ B activity**

amplicon = 260 bp; ICAM-1: 5'-TAT GGC AAC GAC TCC TTC T-3' (forward), 5'-CAT TCA GCG TCA CCT TGG -3' (reverse), 5'-(6-FAM)-CCT TCT GAG ACC TCT GGC TTC G-3'-(BHQ1) (TaqMan probe), amplicon = 238 bp. To correct for differences in RNA quality and quantity between samples, the target gene was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) message levels. Sequences of the GAPDH primer and probe set were: 5'-ACA ACT TTG GTA TCG TGG AAG-3' (forward); 5'-CAG ATG AGG CAG GGA TGA TGT TC -3' (reverse); 5'-(6-FAM)-ACC CAG AAG ACT GTG GAT GG-3'-(BHQ1) (TaqMan probe), amplicon = 138 bp. For some experiments (Figure 1), a set of primers for human *Gax* previously described were used (25).

Reaction mixtures for QRT-PCR were 25  $\mu$ l, containing 0.75 U *Taq* polymerase (Invitrogen), reaction buffer, 0.2 mM dNTPs, plus optimized concentrations of  $MgCl_2$ , probe, and primers. For all reactions, negative controls were run with no template present, and random RNA preparations were also subjected to sham QRT-PCR (no reverse transcriptase) to verify lack of contamination with genomic DNA. The PCR cycle started with an initial 1.5 minute denaturation step at 95° C, followed by 30 to 40 cycles of denaturation at 95° C for 10 seconds; annealing at 50° (VCAM-1), 52° (E-selectin, ICAM-1), 56° (*Gax*, GAPDH) for 20 seconds; and extension at 72° C for 30 seconds. Each sample was run in triplicate and  $C_t$  determined for the target gene. Target gene mRNA levels were estimated and normalized to GAPDH mRNA levels using the  $\Delta\Delta C_t$  method, as we have done previously (26, 31).

***Migration assays***

Prior to the experiment cell culture membranes and flasks were coated with sterile 0.1% gelatin in PBS. HUVECs were infected with adenoviral vectors at MOI=100 for 16 hours before  $5 \times 10^4$  cells/well were plated onto 8.0  $\mu$ m pore size polycarbonate membrane in 24 well plates.

**The homeobox gene *Gax* inhibits endothelial cell activation and nuclear factor  $\kappa$ B activity**

Cells were allowed to attach for one hour in EGM-2 medium. Once the cells had attached, the medium in the upper chamber was replaced with low serum medium (LSM, which consisted of EGM-2 + 0.1% FBS lacking VEGF, bFGF, and EGF), and the lower chamber with LSM supplemented with either 50 ng/ml VEGF, 50 ng/ml bFGF, 15 ng/ml TNF (VEGF, bFGF, and TNF- $\alpha$  all obtained from R&D Systems, Minneapolis, MN), or 10% FBS. After 5 hours the inserts were washed with PBS and the upper surfaces cleaned with a cotton swab to remove any cells that had not migrated. Finally the cells were fixed with Diff-Quik<sup>®</sup> Stain (Dade Behring, Deerfield, IL) and the inserts washed in PBS and photographed for counting. Cells were counted in five high powered fields (hpf) per well. Experiments were repeated at least three times.

***In vivo angiogenesis assay***

The formation of new blood vessels *in vivo* was assayed by the Matrigel plug assay as described previously (36, 50). These experiments were performed under a protocol approved by the Institutional Animal Care and Use Committee at UMDNJ-Robert Wood Johnson Medical School, and this research has complied with all relevant federal guidelines and institutional policies. In brief, cold Low Growth Factor Matrigel (BD Pharmingen, San Diego, CA, 500  $\mu$ l/mouse) containing bFGF 400 ng/ml (R & D Systems, Minneapolis, MN), heparin 10 U/ml (Sigma, St. Louis, MO), and  $10^8$  pfu of either Ad.GFP, Ad.*hGax*, or Ad.*rGax* was injected subcutaneously in C57BL/6 mice (N=8 per experimental group). As a positive control for angiogenesis inhibition by a viral vector, we utilized an adenoviral construct expressing a dominant negative form of Akt (Ad.DN.Akt) provided by Dr. Kenneth Walsh (see above), which has previously been used to show that inhibition of Akt signaling inhibits angiogenesis *in vivo* (50). As another control, to verify that adenovirus itself does not significantly alter *in vivo* angiogenesis as measured by this assay, plugs containing only bFGF were also examined.

After 14 days, the mice were euthanized by CO<sub>2</sub> inhalation followed by cervical dislocation, and the plugs carefully removed *en bloc* with surrounding connective tissue. Tissue and plugs were fixed for 10 minutes in cold acetone and frozen sections made. Tissue sections were cut at 5  $\mu$ m and their endogenous peroxidase activity blocked with dilute H<sub>2</sub>O<sub>2</sub>. Sections were then blocked with 5% bovine serum albumin (BSA) for 15 minutes, washed with PBS, and then incubated with rat anti-mouse CD31 (PECAM) monoclonal antibody (BD PharMingen, San Diego, CA) at a 1:20 dilution in 1%BSA in PBS) overnight. Sections were then washed with cold PBS twice and incubated with Biotinylated mouse anti-rat IgG<sub>1/2a</sub> (BD PharMingen, San Diego, CA) in 1% BSA/PBS at 1:400 dilution. Color was then developed with streptavidin-peroxidase (VectaStain, ABC Kit, Vector Laboratories, Burlingame, CA). Sections were counterstained with Toluidine Blue and vessel counts performed as previously described (44, 50). In brief, vascular hot spots were located for each plug near the interface between the plug and surrounding stroma, and blood vessel density estimated as the number of vessels per high-powered field. The fields chosen for each plug section were all located at the plug-stroma interface. Two sections from each plug were made and at least five high-powered fields per section were counted, and the mean  $\pm$  standard error of the mean determined for each experimental group. The experiment was repeated twice. Statistical differences were determined by one-way ANOVA using Prism v.4.0 (GraphPad Software, Inc., San Diego, CA), followed by Dunnett's multiple comparison test using the Ad.GFP group as the control.

#### *cDNA microarray studies*

We compared global gene expression in control HUVECs transduced with Ad.GFP with that of HUVECs transduced with Ad.r*Gax* or Ad.h*Gax*. Cells were transduced at an MOI=100, incubated 24 hours in normal media, then harvested for total RNA isolation as described above

for quantitative real time RT-PCR. RNA quality was verified by electrophoresis through formaldehyde-containing agarose gels prior to use for generating probes for cDNA microarray analysis. Exogenous *Gax* expression was verified by real time quantitative RT-PCR and Western blot (data not shown). Global gene expression was then compared in two separate experiments using the Affymetrix Human Genome U133A GeneChip<sup>®</sup> array set and standard protocols supplied by the manufacturer, with technical assistance from the cDNA Microarray Core Facility of The Cancer Institute of New Jersey. This chip contains probe sets for over 33,000 known genes, along with probes for housekeeping genes for normalization and genomic DNA for evaluation of hybridization quality. Results were further analyzed with GeneMAPP (19) to identify signal-dependent changes in gene expression.

#### ***Western blots***

Whole cell extracts from TNF- $\alpha$  treated HUVECs were electrophoresed on 8% SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. The membranes were placed in blocking solution (PBS containing 5% non-fat dry milk and 0.1% Tween-20) for 1 hour or overnight at 4° C before being incubated with the appropriate dilution of primary antibody (mouse monoclonal anti-VCAM-1 and anti-ICAM-1 and rabbit polyclonal anti-E-selectin; Santa Cruz Biotechnology, Santa Cruz, CA) in blocking solution for 1-2 hours. Blots were then washed 3 times with blocking solution and incubated for 1 hour in secondary antibody (goat anti-mouse IgG or goat anti-rabbit IgG; Pierce Biotechnology, Inc., Rockford, IL) at a dilution of 1:5000 before being washed 2 times with blocking. A final wash of PBS with 0.1% Tween-20 for 5 minutes was done prior to visualization by chemiluminescence using the ECL-Plus reagent (Amersham, Piscataway, NJ).

***Flow cytometry***

Cells were harvested after the relevant treatment and resuspended in phosphate buffered saline (PBS) containing 0.1% sodium azide. Approximately  $1 \times 10^5$  cells were incubated with FITC-conjugated primary antibody against human E-selectin, VCAM-1, or ICAM-1 (BD Biosciences, San Diego, CA) for 30 minutes on ice. Cells were pelleted and washed twice in PBS/Azide prior to flow analysis on a Beckman-Coulter Cytomics FC500 flow cytometer (Fullerton, CA).

***Electrophoretic mobility shift assays***

HUVEC cells were transduced with Ad.GFP or Ad.r*Gax* and then induced with 10 ng/ml TNF- $\alpha$  for 1 hour. Nuclear extracts were prepared with the NE-PER nuclear extraction reagent (Pierce Biotechnology, Rockford IL). Biotin end-labeled double-stranded oligonucleotides containing the NF- $\kappa$ B consensus sequence, 5'-biotin-AGT TGA GGG GAC TTT CCC AGG C-3' were purchased from IDT technologies - Idaho. The binding reactions contained 6-8  $\mu$ g of nuclear extract protein, buffer (10 mM Tris, pH 7.5, 50 mM KCl, 1 mM dithiothreitol), 1  $\mu$ g of poly(dI-dC), 5  $\mu$ g BSA and 20 fM of biotin-labeled DNA. The reactions were incubated at room temperature for 20 min. The competition reactions were performed by adding up to 200-fold excess unlabeled double-stranded NF- $\kappa$ B consensus oligonucleotide to the reaction mixture. Other controls included competition with random oligonucleotide (5'-TAG CAT ATG CTA-3') and an NF- $\kappa$ B site with a point mutation that abolishes DNA binding (5'-CAC AGT TGA GGC CAC TTT CCC AGG C-3'). The reactions were electrophoresed on a 6% acrylamide gel at 100 V for 1 h in 0.5X Tris-borate-EDTA buffer. The reactions were transferred to positively charged nylon membrane. Biotinylated oligonucleotides were detected with streptavidin linked horseradish peroxidase and the Pierce LightShift kit (Pierce Biotechnology, Rockford, IL).

## **RESULTS**

### ***Gax expression is rapidly downregulated by mitogens and proangiogenic factors in ECs***

Given our previous observations that *Gax* expression inhibits EC proliferation and tube formation *in vitro* (25), we first wished to determine how *Gax* expression is regulated by growth factors and proangiogenic peptides in ECs. Because endogenous *Gax* message is usually expressed at relatively low levels in VSMCs and ECs (25, 27), we developed a quantitative real time PCR assay using *Gax*-specific primers and a TaqMan probe (33) (see Methods). First, we studied the time course of *Gax* downregulation. HUVECs made quiescent by incubation for 24 hrs in 0.1% FBS were stimulated with 10% FBS plus 5 ng/ml VEGF. *Gax* was rapidly downregulated by 5-fold within four hours and slowly returned to basal over 24 to 48 hours (Figure 1, A and C). Conversely, when sparsely plated randomly cycling HUVECs were placed in medium containing 0.1% serum, *Gax* was upregulated nearly 10-fold within 24 hours (Figure 1B). We then stimulated quiescent HUVECs with proangiogenic or proinflammatory factors, including bFGF, VEGF, and TNF- $\alpha$ . *Gax* was rapidly downregulated with a similar time course (Figure 2). Similar results were observed in HMEC-1 cells (2), an immortalized human microvascular endothelial cell line that retains many characteristics of microvascular endothelial cells (data not shown).

Next, we compared the efficacy of serum and different proangiogenic factors at downregulating *Gax* expression in quiescent HUVECs (Figure 3). At 4 hours, serum and all growth factors tested downregulated *Gax* similarly (Figure 2 and Figure 3, A and B). However, at 24 hours, serum, VEGF, and TNF- $\alpha$  tend to be more potent at downregulating *Gax* than bFGF (Figure 2 and Figure 3, C and D), although this may be because bFGF requires a higher concentration than VEGF (Figure 3D). Finally, if *Gax* downregulation is a necessary molecular



**The homeobox gene *Gax* inhibits endothelial cell activation and nuclear factor  $\kappa$ B activity**

event that allows ECs to become activated by tumor-secreted proangiogenic factors, we hypothesized that tumor-secreted factors would also downregulate *Gax* expression *in vitro* and *in vivo*. We therefore incubated breast cancer cell lines in serum-free medium for 24 hours, harvested the conditioned medium, and stimulated quiescent HUVECs with the media for 4 hours. The cell lines varied considerably in their ability to downregulate *Gax*, but all of them downregulated *Gax* expression at least three-fold, and some by as much as 20-fold (Figure 4), suggesting that tumor-secreted proangiogenic factors also regulate *Gax* expression.

***Gax* expression inhibits endothelial cell migration towards proangiogenic factors**

Migration of ECs through the basement membrane and into the surrounding stroma in response to proangiogenic stimuli is a critical step in tumor-induced angiogenesis. We therefore tested the ability of *Gax* to inhibit EC migration towards proangiogenic factors. HUVECs were transduced with Ad.r*Gax* or Ad.h*Gax* at varying MOI and incubated overnight.  $10^5$  viable cells per well were plated in 6-well plates with inserts containing 8  $\mu$ m polycarbonate filters, and we measured their migration towards serum-containing media in the lower chamber. Ad.r*Gax* strongly inhibited the migration of HUVECs towards serum, VEGF, bFGF, and TNF- $\alpha$  (Figure 5), as did Ad.h*Gax* (data not shown). Both homologs also inhibited migration of HMEC-1 cells towards bFGF and VEGF (data not shown).

***Gax* expression inhibits *in vivo* angiogenesis**

Matrigel containing proangiogenic factors, when implanted subcutaneously in mice, can stimulate the ingrowth of blood vessels into the Matrigel plug from the surrounding tissue, and this neovascularization can be estimated by counting CD31-positive cells (36, 50) and/or by measuring hemoglobin concentrations in the plug (35). Moreover, adenoviral vectors diluted in Matrigel implanted as subcutaneous plugs can serve as reservoirs to transduce ECs invading the

plug and drive expression of exogenous genes, producing effects on *in vivo* angiogenesis even when the gene transduced is a transcription factor (55). We took advantage of this observation to test whether exogenously driven *Gax* expression can inhibit angiogenesis *in vivo*, using methodology previously described (36, 50). Matrigel plugs containing bFGF and either Ad.GFP, Ad.*hGax*, or Ad.*rGax* (see Methods) were injected subcutaneously in C57BL/6 mice (N=8 per experimental group). As a positive control for angiogenesis inhibition by a viral vector, we utilized an adenoviral construct expressing a dominant negative form of Akt (Ad.DN-Akt) (22, 50). We observed that the adenoviral vectors expressing *Gax* expression inhibit the neovascularization of the plugs with a potency slightly less than that observed for the Ad.DN-Akt construct (Figure 6), and that the Ad.DN.Akt construct inhibited neovascularization with a potency similar to what has previously been reported (22, 50).

***Gax* expression downregulates the expression of NF- $\kappa$ B target genes**

Next, we compared global gene expression in control HUVECs infected with Ad.GFP with that of HUVECs infected with Ad.*rGax*. Cells were infected at an MOI=100, incubated 24 hours in normal media, then harvested for total RNA isolation. Global gene expression was compared in two separate experiments using the Affymetrix Human Genome U133A GeneChip<sup>®</sup> array set (see Methods). In general, the global changes in gene expression induced by *Gax* in this experiment were consistent with an anti-proliferative, antiangiogenic activity. There were 127 probe sets corresponding to known genes showing greater than two-fold upregulation and 115 showing greater than two-fold downregulation. Differences in gene expression between controls and *Gax*-transduced cells ranged from upregulation by approximately 30-fold to downregulation by 238-fold. This pattern was similar in ECs transduced by Ad.*hGax*, although the magnitude of changes in gene expression tended to be smaller (data not shown).

We first examined genes that were downregulated 24 hours after transduction of HUVECs with Ad.r*Gax* and were immediately struck by the number of CXC chemokines strongly downregulated (Table 1, which shows selected genes that are most strongly downregulated after *Gax* expression and/or most likely to be involved in angiogenesis). Most strongly downregulated of all was GRO- $\alpha$  (CXCL1), a CXC chemokine and a growth factor for melanoma that has also been implicated in promoting angiogenesis (41). Similarly, several other CXC chemokines were also strongly downregulated by *Gax* expression. Many of these peptides are clearly important in mediating EC activation during inflammation and in promoting angiogenesis (18). Consistent with the hypothesis that *Gax* inhibits EC activation, we also observed the downregulation of several cell adhesion molecules known to be upregulated in ECs during activation and angiogenesis, including vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), and E-selectin (37, 69), all of whose downregulation we have now also confirmed by quantitative real time PCR, Western blot, and flow cytometry (Figure 7). These proteins have all been implicated in leukocyte-EC interactions and are upregulated by pro-inflammatory factors and by VEGF during angiogenesis (37). The pattern of downregulation of these adhesion molecules, coupled with the downregulation of CXC chemokines, suggested to us inhibition of genes normally induced by TNF- $\alpha$ , which in turn suggested the possibility that *Gax* may inhibit nuclear factor  $\kappa$ B (NF- $\kappa$ B) activity. Indeed, when we examined our data using GeneMAPP (19) to look for patterns of signal-dependent gene regulation, we found numerous NF- $\kappa$ B-dependent genes (23) downregulated 24 hrs after *Gax* expression (Table 2).

The genes upregulated by *Gax* did not fall into any signal-dependent patterns as striking as the genes downregulated by *Gax* (Table 3). However, we did note results that might suggest

specific pathways upregulated by *Gax*. First, there was a strong upregulation of ALK3 (bone morphogenetic receptor 1a) (34). Although it is known that, in ECs, ALK1 activates ECs through a SMAD1/5 pathway, whereas ALK5 inhibits EC activation through a SMAD2/3 pathway (30), it is not known what role, if any, ALK3 plays in regulating EC phenotype. Second, we noted the upregulation of three CDK inhibitors, p19<sup>INK4D</sup>, p57<sup>Kip2</sup>, and p21<sup>WAF1/CIP1</sup> (11, 59, 62), suggesting redundant mechanisms by which *Gax* can induce G<sub>1</sub> cell cycle arrest. Finally, we note that *Frizzled-2* was upregulated. Little is known about the potential role of *Frizzled* receptors and Wnt signaling in regulating postnatal angiogenesis, although *Frizzled-2* is known to be expressed in ECs (24) and there is evidence suggesting Wnt signaling inhibits EC proliferation (14).

#### ***Gax* expression blocks NF- $\kappa$ B binding to its consensus DNA-binding sequence**

Given that NF- $\kappa$ B activity has been implicated in the changes in phenotype and gene expression ECs undergo during angiogenesis caused by VEGF, TNF- $\alpha$ , and other factors, and that a number of NF- $\kappa$ B targets have been implicated in inducing angiogenesis (39, 40, 43, 46, 52, 56, 57), we wished to confirm the finding from cDNA microarray studies that *Gax* inhibits NF- $\kappa$ B activity in ECs. We therefore performed EMSAs utilizing nuclear extracts from HUVECs transduced with either Ad.r*Gax* or the control adenoviral vector Ad.GFP to measure binding to a probe containing an NF- $\kappa$ B consensus sequence (61). Specific binding to NF- $\kappa$ B consensus sequence by nuclear extracts from HUVECs transduced with Ad.*Gax* and then induced with TNF- $\alpha$  (10 ng/ml) was much reduced compared to that observed in controls (Figure 8), implying that *Gax* expression interferes with the binding of NF- $\kappa$ B to its consensus sequence.

## **DISCUSSION**

Interactions between tumor and stroma, particularly the ability of tumors to induce angiogenesis, are critical to tumor progression and metastasis (21). At the EC level, the process of angiogenesis involves complex temporally coordinated changes in phenotype and global gene expression in response to alterations in the balance between pro- and anti-angiogenic factors. The stimuli for these changes are communicated from the surface of ECs to the nucleus through multiple overlapping signaling pathways. The peptide factors and the receptors they bind to that activate these pathways have been the subject of intense study over the last decade, because the importance of aberrant EC activation and angiogenesis to the pathogenesis of not just cancer, but of other diverse human diseases, such as atherosclerosis, diabetic retinopathy, psoriasis, and others, has become more apparent (20). Because blocking aberrant angiogenesis has the potential to be an effective strategy to treat or prevent multiple diseases,, understanding how downstream transcription factors integrate upstream signals from pro- and anti-angiogenic factors to alter global gene expression and produce the activated, angiogenic phenotype, has become increasingly important.

Homeobox genes represent a class of transcription factors that, given their ubiquitous roles in controlling body plan formation during embryogenesis, organogenesis, cell proliferation and differentiation, and numerous other important cellular processes (1, 13, 28), would be expected to be involved in regulating the conversion of a quiescent, unactivated EC to the activated, angiogenic phenotype. Indeed, several HOX genes have been implicated in this process. For example, *HOXA9* produces an EC-specific isoforms (*HOXA9EC*), whose expression is downregulated by TNF- $\alpha$ , but whose function is as yet unknown (53). *HOXA9* itself, however, has recently been implicated in inducing migration and tube formation through by upregulating

the *EphB4* receptor (6). Two paralogues, *HOXD3* and *HOXB3*, have been shown to induce an angiogenic phenotype (4, 5, 48), *HOXD3* through its upregulation of integrins  $\alpha_v\beta_3$  and  $\alpha_5\beta_1$  and urokinase plasminogen activator (4, 5) and *HOXB3* through its inhibition of ephrin A1 ligand expression (48). In contrast, *HOXD10* inhibits the angiogenic phenotype through an as yet undefined mechanism, producing changes in global gene expression consistent with a quiescent, nonangiogenic phenotype (49). Less is known about the involvement of homeobox genes outside the four HOX clusters in regulating angiogenesis. However, at least one such gene, *Hex*, inhibits EC activation and tube formation, and decreases flk-1/KDR expression in ECs (47, 51). These observations are all consistent with an important role for homeobox genes in regulating the transition to the activated, angiogenic phenotype.

Based on our data in this report, we postulate that at least one additional homeobox gene, *Gax*, is also likely to have an important role in regulating EC angiogenesis. We originally isolated *Gax* from a rat aorta library (27), and subsequently we and others found that in the adult its expression is restricted primarily to mesodermal tissues, particularly the cardiovascular system (10, 27, 58). Moreover, *Gax* expression is rapidly downregulated by growth factors and more slowly upregulated by growth arrest signals in VSMCs both *in vitro* and *in vivo* (27, 66, 68), and its expression results in cell cycle arrest (59), p21 induction (59), inhibition of migration (67), and modulation of integrin expression (67). *In vivo*, *Gax* expression in injured vasculature prevents the proliferative response that leads to restenosis after balloon angioplasty (42, 59). Based on these observations, we examined *Gax* expression in vascular ECs. We found that *Gax* is expressed in this cell type and that it has many of the same activities as in VSMCs. In addition, its expression inhibited EC tube formation on Matrigel *in vivo* (25). These observations led us to the present study, in which we wished to elucidate further the role(s) *Gax* may have in regulating



**The homeobox gene *Gax* inhibits endothelial cell activation and nuclear factor  $\kappa$ B activity**

angiogenesis. Consistent with its regulation in VSMCs, in ECs, *Gax* is rapidly downregulated by serum, proangiogenic, and pro-inflammatory factors (Figures 1 through 4), and is able to inhibit EC migration in vitro (Figure 5) and angiogenesis *in vivo* (Figure 6). These observations led us to examine the mechanism by which *Gax* inhibits EC activation utilizing cDNA microarrays to examine global changes in gene expression due to *Gax*. In addition to observing that *Gax* upregulates cyclin kinase inhibitors (Table 3) and downregulates a number of proangiogenic factors (Tables 1 and 2), we also found that *Gax* inhibits the expression of a number of NF- $\kappa$ B target genes (Table 2). Consistent with the cDNA microarray data, *Gax* inhibits the binding of NF- $\kappa$ B to its consensus sequence (Figure 8).

The NF- $\kappa$ B/Rel proteins are an important class of transcriptional regulators that play a central role in modulating the immune response and promoting inflammation and cancer by regulating the expression of genes involved in cell growth, differentiation, and apoptosis (23). In many cell types, NF- $\kappa$ B promotes cell survival in response to pro-apoptotic stimuli, induces cellular proliferation, or alters cell differentiation (23). The NF- $\kappa$ B/Rel family is composed of at least five mammalian homologs, c-Rel, RelA (p65), RelB, p50/p105 (NF- $\kappa$ B1), and p52/p100 (NF- $\kappa$ B2), which form an array of homo- and heterodimers, known as the NF- $\kappa$ B complex (23). In most cell types, NF- $\kappa$ B exists in the cytoplasm as an inactive form bound to inhibitory proteins known as I $\kappa$ Bs. In the classical pathway of NF- $\kappa$ B activation, NF- $\kappa$ B inducers, such as TNF- $\alpha$  and other proinflammatory cytokines, growth factors, UV light, oxidative stress, and bacterial lipopolysaccharide, initiate a signaling cascade ultimately leading to the nuclear translocation of p50/RelA heterodimers, resulting from signal-induced phosphorylation of I $\kappa$ B by I $\kappa$ B kinase (IKK), which targets it for ubiquitination (17, 23). In addition to this classical

pathway of NF- $\kappa$ B activation, a non-canonical pathway involving activation of p52-containing dimmers through regulated processing of the p100 precursor protein (17, 23).

Several lines of evidence have implicated NF- $\kappa$ B activity in regulating EC phenotype during inflammation and angiogenesis and, in particular, the classic activation of RelA-containing heterodimers (39, 40, 43, 52, 56, 57). For example, proangiogenic factors such as VEGF (37), TNF- $\alpha$  (64), and platelet-activating factor (40) can all activate NF- $\kappa$ B signaling and activity in ECs. In addition, inhibition of NF- $\kappa$ B activity inhibits EC tube formation *in vitro* on Matrigel (29, 57), and pharmacologic inhibition of NF- $\kappa$ B activity suppresses retinal neovascularization *in vivo* in mice (70). Moreover, ligation of EC integrin  $\alpha_v\beta_3$  by osteopontin protects ECs against apoptosis induced by serum withdrawal (56), an effect that is due to NF- $\kappa$ B-dependent expression of osteopontin (43). Similarly,  $\alpha_5\beta_1$ -mediated adhesion to fibronectin also activates NF- $\kappa$ B signaling and is important for angiogenesis, and inhibition of NF- $\kappa$ B signaling inhibits bFGF-induced angiogenesis (39). One potential mechanism by which NF- $\kappa$ B signaling may promote angiogenesis is through an autocrine effect, whereby activation of NF- $\kappa$ B induces expression of proangiogenic factors such as VEGF, as has been reported for platelet-activating factor-induced angiogenesis (40). Alternatively, the involvement of NF- $\kappa$ B in activating EC survival pathways is also likely to be important for sustaining angiogenesis (29).

Although NF- $\kappa$ B activity can influence the expression of homeobox genes (7, 53), there have been relatively few reports of functional interactions between homeodomain-containing proteins and NF- $\kappa$ B proteins. The first such interaction reported was between I $\kappa$ B $\alpha$  and HOXB7, where I $\kappa$ B $\alpha$  was found to bind through its ankyrin repeats to the HOXB7 protein and potentiate HOXB7-dependent gene expression (12). More recently, it was reported that I $\kappa$ B $\alpha$  can also potentiate the activity of other homeobox genes, including *Pit-1* and *Pax-8*, through the

sequestration of specific histone deacetylases (65). In contrast, Oct-1 can compete with NF- $\kappa$ B for binding to a specific binding site in the TNF- $\alpha$  promoter (63). In addition, at least one interaction has been described in which a homeobox gene directly inhibits NF- $\kappa$ B-dependent gene expression, an interaction in which Cdx2 blocks activation of the COX-2 promoter by binding p65/RelA (38). It remains to be elucidated if *Gax* inhibits NF- $\kappa$ B-dependent gene expression by a similar mechanism. Regardless of the mechanism, however, this report represents to our knowledge the first description of a homeobox gene that not only inhibits phenotypic changes that occur in ECs in response to proangiogenic factors, but also inhibits NF- $\kappa$ B-dependent gene expression in vascular ECs. These properties suggest *Gax* as a potential target for the antiangiogenic therapy of cancer or other diseases in which aberrantly increased angiogenesis is an important mechanism of pathogenesis. In addition, understanding the actions of *Gax* on downstream target genes, signals that activate or repress *Gax* expression, and how *Gax* regulates NF- $\kappa$ B activity in ECs is likely to lead to a better understanding of the mechanisms of tumor-induced angiogenesis and the identification of new molecular targets for the antiangiogenic therapy of cancer.

#### **ACKNOWLEDGMENTS**

The work described in this article was supported by grants from the New Jersey Commission on Cancer Research (0139CCRS1), and the U. S. Department of Defense, specifically a U.S. Army Career Development Award (DAMD17-02-1-0511) and an Idea Award (DAMD17-03-1-0292). We would also like to thank Dr. Kenneth Walsh for constructs and for advice on performing the Matrigel plug assay, Dr. Daniel Medina (The Cancer Institute of New Jersey, New Brunswick, NJ) for technical assistance in flow cytometry, and Dr. Arnold Rabson (UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ) for his helpful advice.

## **REFERENCES**

1. **Abate-Shen, C.** 2002. Deregulated homeobox gene expression in cancer: cause or consequence? *Nat Rev Cancer* **2**:777-85.
2. **Ades, E. W., F. J. Candal, R. A. Swerlick, V. G. George, S. Summers, D. C. Bosse, and T. J. Lawley.** 1992. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. *J Invest Dermatol* **99**:683-690.
3. **Bell, S. E., A. Mavila, R. Salazar, K. J. Bayless, S. Kanagala, S. A. Maxwell, and G. E. Davis.** 2001. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. *J Cell Sci* **114**:2755-73.
4. **Boudreau, N., C. Andrews, A. Srebrow, A. Ravanpay, and D. A. Cheresh.** 1997. Induction of the angiogenic phenotype by Hox D3. *J Cell Biol* **139**:257-64.
5. **Boudreau, N. J., and J. A. Varner.** 2004. The homeobox transcription factor Hox D3 promotes integrin  $\alpha_5\beta_1$  expression and function during angiogenesis. *J Biol Chem* **279**:4862-4868.
6. **Bruhl, T., C. Urbich, D. Aicher, A. Acker-Palmer, A. M. Zeiher, and S. Dimmeler.** 2004. Homeobox A9 Transcriptionally Regulates the EphB4 Receptor to Modulate Endothelial Cell Migration and Tube Formation. *Circ Res*:in press.
7. **Bushdid, P. B., C. L. Chen, D. M. Brantley, F. Yull, R. Raghov, L. D. Kerr, and J. V. Barnett.** 2001. NF-kappaB mediates FGF signal regulation of msx-1 expression. *Dev Biol* **237**:107-15.

8. **Bustin, S. A.** 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. *J Mol Endocrinol* **25**:169-93.
9. **Candia, A. F., and C. V. Wright.** 1996. Differential localization of *Mox-1* and *Mox-2* proteins indicates distinct roles during development. *Int J Dev Biol* **40**:1179-1184.
10. **Candia, A. F., and C. V. Wright.** 1995. The expression pattern of *Xenopus Mox-2* implies a role in initial mesodermal differentiation. *Mech Dev* **52**:27-36.
11. **Chan, F. K., J. Zhang, L. Cheng, D. N. Shapiro, and A. Winoto.** 1995. Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. *Mol Cell Biol* **15**:2682-8.
12. **Chariot, A., F. Princen, J. Gielen, M. P. Merville, G. Franzoso, K. Brown, U. Siebenlist, and V. Bours.** 1999. IkappaB-alpha enhances transactivation by the HOXB7 homeodomain-containing protein. *J Biol Chem* **274**:5318-25.
13. **Chen, H., and S. Sukumar.** 2003. Role of homeobox genes in normal mammary gland development and breast tumorigenesis. *J Mammary Gland Biol Neoplasia* **8**:159-75.
14. **Cheng, C. W., S. K. Smith, and D. S. Charnock-Jones.** 2003. Wnt-1 signaling inhibits human umbilical vein endothelial cell proliferation and alters cell morphology. *Exp Cell Res* **291**:415-25.
15. **Cross, M. J., and L. Claesson-Welsh.** 2001. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. *Trends Pharmacol Sci* **22**:201-7.
16. **Cross, M. J., J. Dixelius, T. Matsumoto, and L. Claesson-Welsh.** 2003. VEGF-receptor signal transduction. *Trends Biochem Sci* **28**:488-94.

17. **De Martin, R., M. Hoeth, R. Hofer-Warbinek, and J. A. Schmid.** 2000. The transcription factor NF-kappa B and the regulation of vascular cell function. *Arterioscler Thromb Vasc Biol* **20**:E83-8.
18. **Dias, S., M. Choy, and S. Rafii.** 2001. The role of CXC chemokines in the regulation of tumor angiogenesis. *Cancer Invest* **19**:732-8.
19. **Doniger, S. W., N. Salomonis, K. D. Dahlquist, K. Vranizan, S. C. Lawlor, and B. R. Conklin.** 2003. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. *Genome Biol* **4**:R7.
20. **Folkman, J.** 2001. Angiogenesis-dependent diseases. *Semin Oncol* **28**:536-42.
21. **Folkman, J.** 2002. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol* **29**:15-8.
22. **Fujio, Y., and K. Walsh.** 1999. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. *J Biol Chem* **274**:16349-54.
23. **Ghosh, S., and M. Karin.** 2002. Missing pieces in the NF-kappaB puzzle. *Cell* **109** Suppl:S81-96.
24. **Goodwin, A. M., and P. A. D'Amore.** 2002. Wnt signaling in the vasculature. *Angiogenesis* **5**:1-9.
25. **Gorski, D. H., and A. D. Leal.** 2003. Inhibition of endothelial cell activation by the homeobox gene *Gax*. *J. Surg. Res.* **111**:91-99.
26. **Gorski, D. H., A. D. Leal, and J. S. Goydos.** 2003. Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. *J Am Coll Surg* **197**:408-18.